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ABSTRACT OF DISSERTATION

MULTI-COMPONENT MICROPARTICULATE/NANOPARTICULATE DRY
POWDER INHALATION AEROSOLS FOR TARGETED PULMONARY DELIVERY
The aim of the work was to design, manufacture, and characterize targeted
multi-component dry powder aerosols of (non-destructive) mucolytic agent (mannitol),
antimicrobial drug (tobramycin or azithromycin), and lung surfactant mimic
phospholipids (DPPC:DPPG=4:1 in molar ratio). The targeted dry powder for inhalation
formulation for deep lung delivery with a built-in rationale of specifically interfering
several disease factors of chronic infection diseases in deep lungs such as cystic fibrosis,
pneumonia, chronic bronchitis, and etc. The dry powder aerosols consisting of selected
chemical agents in one single formulation was generated by using spray drying from
organic solution.
The physicochemical properties of multi-component dry powder inhaler (DPI)
formulation were characterized by a number of techniques. In addition, the in vitro
aerosol dispersion performance, storage stability test, and in vitro drug release of selected
spray-dried (SD) multi-component systems were conducted.
The physicochemical study revealed that multi-component aerosol particles possessed
essential particle properties suitable for deep lung delivery. In general, the
multi-component particles (typically 0.5 to 2 µm) indicated that the designed SD aerosol
particles could potentially penetrate deep lung regions (such as respiratory bronchiolar
and alveolar regions) by sedimentation and diffusion, respectively. The essential particle
properties including narrow size distribution, spherical particle and smooth surface
morphologies, and low water content (or water vapor sorption) could potentially
minimize interparticulate interactions. The study of in vitro aerosol dispersion
performance showed that majority of SD multi-component aerosols exhibited low values
(less than 5µm) of MMAD, high values (approximately above 30% up to 60.4%) of FPF,
and high values (approximately above 90%) of ED, respectively. The storage stability
study showed that azithromycin–incorporated multi-component aerosol particles stored at
11 and 40% RH with no partial crystallization were still suitable for deep lung delivery.
Compared to SD pure azithromycin particles, the azithromycin-incorporated
multi-component particles exhibited an enhanced initial release.

The targeted microparticulate and nanoparticulate multi-component dry powder aerosol
formulations with essential particle properties for deep lung pulmonary delivery were
successfully produced by using spray drying from organic solution. The promising
experimental data suggest the multi-component formulations could be further
investigated in in vivo studies for the purpose of commercialization.

KEYWORDS: aerosol dispersion performance, dry powder inhaler (DPI), spray drying,
physicochemical characterization, in vitro storage stability and drug release
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Chapter 1 General Introduction

1.1 Characteristics of the Lung
1.1.1 Anatomy of the Airways
The lungs are the major respiratory organs in human body. The lungs are divided into two
parts, including one on the right and the other on the left as shown in Figure 1.1.
Respiratory system is responsible for transporting oxygen to the blood and removing
carbon dioxide from the blood. It has two airway tracts, including upper and lower
respiratory parts. The upper respiratory tract is defined as the region, starting from nose
or mouth passages, through pharynx and larynx, to the trachea. The lower respiratory
tract includes bronchi, bronchioles (including terminal bronchioles and respiratory
bronchioles), and gas-exchanging regions (including alveolar ducts and alveolar sacs).
However, based on functionality, airways can also be categorized into conducting and
respiratory parts. The conducting airways do not involve in gas exchange, and consist of
regions from the trachea to the terminal bronchioles. The respiratory airways, responsible
for gas exchange, are respiratory bronchioles, alveolar ducts, and alveolar sacs.

Figure 1.1. Schematic of the respiratory system. Adapted from [1].
The lung airways are recognized as a bronchial tree in structure[2]. Analogous to the
trunk and branches of a tree, the trachea bifurcates to form bronchi and bronchioles. The
sac-like alveoli could be viewed as the leaves of a tree. Weibel airway model[3] (Figure
1

1.2) is used to characterize airway structure and represents the airway divisions before
alveolar sacs are reached. Up to 24 airway generations are proposed in the Weibel model,
with trachea and alveolar sacs being generation 0 and 23, respectively. Compared to the
previous generation, the number of airways at each generation is doubled. Each airway
generation exhibits a characteristic range of sizes in lengths and diameters of the
branches[4].

Figure 1.2. Schematic of Weibel airway model. Adapted from [2].
Two characteristics of the lungs exhibit important influences in airway function. The first
characteristic is that airway diameters decrease with increasing generations (in Weibel
model). For instance, with an alveolar diameter being 0.04 cm, a tracheal diameter in the
adult is on the order of 1.8 cm[5]. During inspiration, this physical characteristic permits
easy air penetration into the lower airway regions. The second characteristic is that
surface area in airways increases dramatically with each succeeding generation. With a
presence of ~ 600 millions alveoli, the total surface area in the alveolar region is
estimated to be ~ 140 m2 in an adult human[5] Alveoli are the main region for gas
exchange between air and blood. Each alveolus is surrounded and separated from one
another by thin blood capillaries. An exchanging gas molecule in an alveolus has to travel
a distance of approximately being 500 nm, from the alveolar epithelium, through
capillary endothelium, and to basement membrane before arriving into the blood[5].
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1.1.2 Physiology of the Airways
Lining on the luminal surface is the epithelium of the airways. The epithelial cells are the
barrier of absorption into the bloodstream. The cell productions are markedly different
depending on locations in the lungs. As shown in Figure 1.3, the epithelial cells are
drawn at the corresponding relative sizes. In the bronchial airways, a wide range of cells
make up the epithelium[2]: the basal cells are the stem cells for the epithelium,
differentiating to form the other cells in the case of injury or apoptosis; the goblet cells
secret the mucus; the ciliated cells provide the mechanism for moving the mucus; the
brush cells participate in drug metabolism. The gradually thinning epithelium, with many
mucus and ciliated cells, acts as so called “mucociliary escalator”. Absorptive epithelium
becomes thinner until alveoli are reached. All the above listed types of cells exist in the
smaller airways, but as a thinner layer.

Figure 1.3. Comparison of the lung epithelium at different airways. Adapted from [2].
However, as different to bronchial airways, alveolar epithelium is a monolayer of cells.
The alveolus mainly consists of Type I and Type II alveolar cells as shown in Figure 1.4.
Type I cells are very broad and extremely thin (< 0.1 µm) squamous cells that form most
(about 95 %) of the surface of the alveoli. The exchange of oxygen and carbon dioxide
takes place through the cell membranes and cytoplasm of Type I cells. As numerous as
Type I cells, Type II cells are locate among the Type I cells and cover only 5% of the
alveolar surface. Type II cells possess three main functions[6]: 1) secretion of pulmonary
surfactant; 2) control of alveolar fluid levels; 3) act as the stem cells to replace both Type
I and II cells after injury. On average, about 12-14 alveolar macrophages range over the
air-side of 500 alveoli spaces[2]. A morphometric study of human lung tissue indicated
that 90% of alveolar macrophages are observed at or near alveolar septal junctional
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zones[7]. Alveolar macrophages engulf and ingest any foreign particles and infectious
microorganisms that may exist in the alveoli. The indigestible materials are frequently
transported to the lymph nodes of the lungs[6].

Figure 1.4. Structure of an alveolus. Adapted from [8].
Released by Type II alveolar cells, pulmonary surfactant is a mixture of surface-active
lipids (90% by weight) and proteins (10% by weight). The lipids and proteins have both a
hydrophilic region and a hydrophobic regions. Pulmonary surfactant adsorbs to the
air-water interface of alveoli with the hydrophilic head groups in the water and the
hydrophobic tails facing towards the air. Therefore, it reduces the surface tension of
interface. Dipalmitoylphosphophatidylcholine (DPPC), a predominant lipid (40% by
weight) with saturated fatty acid chains, contributes substantially to the unique properties
of pulmonary surfactant.[9] In addition to DPPC, pulmonary surfactant also contains
unsaturated
phosphatidylcholine
(~35%),
phosphatidylglycerol
(~10%),
phosphatidylinositol (~2%), phosphatidylethanolamine (~3%), sphingomyelin (~2.5%),
and cholesterol (~3%).[10] The proteins are comprised of a highly variable amount of
serum proteins and four apoproteins (surfactant protein A (SP-A), surfactant protein B
(SP-B), surfactant protein C (SP-C), and surfactant protein D (SP-D)). Associated with
lipids, the proteins contribute to specific functions of pulmonary surfactant.[9] Pulmonary
surfactant stabilizes the alveoli during the respiratory cycle by reducing surface tension of
water-air interface. Therefore, it prevents the tendency of alveolar collapse in expiration
and makes lung inflation easy in inspiration.[10] The function of host defense in alveoli
replies on the nature of SP-A and SP-D.[9] In addition, surfactant also possesses
anti-inflammatory functions[11], promotes mucus clearance[12], prevents pulmonary
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infection[11], and eliminates extracellularly generated oxyradicals and enhances
intracellular antioxidant enzyme content[13].

1.1.3 Blood Circulation
Pulmonary and systemic circulation both exist in the lungs. Drug delivered to the lower
airways could be absorbed into body through both of the circulations. Pulmonary
circulation conducts the blood from the heart to the lungs for oxygen. Oxygen-depleted
blood travels through capillaries on alveoli, removing carbon dioxide and absorbing
oxygen into the blood. The alveoli provide the tremendous surface for gas exchanging
during respiration. Thereafter, the oxygenated blood leaves the lungs through pulmonary
vein and returns to the left atrium of heart. Pulmonary circulation operates on a
low-pressure and low-resistance vascular bed with a flow rate of 5 L/min[10].
Systemic circulation is the blood movement from the heart through the body to provide
oxygen and nutrients. During systemic circulation oxygen in the blood diffuses into the
respiratory cells, while waste and carbon dioxide are carried into the blood. In addition,
systemic circulation assists in the humidification and warming of inspired air in the
trachea and bronchi[10]. Moreover, it also plays a key role in anti-inflammation of lungs
by mucosal swelling and delivery of inflammatory cells and mediators to the airways[10].

1.2 Aerosol Particle Deposition Mechanisms in Human Lungs
Local delivery of drugs to the lungs attracts tremendous attention for the treatment of a
variety of pulmonary diseases. The therapeutic efficacy by dry powder for inhalation is
highly influenced the dose delivered to the target regions. Given the characteristics of the
lungs and respiratory pattern, aerosol particle properties (e.g. particle size and size
distribution, particle morphology, hygroscopicity, and etc.) mainly determine the airways
deposition[14]. There are three major particle deposition mechanisms[14] in the lungs,
including inertial impaction, sedimentation, and Brownian diffusion. Other mechanisms,
including interception, electrostatic precipitation, and hygroscopic particle growth, have
also been reported[10]. Various deposition mechanisms may be involved simultaneously
for one particular aerosol formulation.
Inertial impaction is the main deposition mechanism for particles more than 5 µm in
diameter with high velocity[14]. These particles are unable to follow the air streamlines
due to high inertia. It takes place commonly in extrathoracic and large conducting
airways, where air flow velocities are high and airway directional changes are fast. The
probability of inertial impaction of aerosol particles increases with increasing air flow
velocity, rate of breathing, particle size (> 5 µm) and particle density[10]. Stokes number
(Stk) influences the particle deposition by inertial impaction[15]:
Stk =

ρp d2p V
18µD

(Equation 1.1)
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Where ρp is the particle mass density, dp is the particle diameter, V is the air flow velocity,
µ is the dynamic viscosity of the surrounding air, and D is a characteristic dimension of
the obstacle obstructing air flow (usually in a daughter airway).
Sedimentation (gravitational settling) is deposition mechanism for particles (typically 1-5
µm) in the small conducting airways where air flow velocity is slow[14]. The deposition
is high for large particles (gravitational drag) with long residence time[14]. However, it
decreases with increasing breathing rate[10]. As similar to inertial impaction,
sedimentation is dependent on the relaxation time of the particles (the time required for
the particle to respond to a change of the air flow velocity; τ)[16].
τ=

ρp d2p
18µ

(Equation 1.2)

Where ρp is the particle density, dp is the particle diameter, and µ is the dynamic viscosity
of the surrounding air.
Brownian diffusion dominates the deposition of particles with submicron in size
(typically 0.5-1 µm)[14]. Brownian diffusion results from random motion of particles
impacted by the surrounding air molecules. It occurs in the deep lungs, especially
respiratory bronchial and alveolar regions where air flow is minimal. Stokes-Einstein
equation (for diffusion of spherical particle through medium with low Reynolds number)
defines the diffusion constant (D) of Brownian motion:
D=

kB T

6πηr

(Equation 1.3)

Where kB is Boltzmann’s constant, T is the absolute temperature, η is viscosity, and r is
the radius of the spherical particle.
Interception is mainly relevant to particles with high aspect ratio (elongated particles)
such as fibers and aggregates. The use of elongated particles for deep lung delivery has
been attracting attentions due to the characteristic aerodynamic behaviors (such as an
increase in fine particle fraction (FPF))[17-19]. Elongated particles preferably align with
the long axis in air streamlines when penetrating into airways. Therefore, the short axis of
elongated particle is mainly related to the aerodynamic diameters. Moreover, once
deposited, elongated particles are less rapidly cleared by macrophages due to the long
length[20]. However, the aerosol dispersion of elongated particles relies on the form of
loose agglomeration of the particles. Low aerosol performance arises as the particles are
in contact with long axis[21]. In addition, powder flow and content uniformity could be
problematic with elongated particles in dry powder formulations[16].
Electrostatic precipitation could occur on charged particles generated by mechanical
forces. However, this electrostatic attraction/repulsion between charging in particles and
airway surface only is a minor contributor to particle deposition[22].
Particle growth of hygroscopic aerosols at elevated relative humidity and temperature in
the respiratory tracts may affect particle deposition[23].
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1.3 Pulmonary Aerosol Drug Delivery
Efficiency of pulmonary drug delivery is dependent upon both the aerosol formulation
and inhalation device. Modern inhalation devices can be divided into four principle
categories: nebulizers, pressurized metered-dose inhalers (pMDIs), dry powder inhalers
(DPIs), and soft-mist inhalers (SMIs). Each class possesses its unique strengths and
weaknesses.
1.3.1 Nebulizers
Two typical nebulizers are commercially available, including air jet and ultrasonic
nebulizers. Marketed respiratory solutions are usually drug in isotonic aqueous solutions.
In addition, these solutions may contain preservative to inhibit microbial growth.
Jet nebulizers (Figure 1.5), the most commonly used nebulizers, are also named as
“atomizers”[24]. Jet nebulizers are connected to a compressor used as a source of gas.
The compressed air or oxygen in a compressor flows at high velocity through a liquid. It
turns the liquid into aerosol droplets inhaled by patients. Approximately 50 to 60% of the
aerosols produced by jet nebulizers are in the respirable range (< 10 µm)[10].

Figure 1.5. Schematic of a jet nebulizer. Adapted from [25].
Ultrasonic nebulizers (Figure 1.6) use an electronic oscillator to generate a high
frequency ultrasonic wave, causing a mechanical vibration of a piezoelectric transducer.
The vibration provides the energy to aerosolize the liquid. The frequency of the vibrating
piezoelectric transducer determines the droplet size for a given solution. Generated by
ultrasonic nebulizers, approximately 70% of the particles exhibit particle size in range
from 1 to 5 µm[10]. However, heat generated from frictional forces by movement of the
transducer may be detrimental to thermolabile formulations[10].
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Figure 1.6. Schematic of an ultrasonic nebulizer. Adapted from [25].
Commonly used in hospital, the old models of both jet and ultrasonic nebulizers usually
generate a lot of noise and are not portable due to a heavy weight. Advances in
technology have led to the development of novel nebulizers. These miniaturized novel
nebulizers are portable with high-output, generating small droplets capable of penetrating
deeply into the lungs (< 5 µm). New techniques in liquid spray delivery devices are
employed including high pressure micro-spray nozzle systems and electrostatic
generation of aerosol clouds[26]. Some of the commonly available drug solutions
delivered by nebulizers are Ventolin® (salbutamol, beta 2-mimetic bronchodilator),
Bricanyl® (terbutaline, beta 2-mimetic bronchodilator), Atrovent® (ipratropium,
anticholinergic bronchodilator), Pulmozyme® (dornase alpha, mucolytic), and Tobi®
(tobramycin, antibiotic)[10].
In general, the advantages of using nebulizers are: 1) constant output of delivering
aerosols; 2) large dose delivery; 3) low requirement on coordination between aerosol
generation and breathing of patients. However, well-documented disadvantages of using
nebulizers are: 1) time-consuming; 2) high cost; 3) inefficiency[27]; 4) poor
reproducibility and great variability; 5) risk of bacterial contamination; 6) constant
cleaning[28]; 7) inconvenient (bulky)[29]; 8) waste of active ingredient (dead volume of
solution)[30].

1.3.2 Pressurized Metered-Dose Inhaler (pMDIs)
Pressurized metered-dose inhalers (pMDIs) can deliver a specific amount of drug to the
lungs in the form of a short aerosol burst. pMDIs are usually self-administered by the
patient. These devices are commonly used in treatment of asthma, chronic obstructive
pulmonary disease (COPD), and other respiratory diseases.
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pMDIs (Figure 1.7) are composed of three major components[5, 31]: 1) a canister made
of aluminum or stainless steel, where the formulation resides; 2) a metering valve
allowing a metered quantity of the formulation to be dispensed with each actuation; 3) an
actuator (or mouthpiece) allowing the release of aerosols and directing the aerosols into
the patient’s lungs. The formulation itself consists of the medication (either dissolved or
suspended in the propellant), a liquefied gas propellant, and possibly stabilizing
excipients. Actuation of the device releases a single metered dose of the formulation
liquid through the control valve. With expansion and evaporation of propellant in
formulation liquid, it leaves the drug in the form of aerosols at a high velocity. The
liquefied propellant are used both as an energy source for expelling the formulation from
the valve and a dispersion medium for the drug and other excipients.

Figure 1.7. Schematic of a pressurized metered-dose inhaler. Adapted from [32].
Particle size and size distribution of aerosols from a pMDI are dependent on the
physicochemical properties of the formulation. Size of aerosol droplets from suspension
formulation in pMDIs could be reduced by using a low drug concentration, or small drug
particles, or a system with high vapor pressure[33]. In addition, low concentration of a
surfactant helps the dispersion of suspended particles or dissolution of a partially soluble
drug, and lubricates the metering system[34]. Antioxidant or chelating agent may be
added to enhance chemical stability of the formulation[10]. Unpleasant taste of
formulations might be masked by adding flavors or sweeteners[10]. Some of the
commercially available pMDIs include Flixotide® (fluticasone, corticosteroid), Atrovent®
(ipratropium bromide, anticholinergic bronchodilator), Ventolin® (salbutamol, beta
2-mimetic bronchodilator), and Combivent® (ipratropium bromide and salbutamol,
anticholinergic and beta 2-mimetic bronchodilator).
There are several disadvantages of drug delivery by pMDIs. Chlorofluorocarbons (CFCs)
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as a propellant have been banned by 2000 by “Montreal Protocol” (due to the
contribution to ozone depletion and health effects)[35]. The replacement propellant,
hydrofluoroalkane (HFA), is an extremely poor solvent. Therefore, formulation
surfactants are totally insoluble in HFA, resulting in physical stability issue of drug
particles. Numerous approaches are employed to overcome the issues associated with
HFA propellants, including addition of a co-solvent, development of a new surfactant,
and particle engineering[10].
In general, only a small fraction of drug dose (approximately 10 to 20% of emitted dose)
could be delivered by pMDIs to the lungs. A well-known issue, so-called “cold–Freon
effect”, can be experienced by using pMDIs. It is attributed to the evaporation of
propellant when the aerosols impact on the back of the throat, causing patients to stop
inhaling[36]. Poor hand-mouth coordination is another issue associated with the use of
pMDIs[37]. However, the introduction of breath-actuated pMDIs (such as Autohaler®)
provides a convenient means to overcome the poor coordination[10].

1.3.3 Dry Powder Inhalers (DPIs)
Dry powder inhalers (DPIs) are devices that deliver drug to the lungs as a dry powder.
The emergence of DPIs was largely driven by the “Montreal Protocol” that addressed
elimination of CFCs from traditional pMDIs[38, 39]. DPI products combine powder
technology and device design in order to disperse dry aerosol particles in the lungs of
patients. Commercially available DPI devices range from single-dose devices (e.g.,
Aerolizer® (Novartis) and Handihaler® (Boehringer Ingelheim)) to multi-dose devices in
form of a blister pack (e.g., Diskhaler® and Diskus® (GlaxoSmithKine)) or reservoir-type
system (e.g., Turbuhaler® (AstraZeneca))[5]. For instance, a schematic of the
Handihaler® DPI device (open state) from Boehringer Ingelheim (Germany) is shown in
Figure 1.8. Drug particles in a capsule (placed in center chamber (#6 in Figure 1.8)) are
released via a rumbling motion once the capsule is pierced by two pins (placed inside of
the piercing button (#5 in Figure 1.8)). The drug particles are dispersed through the
turbulent air flow generated by a stainless grid (placed inside of the mouthpiece (#2 in
Figure 1.8)) at the time of inhalation[10].
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Figure 1.8. Schematic of the Handihaler® DPI device. Adapted from [40].
DPIs have three basic features including device, formulation, and dose-metering
system[16]. The pre-metered (single-dose or multi-dose) devices are further classified
into active (device actuated) and passive (breath actuated) DPIs. As to passive DPIs, the
inspiration is the only energy source for particle resuspension from static powder state.
The device itself is designed to allow efficient particle resuspension through powder
fluidization and deaggregation[41]. DPI formulation could either be lactose carrier-free
(respirable drug particles alone with aerodynamic diameter about 1-5 µm depending on
the target site)[42-44] or lactose carrier-based (blends of respirable drug particles and
lactose particles)[45]. α-lactose monohydrate is commonly used as carrier particles. In
addition to acting as a bulking agent for uniform capsule filling, the carrier particles
(typically > 30 µm in diameter) are used to increase powder flow and facilitate the release
of respirable drug aerosols[16]. Dose-metering system includes the pre-metered
individual capsules, multiple dose blisters or strips, and dose reservoirs.
Efficiency and reproducibility of aerosols reaching the desired site of action are
determined by DPIs device, formulation, and inspiratory maneuver of patients[45]. The
new generation of DPIs under developments includes extra mechanisms (such as the
employment of impellors, compressed air assistance, vibration, and impact hammers) to
enhance aerosolization of drug particles[16]. Recently novel DPIs, standardized
entrainment tubes (SETs; a series DPIs with unique features and design, but different
turbulent shear forces), have been developed, leading to prediction, modeling, and
fundamental understanding of particle resuspension from static powder state[46-48].

1.3.4 Soft-Mist Inhalers (SMIs)
Soft-mist inhaler (SMI; Respimat®), as shown in Figure 1.9, is a new generation inhaler
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invented by Boehringer Ingelheim in 1997[49]. This device provides a metered dose to
the users. As the bottom of the inhaler is rotated clockwise 180 degrees by hand, a
tension is built up into a spring around the flexible liquid container. Upon activation, the
release of energy from the spring imposes pressure on the flexible liquid container. It
produces two fine jets of liquid that converge at a pre-set angle through precisely
engineered nozzle (in uniblock), forming a soft inhalable mist. With no propellant and no
need for a battery, the device employs only mechanical energy. The relatively long
generation time of aerosol cloud (approximately 1.5 s) facilitates coordination of
actuation and inhalation which is a major problem with pMDIs. With the slow velocity of
the soft mist, it results in larger amounts of the drug deposited in the lungs and less
deposited in the oropharynx compared with either pMDIs and DPIs[49]. In general, the
soft mist contains a high fine particle fraction of approximately 65 to 80%[49].

Figure 1.9. Schematic of the Respimat® soft-mist inhaler. Adapted from [49].

1.4 Interparticulate Forces
Dry powder aerosol particles prepared in respirable sizes exhibit unique properties based
on the forces of interaction. The interparticulate forces need to be overcome before the
inhalable aerosol particles generated in circumstance of either carrier-free or
carrier-based DPI formulations. Interparticulate or surface forces (adhesive and cohesive
forces) in the dry powder formulations are a result of complex combination of physical
forces including van der Waals forces, electrostatic forces, capillary forces[16, 50]. In
addition, other forces, such as mechanical interlocking, frictional forces, and hydrogen
bonding, are not frequently mentioned, but still important[41]. Particle aggregation is a
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result of interparticulate forces. The contribution of each force to the particle aggregation
is dependent on numerous factors such as surface morphology, crystallinity, intrinsic
material properties, and environmental conditions[41]. The calculated magnitude of
interparticulate forces (van der Waals, electrostatic, and capillary forces between ideal
binary system) was previously reported[41, 51]. In general, at normal environmental
conditions, the strength of van der Waals forces is about two orders of magnitude higher
than electrostatic and capillary forces. However, capillary forces would dominate at
condition of high relative humidity[16].
van der Waals forces (Fvdw) can be defined as below[16]:
Fvdw =

A

6h2

R R

∗ R 1+R2 =
1

Fvdw =

2

AR

6h2

AR

12h2

(R1 = R2 = R, for two identical spheres) (Equation 1.4)

(R1 << R2, for sphere and surface) (Equation 1.5)

Where A is the Hamaker constant (typically ~10-19 J) dependent on the molecular
properties of the materials, R is the particle radius (m), and h is the separation distance
(m). As compared to van der Waals force, gravitational forces are lowered greater when
size of drug particles becomes small[16]. Therefore, the dry particles, with size less than
10 µm, become adhesive/cohesive as van der Waals forces become predominant[16].
Based on the Equation 1.4 and 1.5, van der Waals forces, effective within a separation
distance < 100 µm[16], diminish rapidly with increasing separation distance. Therefore,
van der Waals forces are sensitive to the change of particle shape and surface
morphology[52]. The magnitude of van der Waals forces is greatly affected by the
number of mutual points of contact known as the coordination number[41]. The van der
Waals forces of particles could be also influenced by surface roughness (such as kinks
and defects) by several orders of magnitude. The surface roughness of particles can be
evaluated by mathematical models (e.g. Fourier, fractal, and chaos analysis) in terms of
irregular oscillations around a mean value[53].
Electrostatic forces (including contact charging, coulombic interaction, and induced
charging) could be either attractive or repulsive[16]. Contact charging involves the
contact of a charged object to a neutral object until electron transfer reaches equilibrium.
The contact charging force (Fc) is defined as[16, 50]:
Fc =

2πq2
A

(Equation 1.6)

Where q is charge detachment between two objects, A is the contact area between two
objects.
Coulombic interaction occurs in two charged objects. Dependent upon the sign of
electrical charge, it could be either attraction or repulsion. Coulombic force (Fq) is
expressed as[16]:
Fq =

q1 q2

4πεh2

(Equation 1.7)

Where q1 and q2 are the charge on two objects, respectively, ε is the permittivity, and h is
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the separation distance.
Induced charging appears when a charged object approaches an uncharged object.
Induced charging (Fe) is calculated as[16]:
h

1

Fe = q2 �1 − (R2 +h2)0.5 � ∗ 16πεh2 (Equation 1.8)

Where q is the charging on charged object, h is the separation distance, R is the radius of
uncharged object, and ε is the permittivity.
As LaPlace pressure develops, capillary forces cause capillary condensation of water
vapor. The formation of liquid bridge formation between solid particles due to water
vapor condensation brings particles together. Capillary forces take places because of
intermolecular forces between the liquid and surrounding solid surfaces. The capillary
forces (Fcp) between two spherical particles are described as[16, 50]:
Fcp = 4πR∗ γL cosθ + 4πR∗ γSL (Equation 1.9)

Where R* is the harmonic mean of radii of the particles, γL is the surface tension of water,
γSL is the solid-liquid interfacial energy, and θ is the contact angle of liquid film to
particle surface.
Mechanical interlocking arises with an increase in surface roughness. Mechanical
interlocking of the particles is a prominent mechanism preventing particle dispersion for
carrier-based DPI formulations. Moreover, surface roughness may also alter van der
Waals forces, surface charging density, water vapor condensation in dry powders[54]. It
has been reported that increased surface smoothness of carrier particles enhanced the fine
particle fraction (FPF) of the DPI formulations[55-57]. In addition, dependent on the
physicochemical and viscoelastic properties, aerosol particles may deform, which
changes the effective contact area[16].
In reality, the forces of interaction between pharmaceutical particles are difficult to
characterize or be controlled due to the heterogeneity in particle composition and
physicochemical characteristics. Therefore, it is not practical to consider each of the
forces independently. Nonetheless, key features of inhalation powders that critically
influence interparticulate forces could be evaluated, including particle size and size
distribution, particle shape, surface asperities (roughness), crystallinity, particle density,
and presence of impurities[10]. Adhesion/cohesion of dry powder for inhalation could be
indirectly estimated by using inverse gas chromatography (IGC)[58-64] and contact
angle[65], and directly measured by using atomic force microscopy (AFM)[66, 67]. The
efficiency of deaggregation in aerosolization is highly influenced by existing
adhesive/cohesive forces in formulations. For instance of carrier-based dry powder
formulation for inhalation, strong adhesive (drug-carrier) interaction may prevent the
release of respirable drug particles from the surface of carriers, leading into a high
deposition in upper airways. Therefore, the adhesive forces between respirable drug
particles and large carrier particles strongly influences the delivered dose, since only drug
particles separated from carrier surface are able to reach to the deep lungs. Similarly,
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excessive cohesive forces could lead to agglomerate formation, affecting powder
fluidization and dispersion characteristics of formulations[66]. The balance of these
forces is very critical in drug-carrier blending, drug particle deaggregation, and drug
particle resuspension.

1.5 Spray Drying
There are several methods available to make respirable particles for dry powder
inhalation, including micronization, freeze drying, and spray drying, and etc.[68-70].
Micronization, a simple and easy process by particle-particle and particle-solid collisions,
is a classical approach in particle size reduction. However, in addition to produce
cohesive particle aggregates, it is difficult to the control of particle size, size distribution,
and morphology[45]. Many particles (e.g. protein drug) are produced by freeze drying
due to stability issue. However, in addition to formation of undesired particles which are
not suitable for inhalation, it is time and energy consuming[71].
Spray drying is a one-step continuous particle process operation. It exhibits a high ability
to produce particles in a controlled manner, such as directing particle size and size
distribution, particle shape, and particle morphology, which are important particle
features for pulmonary drug delivery by inhalation. The process of spray drying converts
a liquid feed (such as solutions, suspension, emulsions and etc.) to dried particles. A
schematic of spray dryer is shown in Figure 1.10. Some key components of a spray dryer
include: 1) electric device that elevates the temperature of drying gas; 2) nozzle that
atomizes liquid feed into droplets by compressed air; 3) spray drying glass chamber for
primary drying of droplets with drying gas; 4) cyclone that separates dried particles from
drying gas; 5) filter that removes fine particles (not collected by cyclone); 6) aspirator
that generates air flow in system; 7) liquid collecting system (not show in Figure 1.10)
that condenses water vapor, organic vapor, or both into liquid state.
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Figure 1.10. Schematic of a spray dryer. Adapted from [72].
In general, the process of spray drying involves three stages, including atomization,
drying, and separation[30]. Atomization is the process of droplet generation from liquid
feed. A spray of millions of droplets is formed when a liquid feed is forced through a
nozzle by a pressurized atomizing gas at high velocity. The nozzle dimensions influence
the size of produced droplet, and thus the size of resultant dry particle. In addition, pump
feeding rate, liquid feed concentration, liquid feed type (i.e. solution, suspension, or an
emulsion), solvent type (i.e. aqueous vs organic liquid), liquid viscosity, atomizing gas
type, and aspiration rate may impact the particle size of final powder. However, regarding
to the role of viscosity, opposite views has been expressed. It is suggested[30] that an
increase in viscosity of feed increase the size of droplet and its dried particle. It is also
reported[73, 74] that smaller particles are generated by using liquid with higher viscosity
and faster feeding rate. These conditions are thought to generate a larger back-pressure in
a nozzle, producing a finer spray due to an increase in sheer during atomization.
Drying of droplets takes place when contacting heated gas in the primary drying chamber.
The type of drying gas with the associated moisture level may affect particle
properties.[30]The rate of drying is mainly influenced by drying temperatures (both
independent inlet and dependent outlet temperatures) and the flow rate of drying air[75].
The thermal efficiency of spray drying is generally defined as[75, 76].
Tin −Tout

ηoverall = 100 ∗ �T

in −Troom

� (Equation 1.10)

Where ηoverall is overall thermal efficiency, Tin is the inlet temperature, Tout is the outlet
temperature, and Troom is the room temperature. Using a low airflow rate exhibit a high
efficient drying for dried particles due to a long resident time. However, a low airflow
rate during spray drying associate with a low yield and possible large final particles[75].
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Separation of dried particles from air stream is achieved by using a cyclone. With an
application of centrifugal force, particles impact on the wall of cyclone. Particles are
eventually collected in a bottom vial as removed from the cyclone wall. The effective
particle collection is dependent upon geometry of the cyclone. With a given cyclone, the
particle collection efficiency is enhanced with increasing airflow rate and powder mass
loading[30].

1.6 Chronic Infections in the Deep Lungs (Cystic Fibrosis/Pulmonary Infections)
Chronic infection diseases in lower respiratory regions[77] include cystic fibrosis (CF),
pneumonia, chronic bronchitis, and etc. Chronic bronchitis, a type of chronic obstructive
pulmonary disease (COPD), is highly caused cigarette smoking[78]. However,
environment, occupation, and social class have also been associated to the development
of chronic bronchitis[79-81]. Both bacterial (about 90%)[82] and viral (about 10%)[83]
infections were observed in sputum of patients with chronic bronchitis. Pneumonia is an
infectious lung disease, primarily in alveoli, with an inflammatory condition. Pneumonia
is often caused by bacteria or virus such as pneumococcus, klebsiella, Hemophilus
influenza, staphylococcus or rhinoviruses, influenza virus and etc.[77, 84].

1.6.1 Disease Background
As a disease example of deep lung chronic infections, only CF is focused in details in this
section. CF is an inherited life-shortening autosomal recessive disease, affecting about
30,000 children and adults in the United States (70,000 worldwide). The defective gene,
CF transmembrane conductance regulator (CFTR), results in dysfunction of apical
membrane CFTR protein. CFTR protein disrupts ion (chloride and sodium) transport in
systems, including pulmonary airways, pancreatic ducts, sweat ducts, and intestine[85,
86]. Therefore, it results in the production of an abnormally viscous secretion[87].
The clinical consequences of this multi-system disease are characterized by progressive
pulmonary damage leading to respiratory failure, pancreatic dysfunction, liver disease
progressing to cirrhosis, gut motility problems, infertility and elevated sweat
eletrolytes[87, 88]. Nevertheless, the major causes of morbidity and mortality in patients
with CF are obstruction of pulmonary airways and bronchiectasis[89].
CF originates from the deep lungs such as respiratory bronchiolar and alveolar regions.
The lower airways of CF lungs are coated with thick and tenacious secretions, resulting
in diminished function of mucociliary clearance. This creates an ideal environment for
chronic lung infections, leading to cardiopulmonary failure. There are several bacterial
species, such as Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia
cepacia, that appear to be especially well-adapted to cause chronic lung infections in CF
lungs[90]. In young children of CF, Staphylococcus aureus and Haemophilus influenza
are the two predominant pathogens. As increasing age, most patients will eventually
progress to infection with Pseudomonas aeruginosa or a variety of other gram-negative
organisms, including Alcaligenes xylosoxidans, Stenotrophomonas maltophilia, and ect.
17

Even in adult CF patients, the bacterial pathogens may change gradually with time.
However there is one constant: endobronchial bacterial infection, once established, can’t
be completely eradicated. The therapeutic advances over the last several decades largely
responsible for the dramatic increase in life expectancy in CF have been aimed primarily
at decreasing the density of endobronchial Pseudomonas aeruginosa infection, thereby
reducing the local inflammatory reaction that accounts for the progressive airway
destruction characteristic of CF[91].
A proportion of CF patients are also affected by allergic bronchopulmonary aspergillosis
(ABPA). This is a disease characterized by lung hypersensitivity due to endobronchial
colonization with Aspergillus fumigatus[92]. The strains of Aspergillus have been
isolated from the sputum of more than 20% and up to 52% of CF patients[93, 94]. ABPA
is associated with an accelerated decline in lung function of CF patients[95]. The reported
prevalence of ABPA in CF patient is around 10%, which is much higher than the non-CF
population[94-96]. Many of the findings of ABPA overlap with common manifestation of
the lung disease of CF. Scedosporium apiospermum is the second-most-frequent genus of
fungi isolated from the sputa of CF patients. It exhibits a pathogenicity similar to that of
Aspergillus species[97].
Patients suffering from CF are probably at particular risk of losing the ability of the
surfactant to maintain airway potency. The disease is associated with inflammation,
which cause a leakage of plasma proteins into the airway lumen. This is a likely cause of
a disturbed function of the pulmonary surfactant[98, 99]. However, it is probably a more
important reason that surfactant dysfunction is caused by a Pseudomonas aeruginosa
infection in CF patients, in which Pseudomonas aeruginosa bacteria can synthesize and
release phospholipase C (PLC) to the lung lumen[100-104]. This enzyme can catalyze a
hydrolysis of phosphotidylcholine (PC), the main and most active surfactant component.

1.6.2 Disease Treatment
Cystic fibrosis (CF) is a multisystem disorder disease. However, pulmonary disease is the
predominant cause of morbidity and mortality. The treatment of CF is directed toward
alleviation of symptoms and correction of organ dysfunction due to disease complications.
Advances in research and medical treatments have enhanced and extended life for
children and adults with CF. Many patients with CF are expected to live into their 30s,
40s, or beyond. In 2009, the median predicted age of survival was in the mid-30s[105].
There are some standard therapies and advanced treatments for CF patients, including
restoration of airway surface liquid, mucus alteration, antimicrobial therapy, lung
transplantation, and etc.

1.6.2.1 Restoration of Airway Surface Liquid
Hydration of airway secretion offers an approach to improve mucociliary transport by
using osmotic agents. A study[106] has suggested that twice-daily inhalation of a
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hypertonic saline solution (osmotic agent) over 48 weeks has positive effects on two
important aspects (improvement of lung function and reduction in the frequency of
pulmonary exacerbations) of CF lung disease, compared to the control group of inhaled
normal saline. Moreover, the study provided the evidence of long-term efficacy in
patients with CF. In addition, mannitol, another osmotic agent, is being evaluated.
Mannitol can be administered as a dry powder by metered-dose inhaler, which offering a
less time-consuming alternative to hypertonic saline[107]. In addition, hypertonic saline
and dry-powder mannitol are also considered as non-destructive mucolytic agents[108].
These two osmotic agents hydrate the mucus matrix, breaking upon ionic and hydrogen
bonds, rather than covalent bonds, in mucous gel. Without reducing polymer chain length
in mucus matrix, these osmotic agents alter the crosslink density of mucus, decreasing the
physical entanglement. It results into a reduction in both elasticity and viscosity of mucus,
a preferential improvement in mucociliary clearance. The detailed mechanism of
action[108] is discussed in the literature. Hypertonic saline (known as MucoClearTM)[109]
has been marketed. Mannitol dry powder for inhalation (known as BronchitolTM) is in
phase III clinical trial in the US[105].

1.6.2.2 Mucolytics (Destructive)
To alter the physical properties of the viscous and rigid mucus, the direct strategy is
mucolysis (destructive). Normally, it is desirable to reduce the crosslinking and
viscoelasticity in the mucus in order to improve mucus clearance. Mucins, generally, are
secreted as heavily glycosylated peptide oligomers, holding together by –S-S- bridges
derived from unpaired cysteine units near the non-glycosylated C-terminus end of the
mucin peptide[110, 111]. Classical mucolytic, N-acetylcysteine (NAC; a thiol reducing
agent), degrades the three-dimensional network that forms the mucous gel by breaking
macromolecular backbone. Although not in the USA or Canada, NAC has been widely
used as a mucolytic agent in many countries[108]. It is suggested that there is a risk of
bronchospasm in hyper-reactive patients by using NAC.
Mucus also contains products of inflammation including cellular debris, neutrophil
derived DNA, and filamentous actin (F-actin). DNA and F-actin co-localize in mucus to
form a rigid network entangled with the mucins[112]. Dornase alfa (a recombinant
human enzyme DNase I) and gelsolin (F-actin depolymerizing agent) reduces mucus
viscosity and tenacity, leading to a reduction in frequency of pulmonary exacerbation and
an improvement in measured quality of life for CF patients[108]. At present, dornase alfa
(Pulmozyme®) is an only FDA-approved mucolytic medication in the US.

1.6.2.3 Antimicrobial Therapies
Chronic bacterial infection induces inflammation of the airways, obstructive airways
disease, and bronchiectasis. Antibiotic therapies for patients with CF have remained as a
cornerstone of treatment. Indeed, the advance in development of potent broad-spectrum
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antibiotics, particularly antipseudomonal antibiotics, impact on the increasing survival
rate of CF patient[113]. Pseudomonas aeruginosa is not able to be eradicated. However,
the burden of infection usually can be reduced by antibiotic therapy, with improvement in
symptoms and lung function[114]. Antibiotics can be administrated via oral, parenteral,
and pulmonary deliveries. The aminoglycoside (e.g., tobramycin)[115], macrolide (e.g.,
azithromycin)[116], and quinolone (e.g., ciprofloxacin)[117] antibiotic drugs are often
administrated to CF patient with improvement of pulmonary functions. Administration of
antibiotics by inhalation offers an attractive way to deliver high dose to the site of
infection. It minimizes the systemic effects which are often observed when antibiotics are
administrated in other delivery routes. For instance, the therapeutic plasma concentration
of tobramycin may cause severe ototoxicity and nephrotoxicity in a long-term
therapy[115]. Studies have shown that inhalation of antibiotics increased the therapeutic
index of the drugs[118]. The inhaled tobramycin (solution), TIP® (tobramycin inhaled
powder), azithromycin (tablet), and Cayston® (inhaled aztreonam solution) are available
on the market[105].
Allergic bronchopulmonary aspergillosis (ABPA), due to lung hypersensitivity to
Aspergillus, has been reported to occur in some CF patients. Steroids remain the mainstay
of treatment for ABPA[119]. An oral antifungal agent, itraconazole, has been reported to
be of benefit in patients when used in addition to prednisone treatment[120].

1.6.2.4 Lung Transplantation
In terms of facing of incipient death due to respiratory failure, attention has been directly
at ensuring comfort and minimizing distress of CF patients. The development of
successful lung transplantation brings a new hope for CF patient with severe respiratory
disease. Lung transplantation offers an opportunity to prolong the duration and to
significantly improve the quality of patients’ lives[121, 122]. However, Infectious,
pharmacologic, and nutritional issues inherent to CF add some complexity to the care of a
given lung transplant patients. The 5-year survival rate of lung transplantation is
48%[123, 124].

1.6.2.5 Advanced Therapies
1.6.2.5.1 Gene Therapies
Currently, an intense research effort is underway to develop more specific therapies for
CF patients. These specific therapies target the underlying pathophysiology of the disease.
The new approaches could address the underlying pathophysiological defects resulting
from the mutated CFTR at several levels[119]. Rather than only treating the symptoms,
gene therapies treat the disease by tackling the root cause of CF. The basic concept
behind gene therapies is to identify the defective gene and replace the defect with a
normal one. There are two forms of gene therapies, including germ line gene therapy
(inheritable to future generations) and somatic gene therapy (not inheritable to future
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generations)[125]. Several promising clinical trials of using virus and non-viral vectors
have been carried out, supporting gene transfer to the airway epithelium is feasible[126].
However, gene therapy studies have revealed safety and efficiency issues in gene transfer
in the lungs[127]. Additionally, it has been shown that the immune system of CF patient
posed a significant barrier, hampering the efforts of vector administration[127].

1.6.2.5.2 CFTR modulation
Unlike gene therapy which replacing defective gene, the CFTR modulation approaches
either repair the defective gene or play a role in fixing CFTR proteins. This approach is
directed at the ion transport defects in CF, including the use of amiloride and
uridine-5’-triphosphate (UTP). The approach of CFTR modulation normalizes ion
transport by inhibiting excessive sodium absorption and enhancing defective chloride
secretion[128]. Amiloride blocks the excessive sodium transport into CF airway epithelia.
UPT stimulates chloride secretion via the alternative (not the CFTR) chloride channel.
The studies have shown that inhaled amiloride[129, 130] and UTP[131, 132] improved
mucociliary clearance in healthy subjects and CF patients. Several CFTR modulation
therapies are currently in clinical trials, such as Ataluren, VX-809 + ivacaftor, VX-661 +
ivacaftor, and N6022[105]. KalydecoTM is currently in market in the US[105].

Copyright © Xiaojian Li 2014
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Chapter 2 Statement of Aims

2.1 Statement of Problem
Chronic infection diseases in the deep lungs (such as cystic fibrosis (CF), pneumonia, and
etc.) are characterized by accumulation of thick and sticky mucus, chronic lung infections,
and compromised lung surfactant composition. These multi-factored diseases, originating
in the deep lungs (respiratory bronchiolar and alveolar regions), mainly contributes to the
death of patients in the early ages. However, the unmet medical needs in the chronic deep
lungs infections are not fulfilled. This is mainly due to a lack of a multiple-component
formulation specifically targeting the deep lung regions with co-deposition of medicines
and effectively interfering several disease factors simultaneously. As a consequence,
patients with chronic infections in the deep lungs massively are under threats of
progressive pulmonary damage and respiratory failure.
This dissertation is designed to test whether the proposed multi-component dry powder
formulation for inhalation could be produced with essential particle properties suitable
for deep lung delivery. Specifically, microparticulate and nanoparticulate aerosol
particles (typically 0.5 to 2 µm) are required to have efficient particle deposition in
respiratory bronchiolar and alveolar regions by sedimentation and diffusion, respectively.
In addition, in the proposed multi-component particles, mannitol, azithromycin or
tobramycin, dipalmitoylphosphatidylcholine (DPPC):dipalmitoylphosphatidylglycerol
(DPPG)=4:1 (molar ratio) are used as (non-destructive) mucolytic agent, antimicrobial
drug, lung surfactant mimic phospholipids, respectively.

2.2 Goal of Dissertation and Specific Aims
2.2.1 Goal of Dissertation
The overall goal of this dissertation is to manufacture and characterize multi-component
inhalable microparticulate and nanoparticulate aerosol particles with essential particle
properties suitable for deep lung delivery by spray drying from organic solution.
2.2.2 Specific Aims
In order to achieve the goal of this dissertation in Section 2.2.1, there are five specific
aims for this dissertation:
1)

2)
3)
4)
5)

Produce multi-component microparticulate and nanoparticulate aerosols in
solid-state with particle properties of narrow size distribution, and spherical and
smooth surface morphologies (Chapter 3)
Characterize physicochemical properties of aerosol particles (Chapter 4)
Conduct in vitro aerosol dispersion performance of aerosol particles (Chapter 5)
Evaluate storage stability of aerosol particles (Chapter 6)
Assess in vitro drug release of aerosol particles (Chapter 7)
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2.3 Significance
It is envisioned that successful completion of this work can provide a novel and targeted
multi-component dry powder aerosol formulation for the treatment of chronic infection in
the deep lungs. The multi-component therapies in a single inhalation aerosol formulation
(co-deposition) of targeting deep lung regions could potentially enhance the therapeutic
outcome in CF treatment. Administration by multi-component formulations would likely
reduce the total dosing frequencies with a single therapy, lowering the burden of diseased
lungs and improving the quality-of-life for patients. Moreover, understanding of
physicochemical properties and pharmaceutical performance of the formulations may aid
formulation scientist in more rationally selecting the components to achieve desired
performance of multi-component dry powder formulations in future.

Copyright © Xiaojian Li 2014
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Chapter 3 Aerosol Particle Design and Manufacturing

3.1 Introduction
In order to deliver aerosol particles to the lower respiratory tract and small peripheral
airways[133], nano and microparticles (~0.5-2µm)[134-136] are required. Moreover,
with a relatively narrow (unimodel) size distribution (~0.5-2µm) of aerosol particles,
reproducibility of deposition in a specific deep lung region may be ensured.
Interparticulate forces in dry powders[64] are illustrated in Figure 3.1. Interparticulate
forces including cohesive/adhesive van der Waals, electrostatic, capillary forces, and
mechanical interlocking, impact particle interactions during aerosol dispersion[41, 63,
64]. van der Waals forces dominate interparticulate forces at low relative humidity (RH)
< 65%, while capillary forces may exhibit a major influence at RH > 65%[41]. The extent
of the forces is dependent on the particle properties (size, shape, geometry, and etc.) and
ambient conditions (humidity, electrostatics, and etc.)[41, 63, 64]. The magnitude of
interparticulate forces could be lowered by producing spherical particles with smooth
surface and low water content[63, 64]. For example, spherical particles enable one-point
contact, lowering van der Waals forces. Moreover, the curvature of particles decreases
surface charge density, leading to a drop in electrostatic forces[63, 64]. In addition,
relatively smooth surface morphology of particles could minimize the potential of
mechanical interlocking, as well as further decrease van der Waals and electrostatic
forces. Reproducibility of dosing in specific regions in lungs is a primary advantage of
spherical particles with narrow size distribution. Capillary forces, forming high tensile
liquid bridges between particles, are lowered by decreasing the condensation of water
vapor. For the purpose of flow of dissertation, water content determination will be coverd
in Chapter 4.

Figure 3.1. Illustration of interparticulate forces in static dry powder. Adapted from [64].
There are several methods available to make respirable particles, including micronization,
precipitation, supercritical fluids, and spray drying[68-70]. Spray drying (SD) is a
one-step high through-put process with the ability to produce particles in a controlled
manner, such as directing particle size and size distribution, particle shape, and particle
morphology, which are important particle features for pulmonary drug delivery by
inhalation. Co-spray drying a solution containing two APIs is a potential alternative to
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produce particles with uniform drug composition[137]. Several studies of co-spray drying
of two drugs have been reported, including inhaled corticosteroid (ICS)/short-acting
β2-agonist[138, 139], antibiotics[140, 141], terbutaline sulfate and beclomethasone
propionate[139]. Alcohols, such as methanol (which is regarded as a “green chemical”),
have lower surface tension in the range of 22 to 25 mN/m with comparison to water (72
mN/m). Due to the lower surface tension, spray drying from an alcohol solution
efficiently reduces the size of droplets during atomization and results in small particle
size of powders. Furthermore, the moisture % in the SD powders could be minimized by
employing organic solvents.
Particle morphology and surface morphology of spray-dried (SD) particles are examined
by microscopy. Scanning electron microscopy (SEM) employs electrons, instead of light,
for particle viewing by scanning a focused beam of electrons on a sample. Electrons
interact with the sample, producing secondary electrons. The secondary electrons are
collected, converted to voltage, and amplified. Depending upon the topography of the
sample, a SEM image consists of countless spots with various signal intensities. In order
to have electrically conductive, most organic substances require a thin coating of
conductive material (e.g., gold, platinum, and etc.). With a resolution better than 1
nanometer, SEM is an excellent technique to evaluate particle structure and characteristic
surface appearance of SD particles.
Laser diffraction is commonly used for the determination of particle size and distribution
of a sample. The measurement is based on the scattering light with an intensity pattern at
various angles after particles are passing through a beam of a monochromatic light laser.
An algorithm, based on Fraunhofer or Mie theory, is used to calculate particle size and
distribution from the diffraction pattern. Laser diffraction analysis yields volume-average
size and distribution in volume, based upon the theory of “equivalent spherical diameter”.
Besides the media of particle size, a series of distribution parameters from laser
diffraction could be calculated: DV10 = 10% of particles are below this size; DV50 = 50%
of particles are smaller (volumetric median diameter); DV90 = 90% of particles are below
this size. Thereafter, size distribution of samples could be expressed by span value as
below:
span value = (DV90 − DV10 )/DV50

(Equation 2.1)

The laser diffraction is conducted through a wet sampling system in this study, requiring
spray-dried particles to be dispersed in an appropriate dispersant. Occasionally, due to the
lack of an appropriate dispersant, image size analysis is used as an alternative method.
SigmaScanTM is used to determine primary particle size (projected geometric diameter)
and distribution for some particular formulations to which laser diffraction approach is
not applicable. To determine the projected geometric particle size, a line is drawn, across
the center, on a primary particle on SEM micrograph. The mean particle size (projected
mean geometric diameter) and size range are determined by measuring over 100 primary
particles to get statistically meaningful data.
In this chapter, the effects of spray-drying conditions (such as pump rate) of
one-component and multi-component systems on particles size, particle morphology and
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surface morphology of SD particles will be examined.

3.2 Materials and Methods
3.2.1 Materials
Tobramycin (TOB) (U.S.P. grade) (C18H37N5O9; MW.: 467.515 g/mol) was obtained
from Spectrum (New Brunswick, New Jersey). Azithromycin (AZI) (U.S.P. grade)
(C38H72N2O12; MW.: 748.984 g/mol) was purchased from APAC pharmaceutical LLC
(Hangzhou, China) with purity of 98%. Dipalmitoylphosphatidylcholine (DPPC)
(C40H80NO8P; MW.: 734.05g/mol) and dipalmitoylphosphatidylglycerol sodium (DPPG)
(C38H74NO10PNa; MW.: 744.96g/mol) were purchased from Avanti Polar Lipids, Inc.
(Alabaster, Alabama). D-Mannitol (MAN) (SigmaUltra) (C6H14O6; MW.: 182.17 g/mol)
was from Sigma-Aldrich (France). The chemical structures of the compounds are shown
in Figure 3.2. Methanol (HPLC grade, ACS-certified grade, purity 99.9%) was obtained
from Fisher Scientific (Fair Lawn, New Jersey). All nitrogen gas used for experiments
was an ultra-high purity (UHP) nitrogen gas manufactured by Scotts Gross (Lexington,
Kentucky). TOB and AZI were stored in the sealed glass desiccators over Indicating
Drierite/DrieriteTM desiccant at 4oC under ambient pressure. DPPC and DPPG were
stored in the sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at
-20oC under ambient pressure. MAN was stored under room conditions. All materials
were used as received.
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Figure 3.2. The chemical structures for: (a) tobramycin; (b) azithromycin; (c)
dipalmitoylphosphatidylcholine (DPPC); (d) dipalmitoylphosphatidylglycerol sodium salt
(DPPG); and (e) D-mannitol.

3.2.2 Methods
3.2.2.1 Preparation of Spray-dried (SD) Particles by Organic Solution Spray Drying
Neat organic solution spray-drying process was performed using a Büchi B-290 Mini
Spray Dryer (Büchi, Switzerland) in closed-mode. With connection to a B-295 Inert Loop
(Büchi, Switzerland), the spray dryer employed a high performance cyclone to increase
powder yield. Dry nitrogen gas (UHP) was used as the atomizing drying gas. Feeding
stock solution was made by dissolving as received material(s) to make a concentration of
0.1% w/v in methanol. Inlet temperature was set at 150oC. A stainless steel nozzle with
diameter of 0.7mm was used. Atomization rate of 600L/h and aspirate rate of 35m3/h
were used. Spray-drying pump rates varied with formulation systems: A) one-component
system: 3 ml/min (10%; low pump rate), 15 ml/min (50%; medium pump rate), and 30
ml/min (100%; high pump rate); B) multi-component system (with change of formulation
composition): 15 ml/min (50%; medium pump rate). The corresponding outlet
temperatures for each SD formulations of tobramycin and azithromycin are summarized
in Table 3.1 and Table 3.2, respectively. SD particles were separated from the nitrogen
drying air in a cyclone and collected in a sample collection vial. All SD powders were
carefully stored in sealed glass vials that were stored in sealed glass desiccators over
Indicating Drierite/DrieriteTM desiccant at -20oC under ambient pressure.
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Table 3.1. Summary of spray drying conditions of tobramcyin relevant formulations.
Formulation System
Pure TOB
TOB:MAN=1:0.1
TOB:MAN=1:0.25
TOB:MAN=1:0.5
TOB:MAN=1:0.75
TOB:MAN=1:1
TOB:PLS=1:2
TOB:PLS=1:1
TOB:PLS=1:0.5
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.25
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:0.75
TOB:PLS:MAN=1:0.5:1

Pump Rate (%)
10
50
100
50
50
50
50
50
50
50
50
50
50
50
50
50

Outlet Temperature (oC)
88
69
35
63
61
59
58
55
57
54
65
58
65
54
66
61

Table 3.2. Summary of spray drying conditions of azithromycin relevant formulations.
Formulation System
Pure AZI
AZI:MAN=1:0.1
AZI:MAN=1:0.25
AZI:MAN=1:0.5
AZI:MAN=1:0.75
AZI:MAN=1:1
AZI:PLS=1:2
AZI:PLS=1:1
AZI:PLS=1:0.5
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.25
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:0.75
AZI:PLS:MAN=1:0.5:1

Pump Rate (%)
10
50
100
50
50
50
50
50
50
50
50
50
50
50
50
50
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Outlet Temperature (oC)
89
75
50
67
66
64
65
59
66
60
59
60
68
67
66
58

3.2.2.2 Scanning Electron Microscopy (SEM)
Visualization of particle morphology (or structure) and surface morphology of samples
was achieved by using a Hitachi S-800 microscope (Tokyo, Japan). Samples were placed
on double-sided adhesive carbon tabs (TedPella, inc.) which were adhered to aluminum
stubs (TedPella, inc.) and coated with gold/palladium alloy thin film using a Hummer VI
sputtering system (Technics). The coating process operated at 10 AC milliAmperes with
8 kV of voltage for 3min. The electron beam with an accelerating voltage of 20 kV was
used at a working distance of 30mm. SEM images were captured by Evex NanoAnalysis.
Several magnification levels were used.

3.2.2.3 Particle Sizing and Size Distribution
3.2.2.3.1 Laser Light Diffraction
Particle size and size distributions of SD particles (SD pure tobramycin and SD
tobramycin:mannitol) were determined by laser diffraction using SALD-7101 (Shimadzu
Scientific Instruments, Japan). Samples were dispersed in chloroform and ultrasonicated
for 10 s in a water bath ultrasonicater Branson 5210 (Danbury, Connecticut) before
measuring particle size. Particle dispersions of samples were immediately transferred to a
measuring cell and kept stirring during measurement in the nano particle size analyzer.
Due to the use of chloroform, a refractive index 1.60-0.10 was selected for the
experiments. Volume-based dimension of particle amount distribution was obtained for
samples. DV10, DV50, and DV90 from Shimadzu software were used as particle size
characterization parameters. The span value was calculated using Equation 2.1. All
experiments were done in triplicate (n=3) for each formulation.

3.2.2.3.2 Image Size Analysis
As an alternative way to determine primary particle size and size distribution,
SigmaScanTM Pro 5 (Jandel Scientific, CA) was used due to the difficulty of samples
being dispersed in various dispersants for laser diffraction. Image size analysis was based
on SEM micrographs. Calibration of distance measurement was done on the scaling bar
on micrographs. The diameter was measured for at least 100 particles and statistical data
was calculated (mean ± S.D. & size range).
3.3 Results
3.3.1 Scanning Electron Microscopy (SEM)
3.3.1.1 One-component System (Spray-dried Pure Drug)
SEM micrographs of spray-dried (SD) pure tobramycin (TOB) and pure azithromycin
(AZI) particles[43], produced from low (10%), medium (50%), and high (100%) pump
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rates, respectively, are shown in Figure 3.3. As received particles of TOB and AZI
possessed sharp edges and particle sizes far beyond the respiratory range for dry powder
inhalation (DPI), a value less than 10µm[142]. In general, relatively spherical particle
morphology and smooth surface morphology of SD particles were produced for each
component from various pump rates. However, as shown in Figure 3.3d and 3.3h, more
corrugated surface of SD particles generated from high pump rate was also observed.
3.3.1.2 Two-component System
3.3.1.2.1 Spray-dried Drug:Mannitol
SEM micrographs of SD tobramycin:mannitol (TOB:MAN) and azithromycin:mannitol
(AZI:MAN) particles[143] are shown in Figure 3.4. Under the same spray-drying
conditions, relatively spherical particle morphology and smooth surface morphology of
SD particles were produced for each system with various composition ratios. In addition,
it was noticed that some AZI:MAN (e.g., Figure 3.4i and 3.4j) appeared to have
relatively more corrugations on surface than TOB:MAN.
3.3.1.2.2 Spray-dried Drug:Phospholipids
SEM
micrographs
of
SD
tobramycin:phospholipids
(TOB:PLS)
and
azithromycin:phospholipids (AZI:PLS) particles are shown in Figure 3.5. Relatively
spherical particle morphology and smooth surface morphology of TOB:PLS were
produced with various PLS content in the system. However, it is noticed that incomplete
particle formation was observed for AZI:PLS=1:1 (Figure 3.5e) and AZI:PLS=1:2
(Figure 3.5d). Contrastingly, relatively spherical particle morphology and smooth surface
morphology of AZI:PLS were produced at molar ratio of 1:0.5 in Figure 3.5f.

3.3.1.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
SEM micrographs of SD tobramycin:phospholipids:mannitol (TOB:PLS:MAN) and
azithromycin:phospholipids:mannitol (AZI:PLS:MAN) particles are shown in Figure 3.6.
For the three-component systems, the ratio of antibiotics:phospholipids was fixed at 1:0.5
in order to get a high antibiotic drug loading. The MAN content in three-component
formulations varied from 0.1 to 1. All TOB:PLS:MAN particles possessed relatively
spherical particle shape and smooth surface except for TOB:PLS:MAN=1:0.5:0.75
(Figure 3.6d) with incomplete particle formation. In general, regardless of
AZI:PLS:MAN=1:0.5:0.25 (Figure 3.6g) with some aggregation, AZI:PLS:MAN
particles were produced with desired particle properties of relatively spherical particle
morphology and smooth surface morphology.
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(a)

Figure 3.3. SEM micrographs of as received particles (magnification 100X) and SD pure particles (magnification 10,000X) of
tobramycin (TOB) and azithromycin (AZI)[43] for: (a) As received TOB; (b) SD pure TOB (10%P); (c) SD pure TOB (50%P);
(d) SD pure TOB (100%P); (e) As received AZI; (f) SD pure AZI (10%P); (g) SD pure AZI (50%P); and (h) SD pure AZI
(100%P).
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(a)

Figure 3.4. SEM micrographs of SD tobramycin:mannitol (TOB:MAN) and SD azithromycin:mannitol (AZI:MAN)
particles[143] (magnification 10,000X) for: (a) TOB:MAN=1:0.1; (b) TOB:MAN=1:0.25; (c) TOB:MAN=1:0.5; (d)
TOB:MAN=1:0.75; (e) TOB:MAN=1:1; (f) AZI:MAN=1:0.1; (g) AZI:MAN=1:0.25; (h) AZI:MAN=1:0.5; (i)
AZI:MAN=1:0.75; and (j) AZI:MAN=1:1.
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(a)

(d)

Figure 3.5. SEM micrographs of SD tobramycin:phospholipids (TOB:PLS) and SD azithromycin:phospholipids (AZI:PLS)
particles (magnification 10,000X) for: (a) TOB:PLS=1:2; (b) TOB:PLS=1:1; (c) TOB:PLS=1:0.5; (d) AZI:PLS=1:2; (e)
AZI:PLS=1:1; and (f) AZI:PLS=1:0.5.
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(a)

Figure 3.6. SEM micrographs of SD tobramycin:phospholipids:mannitol (TOB:PLS:MAN) and SD
azithromycin:phospholipids:mannitol (AZI:PLS:MAN) particles (magnification 10,000X) for: (a) TOB:PLS:MAN=1:0.5:0.1;
(b) TOB:PLS:MAN=1:0.5:0.25; (c) TOB:PLS:MAN=1:0.5:0.5; (d) TOB:PLS:MAN=1:0.5:0.75; (e) TOB:PLS:MAN=1:0.5:1;
(f) AZI:PLS:MAN=1:0.5:0.1; (g) AZI:PLS:MAN=1:0.5:0.25; (h) AZI:PLS:MAN=1:0.5:0.5; (i) AZI:PLS:MAN=1:0.5:0.75;
and (j) AZI:PLS:MAN=1:0.5:1.

3.3.2 Particle Sizing and Size Distribution
3.3.2.1 One-component System (Spray-dried Pure Drug)
By laser diffraction, SD pure TOB particles all exhibited a unimodal size distribution.
The detailed sizing data of SD pure TOB are summarized in Table 3.3[43]. The median
volumetric diameter (DV50) slightly increased from 0.6µm to 0.8µm for SD pure TOB as
spray-drying pump rates increased from 10% (low) to 100% (high). The DV90 of particles
was in the range from 1.1 to 1.6µm for SD pure TOB, consistent with the presence of
microsized particles. However, majority of SD pure TOB particles were under micro-size
range. Span value of SD TOB was in the range between 1.3 and 1.4, suggesting a
relatively narrow size distribution.
Image sizing analysis results of SD AZI primary particles are summarized in Table
3.4[43]. SD AZI increased projected mean geometric diameter from 0.5µm to 0.7µm as
pump rates employed in spray drying increased from low to high. With upper limit value
being equal or over 1µm (but less than 2µm), size range data suggests that SD AZI
particles possessed microsized particles. In addition, size range data also indicated a
relatively narrow size distribution for SD AZI particles.

Table 3.3. Laser diffraction sizing of SD pure tobramycin particles[43] (mean ± SD,
n=3).
SD Drug
Tobramycin

Pump Rate (%)
10
50
100

DV10(µm)
0.4±0.0
0.4±0.0
0.5±0.0

DV50(µm)
0.6±0.0
0.6±0.0
0.8±0.0

DV90(µm)
1.1±0.0
1.4±0.0
1.6±0.0

Span Value
1.3±0.0
1.4±0.1
1.4±0.0

Table 3.4. Image sizing of SD pure azithromycin primary particles[43] (mean ± SD,
n≥100).
SD Drug
Azithromycin

Pump Rate (%)
10
50
100

Particle Size (µm)
0.5±0.1
0.6±0.3
0.7±0.3

Size Range (µm)
0.2-1.0
0.3-1.9
0.2-1.8

3.3.2.2 Two-component System
3.3.2.2.1 Spray-dried Drug:Mannitol
By laser diffraction, SD TOB:MAN particles all exhibited a unimodal distribution.
Detailed data of TOB:MAN are summarized in Table 3.5[143]. Relatively consistent size
was achieved with changing of composition in TOB:MAN. The DV50 (volumetric median
diameter) was in the range from 0.6µm to 0.7µm for TOB:MAN particles. DV90 of
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TOB:MAN indicating microparticulate particles were also present in formulations. Span
value of TOB:MAN was in the range between 1.5 and 1.7, indicating a relatively narrow
size distribution.
Image sizing analysis of SD AZI:MAN primary particles are summarized in Table
3.6[143]. With the change of composition in formulations, projected mean geometric
diameter of AZI:MAN were constant at 0.6µm. Size range data indicates the presence of
micropaticulate particles and a relatively narrow size distribution for AZI:MAN.

Table 3.5. Laser diffraction sizing of SD tobramycin:mannitol particles[143] (mean ±
SD, n=3).
Particles
TOB:MAN=1:0.1
TOB:MAN=1:0.25
TOB:MAN=1:0.5
TOB:MAN=1:0.75
TOB:MAN=1:1

DV10(µm)
0.4±0.0
0.4±0.0
0.4±0.0
0.4±0.0
0.4±0.0

DV50(µm)
0.6±0.0
0.7±0.0
0.7±0.0
0.6±0.0
0.7±0.0

DV90(µm)
1.4±0.0
1.4±0.1
1.4±0.1
1.4±0.0
1.5±0.1

Span Value
1.6±0.1
1.5±0.1
1.5±0.0
1.7±0.1
1.6±0.0

Table 3.6. Image sizing of SD azithromycin:mannitol primary particles[143] (mean ±
SD, n≥100).
Formulation
AZI:MAN=1:0.1
AZI:MAN=1:0.25
AZI:MAN=1:0.5
AZI:MAN=1:0.75
AZI:MAN=1:1

Particle Size (µm)
0.6±0.2
0.6±0.2
0.6±0.2
0.6±0.2
0.6±0.2

Size Range (µm)
0.2-1.4
0.2-1.3
0.2-1.4
0.2-1.8
0.3-1.1

3.3.2.2.2 Spray-dried Drug:Phospholipids
Image size analysis of SD TOB:PLS and SD AZI:PLS primary particles are summarized
in Table 3.7. All particles possessed mean particle size in the range from 0.6 to 0.8µm. In
addition to the presence of micropaticulate particles, size range data indicated a relatively
narrow size distribution for both TOB:PLS and AZI:PLS. Due to incomplete particle
formation, size analysis of AZI:PLS=1:2 was not conducted.
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Table 3.7. Image sizing of SD drug:phospholipids primary particles (mean ± SD, n≥100).
Formulations
(molar ratio)
TOB:PLS=1:2
TOB:PLS=1:1
TOB:PLS=1:0.5
AZI:PLS=1:2
AZI:PLS=1:1
AZI:PLS=1:0.5

Particle Size (µm)

Size Range (µm)

0.7±0.2
0.7±0.2
0.7±0.3
0.8±0.2
0.6±0.2

0.4-1.2
0.3-1.4
0.3-1.6
0.4-1.4
0.3-1.5

3.3.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
Image sizing analysis of SD TOB:PLS:MAN and SD AZI:PLS:MAN primary particles
are summarized in Table 3.8. Similar projected mean particle size in the range from 0.6 to
0.7µm was observed for both TOB:PLS:MAN and AZI:PLS:MAN. Moreover, the
consistent particle size range from 0.2 to 2.1µm showed the presence of microparticulate
particles and indicated a relatively narrow size distribution for both TOB:PLS:MAN and
AZI:PLS:MAN. Due to (partially) incomplete particle formation, particle size of
TOB:PLS:MAN=1:0.5:0.75 and AZI:PLS:MAN=1:0.5:0.25 were not conducted.

Table 3.8. Image sizing of SD drug:phospholipids:mannitol primary particles (mean ±
SD, n≥100).
Formulations
(molar ratio)
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.25
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:0.75
TOB:PLS:MAN=1:0.5:1
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.25
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:0.75
AZI:PLS:MAN=1:0.5:1

Particle Size (µm)

Size Range (µm)

0.7±0.3
0.6±0.3
0.7±0.3
0.7±0.2
0.7±0.2
0.6±0.2
0.6±0.2
0.6±0.2

0.3-2.1
0.2-1.7
0.2-1.6
0.3-1.2
0.2-1.4
0.3-1.1
0.3-1.1
0.3-1.4
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3.4 Discussion
Spray drying is a continuous high through-put particle processing operation. It transforms
a liquid feed into dried particles via four stages[144]: (a) atomization of the feed solution
into droplets; (b) droplets-air contact; (c) drying of the droplets; and (d) separation of the
dried product from air stream. It has been suggested that spray-drying conditions (such as
nozzle size, aspirator rate, airflow rate, inlet temperature, concentration of feeding
solution, solvent type and etc.) would have potential influence on particle size. Our
research group has previous optimized the spray-drying conditions[145] for producing
nanoparticulate and microparticulate dry powder aerosol particles as pulmonary drug
delivery for the deep lung delivery. Effects of pump rate and formulation composition on
particle size, particle morphology, and surface morphology of spray-dried particles were
examined in this chapter.
3.4.1 Pump Rate Effect
The pump rate effect was studied on one-component formulations including SD pure
tobramycin (TOB) and pure azithromycin (AZI). It appears that the pump rates resulted
in slightly increased (medium volumetric or projected geometric mean) particle size, but
generated relatively constant size distribution of nanoparticulate and microparticulate
particles. In addition, relative spherical particle morphology was generated for SD TOB
and SD AZI with various pump rates. However, as pump rate changed from low to high,
the particle surface morphology was altered to be relatively more corrugated as shown in
Figure 3.3d and 3.3h. It is suggested that larger droplets could be produced from high
pump rate during atomization[75]. Consequently, given that the use of dilution
concentration of feeding solution and high evaporation rate of organic solvent, the solid
shells of larger particles were potentially subject to collapse on surface during drying
process. Alternatively, it is reported[146, 147] that an increase in particle surface
roughness could be achieved by reducing the viscosity of the feed. However, it is also
observed[73, 74] that smaller particles are generated by using liquid with higher viscosity
and faster feeding rate. It is speculated that this was caused by the generation of a larger
back-pressure in a nozzle, producing a finer spray due to an increase in sheer during
atomization.
3.4.2 Formulation Composition Effect
In general, at studied formulation compositions, the two-component and three-component
systems were successfully produced with desired particle properties (such as nano and
microsized particles with relatively narrow size distribution; relative spherical particle
morphology and smooth surface morphology). It is reasonable to expect that the
spray-dried particles exhibited similar particle size and size distribution, since a same
total powder concentration in solvent was used in this study. The particles with undesired
particle properties were also observed for some formulations such as AZI:PLS=1:2
(Figure 3.5d), AZI:PLS=1:1 (Figure 3.5e), TOB:PLS:MAN=1:0.5:0.75 (Figure 3.6d), and
AZI:PLS:MAN=1:0.5:0.25 (Figure 3.6g). As to be discussed in detail in aerosol
dispersion chapter, the partial particle aggregation of AZI:PLS=1:2 and 1:1 formulations
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may correlate with outlet temperature of spray drying (To) and main phase transition
temperature of phospholipid bilayer (Tm). As a consequence, AZI:PLS=1:2 and 1:1
exhibited an worse aerosol dispersion performance in terms of mass median
aerodynamic diameter (MMAD) compared to AZI:PLS=1:0.5 with desired particle
properties (as shown inTable 5.6 in Chapter 5). In sum, it is believed that particle surface
component(s) that undergoes phase transition during both in spray drying and storage
plays a critical role in facilitating particle aggregation. Liao YH et al reported[148] that
the surface morphology of spray-dried stabilized lysozyme particles was independent in
excipient composition. However, the volume median diameter of the powders exhibited a
dependence upon the amount of excipients. The proposed possible mechanism(s) for
formation of spray-dried particles leading to resultant aerosol dispersion performance will
be elaborated in Chapter 5.

3.5 Conclusions
Nanoparticulate and microparticulate aerosol particles with desired particle properties
necessary for deep lung penetration by pulmonary delivery were successfully designed
and produced from dilute organic solution by spray drying. Under optimized spray-drying
conditions, pump rate may possibly be used to effectively tailor (volume medium or
projected geometric mean) particle size of formulations. With change of formulation
composition, relatively constant particle properties of spray-dried particles were obtained
after spray drying. However, the detailed explanation on some (partially) incomplete
particle formations by change formulation composition still remained unexplored.

Portions of Chapter 3 were reproduced with kind permission from: Li, X, Vogt, F.G.,
Hayes, D. Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol
Dispersion Performance of Organic Solution Advanced
Spray Dried
Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and
Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of
Pharmaceutical Sciences, 2014, 15:191-205. Copyright © 2014 Elsevier.
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Chapter 4 Physicochemical Characterization

4.1 Introduction
Spray-dried powders are examined in terms of particle size and size distribution, particle
morphology, and particle surface morphology. There are, however, a number of
important physicochemical properties[41] of aerosol particles that have an impact on the
dispersibility in aerosolization and stability of aerosol particles intended for pulmonary
delivery. They include crystallinity and polymorphism, solid-state phase transition, water
content and vapor sorption, and chemical spectroscopy of component in particles.
In general, pharmaceutical solid compounds are divided into crystalline and amorphous
materials. Crystalline materials present structure units that are repeated in a regular
manner and form a well-defined lattice[63]. Therefore, it possesses long-range molecular
order. The crystalline materials could form a variety of polymorphs[149, 150] and
pseudo-polymorphs[151]. Polymorphism describes the ability of a crystalline substance
to exhibit different lattice structures and/or molecular conformations. Polymorphs,
exhibiting various particle shape, solubility, and water content and hygroscopicity, may
have an impact on particle aggregation, through mechanical interlocking, electrostatic
charge, and capillary force[41, 63]. Pseudo-polymorphs refer to crystalline hydrate and
solvates, having bound water and organic solvent molecules, respectively[63]. Unlike
crystalline state, amorphous phase of a material lacks long-range molecular packing,
present in metastable state. Therefore, it possesses a relatively higher solubility and
molecular mobility, but a less stability over pharmaceutically relevant time scales[63].
Crystallinity is the degree of crystalline phase in a solid. Crystallinity of particles has an
impact on the nature of powder mixing and aggregation through energetic forces (e.g.,
cohesion and adhesion)[41]. In addition, it has an influence on stability of solid-state
formulations. Crystallinity of dry powder for inhalation, a main indicative of physical
stability affecting aerosol dispersion performance, needs to be studied. Crystallinity and
polymorphism of powder are commonly examined by x-ray powder diffraction (XRPD).
Atoms or molecules in a crystalline material scatter x-ray beams into many specific
directions. In some of the directions, the scattered beams are completely in phase and
reinforce into diffracted beams. As defined by Bragg’s law[152] (Equation 4.1),
diffraction of a x-ray beam is incident on crystalline planes, satisfying the Bragg’s law
equation:
𝑛𝜆 = 2𝑑 sin 𝜃

(Equation 4.1)

Where n is any integer, λ is the wavelength of the beam, d is the spacing between
diffracting planes, and θ is the incident angle. In general, XRPD pattern of a crystalline
sample shows a series of intensive peaks measured at different incident angles. No peak
is observed for an amorphous sample in its XRPD pattern as an amorphous sample lacks
long-range molecular range.
A solid particle may undergo several phase transitions when heated[63]. In general, a
crystalline solid could melt upon heating from a solid to a liquid. This is a first-order
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thermodynamic phase transition. Upon heating, an amorphous (non-crystalline) solid
would possibly exhibit a characteristic reversible transition from the glassy state to the
rubbery state with a step change in heat capacity. The temperature at which glassy state
converts to rubbery state for an amorphous solid is defined as the glass transition
temperature (Tg). This is a second-order phase transition. Rubbery state of a solid may
further exhibit an exothermic crystallization or/and a melting the crystallized form with
heating. A glassy state (low molecular mobility) of an amorphous solid is usually
preferred than rubbery state (high molecular mobility) since physical/chemical reactivity
and stability are minimized[153]. To understand thermal-induced phase transition(s) of
aerosol dry powder is important, especially for a non-crystalline formulation.
Understanding the thermal-induced phase transitions of particles, especially for surface
component leading to solid bridge, is necessary for dry powder for inhalation.
Differential scanning calorimetry (DSC) is a frequently used technique to monitor phase
transition of a solid associated with heat transfer. In principle, it measures the heat flow
difference between a sample pan and an empty pan in order to keep them at the sample
temperature.
Capillary forces take place as water moisture interacts with solid surface. Capillary forces
cause formation of liquid bridge between particles by vapor condensation due to lowering
of the LaPlace pressure which occurs between particles. Aerosol dispersion performance
can be lowered as the result of the presence of liquid bridge between particles. In addition,
water molecules act as a plasticizer in amorphous solids by lowering Tg. Low Tg of dry
powder could trigger the potential physical and chemical instabilities. The equilibrium
moisture content at ambient temperature and relative humidity is suggested to be a good
indicator of the suitability of aerosol product[41]. Therefore, water content of powder
needs to be assessed for dry powder formulations. Coulometric titration is commonly
employed to determine water content of powder. Determination of water content based
on a quantitative reaction of water (H2O) with iodine (I2), sulfur dioxide (SO2), alcohol
(ROH; e.g. methanol), and an organic base (B; e.g. imidazole) as shown in Equation
4.2[154]:
SO2 + ROH + B → RSO3- + HB+
H2O + I2 + RSO3- + 2B → RSO4- + 2HB+ + 2I-------------------------------------------------------------------------------------

(Equation 4.2)

H2O + ROH + SO2 + I2 + 3B → RSO4- + 3HB+ + 2I-

Water content of sample is determined by measuring the quantity of electric current
required for production of I2 by electrolysis of iodine ions in reagent.
Hygroscopicity is an intrinsic nature of a material with tendency to take up moisture from
surrounding environment. Hygroscopic material suffers a great risk of physical and
chemical instability. Hygroscopic aerosols are susceptible to hygroscopic growth
resulting in larger particles in aerosolization[41]. In addition, moisture uptaking and
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losing over a narrow range of relative humidity (RH) could result in local dissolution and
recrystallization. This leads to an irreversible aggregation through formation of solid
bridge, which adversely affects aerosol dispersion and lung deposition.[41, 155-157]
Thus, it is essential to examine water vapor sorption of aerosol particles. Gravimetric
water vapor sorption (GVS) is used to study equilibrium water content of aerosol
particles at a series of RH %. The weight change of particle due to moisture uptake and
loss is monitored by an integrated microbalance in GVS as exposed to increment of
RH %. Regarding to metastable materials (e.g. amorphous), the lyotropic-induced phase
transition would possibly be detected[43, 145, 158]. As similar to thermal-induced phase
transition, the lyotropic-induced phase transition would also have an adverse effect on
aerosol performance.
Component homogeneity in powder necessarily needs to be characterized for
multi-component aerosol particles. An indication of heterogeneity of powder has an
impact on physical stability of molecularly mixed particles. Confocal Raman microscopy
(CRM) has demonstrated an utility in the non-invasive and non-destructive
microspectroscopic analysis of aerosol formulations as described in detail in the
studies[159, 160]. Confocal Raman microscopy (CRM) and spectroscopy provides
chemical imaging and mapping of particles[160]. These functions can reveal component
homogeneity for molecularly mixed particles. Raman spectroscopy is a spectroscopic
technique used to observe vibrational, rotational, and other low-frequency modes in a
system. A laser light (in visible, near infrared, or near ultraviolet range) interacts with
molecular vibrations, photons, or other excitations in system. It results in the energy of
the laser photons shifts up or down. The shift in energy usually reveals information on the
vibrational modes in a system. Infrared spectroscopy yields similar, but complementary,
information to Raman spectroscopy. Both Raman and infrared spectroscopies are capable
of probing molecular conformation, degree of molecular order, and polymorphic system.
In the following sections, the physicochemical properties of crystallinity and
polymorphism, solid-state phase transition (thermal analysis), water content and vapor
sorption, and chemical spectroscopy of component of spray-dried aerosol particles are
described.

4.2 Materials and Methods
4.2.1 Materials
The spray-dried (SD) particles selected for physicochemical characterization are listed in
Table 4.1. TOB, AZI, MAN, and PLS stand for tobramycin, azithromycin, mannitol, and
phospholipids, respectively. All the studied particles were generated employing a 50%
pump rate in spray drying. All SD powders were carefully stored in sealed glass vials that
were stored in sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at
-20oC under ambient pressure for up to one week. The outlet temperatures of SD particles
are referred to Table 3.1 and Table 3.2 in Chapter 3.
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Table 4.1. SD particles for physicochemical characterization.
Formulation System
One-component

Two-component

Three-component

SD TOB formulations
(molar ratio)
Pure TOB
TOB:MAN=1:0.1
TOB:MAN=1:0.25
TOB:MAN=1:0.5
TOB:MAN=1:1
TOB:PLS=1:0.5
TOB:PLS=1:1
TOB:PLS=1:2
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:1

SD AZI formulations
(molar ratio)
Pure AZI
AZI:MAN=1:0.1
AZI:MAN=1:0.25
AZI:MAN=1:0.5
AZI:MAN=1:1
AZI:PLS=1:0.5
AZI:PLS=1:1
AZI:PLS=1:2
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:1

4.2.2 Methods
4.2.2.1 Crystallinity and Polymorphism
X-ray powder diffraction (XRPD) patterns of samples were collected with a Rigaku x-ray
diffractometer (Japan) with Cu Kα radiation (40kV, 44mA, and λ = 1.5406Å) between
5.0 – 60.0º (2θ) using a scan rate of 2.00o/min at ambient temperature as
reported[161-164]. Samples were placed on a quartz plate in an aluminum sample holder
without further grinding. Only one experiment was done for each formulation in this
study.
4.2.2.2 Solid-State Phase Transition
Thermal properties of samples were measured using a TA Q200 differential scanning
calorimetry (DSC; TA Instruments, New Castle, DE, USA) equipped with T-Zero®
technology and an automated computer-controlled RSC-90 cooling accessory as
reported[161-164]. Approximate 3mg of samples was packed into hermetic anodized
aluminum T-Zero® DSC pan. It was then hermetically sealed with the Tzero hermetic
sealer (TA Instruments, New Castle, DE, USA) unless otherwise specified. An empty
hermetically sealed aluminum pan was used as a reference pan. Experiments were
conducted under both hermetic and non-hermetic conditions. In hermetic conditions,
hermetically sealed sample pan and reference pan were used. Whereas in non-hermetic
conditions, both pin-holed sample pan and reference pan were used. The non-hermetic
DSC conditions will be specially mentioned in this chapter if necessary. The use of
non-hermetic conditions allowed the release of moisture from samples, minimizing
moisture effect on thermal events. Ultra-high purity (UHP) nitrogen was used as a
purging gas at a rate of 50 ml/min. Sample was heated from 10-200oC at a scanning rate
of 5.00oC/min. The onset temperature of main phase transition (Tm) was reported for
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phospholipid-containing powders. Detailed report methods are referred to Section 4.3.2.
All experiments were done in triplicate (n=3).
4.2.2.3 Water Content
Water content of powders was assessed by Karl Fischer (KF) coulometric titration. The
measurements were performed with a 737 KF Coulometer coupled with 703 Ti Stand
(Metrohm Ltd., Antwerp, Belgium) as reported[161-164]. Approximately 6 to 7mg of
sample was dissolved in AQUA STAR methanol using a 5mL volumetric. The solution
was injected into reaction cell filled with HYDRANAL KF reagent. After obtaining the
reading from KF coulometer, the water content of sample was obtained from simple
calculation. The experiments were done in triplicate (n=3).
4.2.2.4 Water Vapor Sorption
Water vapor sorption isotherms of powders were measured gravimetrically using an
automated microelectronic balance coupled to a computerized VTI SGA-CX symmetric
vapor sorption analyzer (Hialeah, Florida) as previously reported[161, 162, 164, 165]. All
measurements were taken at 25oC using a sample size of ～1.0 to 1.5mg. Samples were
subjected to pre-drying treatment at 25oC under 0% relative humidity (RH) (nitrogen gas
purging) for up to a maximum of 7h with equilibrium criterion of weight change less than
or equal to 0.0001% in 10min interval. At the end of the pre-drying cycle, the samples
were exposed to a sequence of increasing RH with increment of 5% RH on each step,
which started at 5% RH until 95% RH. The criterion used to establish equilibrium during
sorption was a weight change of less than or equal to 0.03% in 10min interval for up to
3h. The data point was acquired at every 2min or 0.01% weight change. Standby
temperature was set at 25oC.
4.2.2.5 Chemical Spectroscopy
4.2.2.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging and
Mapping
Using conditions previously reported[160, 166], dispersive Raman spectra and mapping
images of samples were obtained using an Aramis confocal Raman spectrometer and
fluorescence microscope system (Horiba Jobin Yvon, Edison, NJ, USA). The system was
equipped with an Olympus BX41 confocal optical microscope, an Olympus U-LH 100W
Hg lamp, and a U-RFL-T power source used for fluorescence excitation and brightfield
illumination (Olympus America, Inc., Chester Valley, PA). Filters were used to achieve
fluorescence excitation in the range of 330-385nm, with emission observed using a
425nm cutoff filter. Neutral density filters were used to adjust fluorescence intensity.
Raman spectra were obtained using both a 785nm diode laser and a 633nm HeNe laser.
Raman spectral maps were obtained using either a 10x or 50x objective with the stage
moved in increments of 5 to 10µm. Each map point was acquired using 32 to 128
accumulations each with 2s of detector exposure time. A confocal hole of 500µm with a
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grating of 600-900 grooves/mm and a slit width of 100µm were used. Spectra were
subjected to baseline correction and smoothing prior to further analysis.
4.2.2.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy
A Varian FTS-7000e attenuated total reflectance-Fourier transform infrared spectrometer
(ATR-FTIR; Varian Inc., CA) equipped with a DTGS detector and a PIKE MIRacle ATR
ZnSe accessory was used. Each spectrum was collected for 32 scans at a spectral
resolution of 8cm-1 over the wavelength number range of 4,000-700cm-1. A background
spectrum was done under the same experimental conditions. Spectral data were acquired
with Varian Resolutions Pro software.
4.3 Results
4.3.1 Crystallinity and Polymorphism
4.3.1.1 One-component System (Spray-dried Pure Drug)
X-ray powder diffraction (XRPD) pattern in Figure 4.1a indicates as received tobramycin
(TOB) was partially crystalline as the peaks were broad and not well-defined.[43] As
shown in Figure 4.1b, as received azithromycin (AZI) appeared to be in crystalline phase
with intensive peaks[43]. Both SD pure TOB (Figure 4.1a) and SD pure AZI (Figure 4.1b)
particles lacked their characteristic crystalline peaks[43]. The data indicated SD pure
TOB and SD pure AZI lost long-range molecular order compared to the corresponding as
received material.

(a)
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(b)
Figure 4.1. X-ray powder diffractograms for: (a) SD pure and as received tobramycin
particles (offset by 4000 counts); and (b) SD pure and as received azithromycin particles
(offset by 7000 counts)[43].

4.3.1.2 Two-component System
4.3.1.2.1 Spray-dried Drug:Mannitol
The XRPD patterns suggest that SD tobramycin:mannitol (TOB:MAN) (Figure 4.2a) and
azithromycin:mannitol (AZI:MAN) (Figure 4.2b) were lacking of long-range molecular
order as the characteristic peaks of crystalline phase were not observed[143]. Apparently,
at the studied molar ratios, MAN component exhibited no effect on XRPD patterns for
both TOB:MAN and AZI:MAN.
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(a)

(b)
Figure 4.2. X-ray powder diffraction patterns for: (a) SD tobramycin:mannitol
formulations (offset by 500 counts between patterns); and (b) SD azithromycin:mannitol
formulations (offset by 500 counts between patterns for the bottom four; offset by 1000
counts between patterns for the top two)[143].
4.3.1.2.2 Spray-dried Drug:Phospholipids
As shown on XRPD patterns of SD tobramycin:phospholipids (TOB:PLS) in Figure 4.3a,
intensive characteristic peak of phospholipid bilayer structure at ~20-23o of 2 theta was
observed with various molar ratios of PLS. In addition, the characteristic peak of
47

phospholipid bilayer structure of SD azithromycin:phospholipids (AZI:PLS) on XRPD
patterns was observed in Figure 4.3b. In comparison, the peak intensity of phospholipid
bilayer structure from AZI:PLS was lower than TOB:PLS at same molar ratio of PLS.
The crystalline peaks of TOB and AZI were not observed in any TOB:PLS and AZI:PLS
samples.

(a)

(b)
Figure 4.3. X-ray powder diffraction patterns for: (a) SD tobramycin:phospholipids
formulations (offset by 500 counts between patterns); and (b) SD
azithromycin:phospholipids formulations (offset by 500 counts between patterns).
48

4.3.1.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
With the incorporation of MAN, SD tobramycin:phospholipids:mannitol
(TOB:PLS:MAN) in Figure 4.4a and SD azithromycin:phospholipids:mannitol
(AZI:PLS:MAN) in Figure 4.4b exhibited a similar characteristic of XRPD patterns to
the corresponding TOB:PLS=1:0.5 and AZI:PLS=1:0.5. Phospholipid bilayer structure
was retained for both TOB:PLS:MAN and AZI:PLS:MAN. The characteristic crystalline
peaks from other components (e.g., TOB/AZI and MAN (Appendix A)) were not
observed.

(a)
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(b)
Figure
4.4.
X-ray
powder
diffraction
patterns
for:
(a)
SD
tobramycin:phospholipids:mannitol formulations (offset by 500 counts between patterns);
and (b) SD azithromycin:phospholipids:mannitol formulations (offset by 500 counts
between patterns).

4.3.2 Solid-State Phase Transition
In order to present clear differential scanning calorimetry (DSC) data, a scheme for a
typical glass transition of a drug and a main phase transition of phospholipid bilayer in
spray-dried (SD) particles is shown in Figure 4.5. The two phase transitions result in an
increased molecular mobility of the corresponding component. Glass transition is a
second-order phase transition with a step change in heat capacity that an amorphous
phase of drug component undergoes from the glassy state to rubbery state. The glass
transition temperature (Tg) is the mid-point temperature at which glass transition takes
place. The main phase transition of phospholipid bilayer is the first-order thermodynamic
process that phospholipid bilayer changes from the gel phase (low degree of molecular
mobility) to liquid crystalline phase (high degree of molecular mobility). The ΔHm and
Tm are defined as the adjusted enthalpy change and the onset temperature of main phase
transition of phospholipid bilayer. The ΔHm data in this dissertation is adjusted to the
weight of phospholipids in a particular phospholipid containing formulation. Due to some
baseline shift on thermograms and for purpose of consistent reporting, the peak
tempertures are used to define the temperatures for other phase transitions.
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Figure 4.5. Schematic of a typical glass transition of drug and a main phase transition of
phospholipid bilayer in the spray-dried powder.

4.3.2.1 One-component System (Spray-dried Pure Drug)
Differential scanning calorimetry (DSC) thermograms of TOB and AZI one-component
powders[43] are shown in Figure 4.6. As received TOB (Figure 4.6a) exhibited three
major endotherms at temperatures of ~ 146oC, 156oC and 200oC, respectively. As
expected, there was no glass transition observed for as received TOB. As shown Figure
4.6b, SD pure TOB showed a glass transition at ~ 50oC and a major endotherm peak at ~
158oC.
Only a single endothermic peak was observed at ~ 137oC for as received AZI (Figure
4.6c). Thermogram of SD pure AZI is shown in Figure 4.6d. An evident glass transition
was present at ~ 94oC for SD pure AZI. The glass transition was followed by an
endotherm at temperature range between 160oC and 170oC for SD pure AZI.
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(a)

(b)

(c)

(d)

Figure 4.6. DSC thermograms for: (a) as received tobramycin; (b) SD pure tobramycin;
(c) as received azithromycin; (d) SD pure azithromycin.[43]

4.3.2.2 Two-component System
4.3.2.2.1 Spray-dried Drug:Mannitol
SD TOB:MAN (Figure 4.7) exhibited three phase transitions[143]. A glass transition was
observed at temperature range between ~ 42oC and 69oC. It was followed by a small
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endotherm at temperature around from 95oC to 96oC. The last phase transition with base
line shift took place at ~ 169oC to 180oC. The detailed glass transition temperatures (Tg)
of SD TOB:MAN were presented in Table 4.2[143].
SD AZI:MAN (Figure 4.8) showed two different thermograms as molar ratio of MAN
increased from 1:0.1 to 1:1[143]. SD AZI:MAN with molar ratios of 1:0.1, 1:0.25, and
1:0.75 presented similar characteristic thermograms. SD AZI:MAN=1:0.5 and 1:1
exhibited similar thermal events with more complication than the formulations with other
molar ratios. Glass transitions were observed for all SD AZI:MAN. DSC thermograms
from non-hermetic conditions (Figure 4.9) revealed a similarity for AZI:MAN=1:0.1 and
1:0.75, and AZI:MAN=1:0.5 and 1:1, respectively. Interestingly, AZI:MAN=1:0.25
(Figure 4.9b) exhibited a characteristic thermogram under non-hermetic conditions. The
detailed glass transition temperatures (Tg) of SD AZI:MAN from hermetic DSC studies
were presented in Table 4.2[143].
Table 4.2. Glass transition temperatures for SD tobramycin:mannitol and SD
azithromycin:mannitol[143] (mean ± SD, n=3).
Molar Ratio
1:0.1
1:0.25
1:0.5
1:0.75
1:1

Glass Transition Temperature (oC)
TOB:MAN
AZI:MAN
69.2±0.2
92.9±0.5
66.5±0.2
93.7±0.5
59.4±0.9
94.9±0.0
55.2±0.9
94.0±0.2
41.7±0.4
93.8±0.6
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Figure 4.7. DSC thermograms for: (a) tobramycin:mannitol=1:0.1; (b) tobramycin:mannitol=1:0.25;
tobramycin:mannitol=1:0.5; (d) tobramycin:mannitol=1:0.75; and (e) tobramycin:mannitol=1:1[143].
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Figure 4.8. DSC thermograms for: (a) azithromycin:mannitol=1:0.1; (b) azithromycin:mannitol=1:0.25;
azithromycin:mannitol=1:0.5; (d) azithromycin:mannitol=1:0.75; and (e) azithromycin:mannitol=1:1[143].
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Figure 4.9. DSC thermograms (non-hermetic) for: (a) azithromycin:mannitol=1:0.1; (b) azithromycin:mannitol=1:0.25; (c)
azithromycin:mannitol=1:0.5; (d) azithromycin:mannitol=1:0.75; and (e) azithromycin:mannitol=1:1[143].

4.3.2.2.2 Spray-dried Drug:Phospholipids
DSC thermograms of TOB:PLS (Figure 4.10a-c) exhibited four phase transitions,
including a glass transition of TOB[43], a main phase transition of phospholipid
bilayer[167], a exothermic crystallization transition, and an endothermic melting. As
shown in DSC thermograms (Figure 4.10d-e), AZI:PLS mainly showed three phase
transitions. It included a main phase transition of phospholipid bilayer, a glass
transition of AZI[43], and one endothermic melting peak. The detailed DSC data of
the formulations are summarized in Table 4.3.

Table 4.3. Summary of glass transition temperature (Tg), main phase transition
temperature of phospholipid bilayer (Tm), adjusted enthalpy of main phase transition
of phospholipid bilayer (ΔHm), crystallization temperature (Tc), and melting
temperature (Tm1) for SD tobramycin:phospholipids (TOB:PLS) and SD
azithromyin:phospholipids (AZI:PLS) formulations in DSC (mean ± SD, n=3).
Formulations
(molar ratio)
1:2
TOB:PLS 1:1
1:0.5
1:2
AZI:PLS 1:1
1:0.5

Tg (oC)

Tm (oC)

ΔHm (J/g)

Tc (oC)

Tm1 (oC)

32.6 ± 0.9
37.7 ± 1.1
41.9 ± 2.4
77.9 ± 0.9
79.9 ± 0.2
76.6 ± 0.6

61.9 ± 0.4
62.6 ± 1.0
66.4 ± 0.1
61.2 ± 0.2
61.5 ± 0.1
60.4 ± 0.1

36.6 ± 2.8
34.7 ± 1.8
27.9 ± 0.9
29.1 ± 0.2
22.9 ± 0.3
7.6 ± 0.1

143.1 ± 0.8
141.0 ± 1.0
152.2 ± 1.1
-

149.4 ± 2.2
147.4 ± 1.5
156.2 ± 1.9
159.2 ± 5.3
158.8 ± 7.8
163.3 ± 2.8
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Figure 4.10. DSC thermograms of SD drug:phospholipids formulations for: (a)
tobramycin:phospholipids=1:2;
(b)
tobramycin:phospholipids=1:1;
(c)
tobramycin:phospholipids=1:0.5;
(d)
azithromycin:phospholipids=1:2;
(e)
azithromycin:phospholipids=1:1; and (f) azithromycin:phospholipids=1:0.5.
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4.3.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
DSC thermograms of TOB:PLS:MAN and AZI:PLS:MAN are shown in Figure 4.11
and Figure 4.12, respectively. In Figure 4.11a-c, a glass transition of TOB, a main
phase transition of phospholipid bilayer, and one endothermic melting peak were
observed for TOB:PLS:MAN=1:0.5:0.1, 1:0.5:0.25, and 1:0.5:0.5. Additionally, a
possible phase transition from lamellar to hexagonal of PLS (after main phase
transition of phospholipid bilayer)[167] and an exothermic crystallization peak
(before endothermic melting peak) were observed for TOB:PLS:MAN=1:0.5:0.75
(Figure 4.11d) and 1:0.5:1 (Figure 4.11e).
Similarly, AZI:PLS:MAN exhibited a main phase transition of phospholipid bilayer, a
glass transition of AZI and one or two endothermic melting peak(s) depending on
amount of MAN in the formulations. As shown in Figure 4.12a-c, one endothermic
peak was observed for AZI:PLS:MAN with molar ratios from 1:0.5:0.1 to 1:0.5:0.5.
However, additional endothermic peak was present for AZI:PLS:MAN=1:0.5:0.75
(Figure 4.12d) and 1:0.5:1 (Figure 4.12e). Table 4.4 summarizes the detailed DSC
data for TOB:PLS:MAN and AZI:PLS:MAN.
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Formulations
1:0.5:0.1
1:0.5:0.25
TOB:PLS:MAN 1:0.5:0.5
1:0.5:0.75
1:0.5:1
Formulations
1:0.5:0.1
1:0.5:0.25
AZI:PLS:MAN 1:0.5:0.5
1:0.5:0.75
1:0.5:1

Tg (oC)
37.2 ± 1.2
43.1 ± 0.1
37.0 ± 1.5
44.1 ± 0.2
43.6 ± 0.1
Tg (oC)
80.4 ± 0.4
84.2 ± 0.6
84.6 ± 0.8
83.5 ± 1.3
76.7 ± 0.1

Tm (oC)
63.8 ± 0.1
61.2 ± 0.2
59.9 ± 0.0
57.6 ± 0.1
55.8 ± 0.1
Tm (oC)
55.7 ± 0.1
50.5 ± 0.1
44.2 ± 0.1
44.0 ± 0.2
42.2 ± 0.2

ΔHm (J/g)
30.6 ± 0.2
28.7 ± 0.9
39.8 ± 0.8
38.9 ± 1.8
42.1 ± 1.0
Hm (J/g)
7.7 ± 0.4
4.8 ± 0.1
7.1 ± 0.6
11.7 ± 1.7
12.2 ± 0.3

Tc (oC)
156.1 ± 0.6
158.7 ± 0.3
Tm1 (oC)
142.4 ± 1.0
147.1 ± 0.4

Tm1 (oC)
156.9 ± 3.9
163.7 ± 3.3
160.4 ± 3.5
160.8 ± 1.3
169.4 ± 1.2
Tm2 (oC)
161.7 ± 2.3
158.7 ± 2.7
162.3 ± 5.4
157.3 ± 3.0
161.3 ± 4.9
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Table 4.4. Summary of glass transition temperature (Tg), main phase transition temperature of phospholipid bilayer (Tm), adjusted enthalpy of
main phase transition of phospholipid bilayer (ΔHm), crystallization temperature (Tc), and melting temperature (Tm1 and Tm2) for
tobramycin:phospholipids:mannitol and azithromycin:phospholipids:mannitol in DSC (mean ± SD, n=3).
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Figure 4.11. DSC thermograms of SD tobramycin three-components formulations for:
(a)
tobramycin:phospholipids:mannitol=1:0.5:0.1;
(b)
tobramycin:phospholipids:mannitol=1:0.5:0.25;
(c)
tobramycin:phospholipids:mannitol=1:0.5:0.5;
(d)
tobramycin:phospholipids:mannitol=1:0.5:0.75;
and
(e)
tobramycin:phospholipids:mannitol=1:0.5:1.
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Figure 4.12. DSC thermograms of SD azithromycin three-components formulations
for:
(a)
azithromycin:phospholipids:mannitol=1:0.5:0.1;
(b)
azithromycin:phospholipids:mannitol=1:0.5:0.25;
(c)
azithromycin:phospholipids:mannitol=1:0.5:0.5;
(d)
azithromycin:phospholipids:mannitol=1:0.5:0.75;
and
(e)
azithromycin:phospholipids:mannitol=1:0.5:1.
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4.3.3 Water Content
The water content of all formulations (as received drugs and spray-dried powders) is
listed in Table 4.5. SD powders exhibited water content less than 7% except for
TOB:PLS:MAN=1:0.5:0.25 with 11%.

4.3.3.1 One-component System (Spray-dried Pure Drug)
Theoretically, the monohydrate, dihydrate, and trihydrate crystalline forms of
TOB[168] contain 3.7, 7.1, and 10.3% (w/w) water, respectively. KF data shows as
received TOB contained 7.47±0.18% (w/w)[43]. It suggests as received TOB was
possibly present as a dihydrate with some moisture sorbed[43]. Monohydrate and
dihydrate of AZI[169] possess 2.29% and 4.58% (w/w) water, respectively.
As-received AZI was possibly present in dihydrate rich as supported by water content
of 4.35±0.14% (w/w)[43]. Compared to the corresponding crystalline material,
residual water content of SD pure TOB and SD pure AZI powders was lower after
spray drying.

4.3.3.2 Two-component System
4.3.3.2.1 Spray-dried Drug:Mannitol
As expected, the incorporation of non-hygroscopic MAN[170] lowered water content
of TOB:MAN from 3.54% (w/w) to 0.41% (w/w) as increasing MAN from 1:0.1 to
1:1[143]. A similar descending trend was observed for AZI:MAN with an increase in
amount of MAN from 1:0.1 to 1:0.25[143]. However, water content of AZI:MAN
increased as MAN further increased from 1:0.25 to 1:1[143].
4.3.3.2.2 Spray-dried Drug:Phospholipids
PLS showed an molar ratio effect on water content of TOB:PLS and AZI:PLS. With
molar ratios of 1:2 and 1:1, the water content of TOB:PLS and AZI:PLS was
approximately from 5% to 7%. However, it was significantly reduced down to < 2%
in the formulations of 1:0.5.

4.3.3.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
A notable water content of 11% was observed for the TOB:PLS:MAN=1:0.5:0.25
formulation. It is unclear as to why such high water content was observed.
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Tobramycin
Formulations
As received TOB
SD pure TOB
TOB:MAN=1:0.1
TOB:MAN=1:0.25
TOB:MAN=1:0.5
TOB:MAN=1:0.75
TOB:MAN=1:1
TOB:PLS=1:2
TOB:PLS=1:1
TOB:PLS=1:0.5
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.25
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:0.75
TOB:PLS:MAN=1:0.5:1

Water Content
(% w/w)
7.47±0.18
5.24±0.12
3.54±0.23
2.79±0.87
2.21±0.45
0.89±0.18
0.41±0.17
6.35±1.53
6.84±0.90
1.53±0.26
3.15±0.41
11.00±0.86
3.38±0.39
4.10±0.43
4.55±0.25

Azithromycin
Formulations
As received AZI
SD pure AZI
AZI:MAN=1:0.1
AZI:MAN=1:0.25
AZI:MAN=1:0.5
AZI:MAN=1:0.75
AZI:MAN=1:1
AZI:PLS=1:2
AZI:PLS=1:1
AZI:PLS=1:0.5
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.25
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:0.75
AZI:PLS:MAN=1:0.5:1

Water Content
(% w/w)
4.35±0.14
1.30±0.21
2.67±0.66
0.24±0.05
0.50±0.14
1.50±0.52
2.25±0.54
4.92±1.11
6.21±1.05
1.42±0.72
2.47±0.45
5.20±0.74
4.57±0.63
3.28±0.38
4.43±0.84
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Table 4.5. Water content for tobramycin and azithromycin formulations[43, 143] (mean ± SD, n=3).

4.3.4 Water Vapor Sorption
4.3.4.1 One-component System (Spray-dried Pure Drug)
Equilibrated water vapor sorption isotherms at 25oC of as received TOB and AZI[43]
with corresponding SD samples are plotted in Figure 4.13. Overall, TOB powders
exhibited a higher water vapor sorption than AZI.
As-received TOB slowly increased weight with RH %, exhibiting ~ 22% weight
change at 95% RH. Water vapor isotherm was more complex for SD TOB. SD TOB
took up relatively higher water vapor (than as received TOB) until 60% RH, reaching
a ~ 20% weight increase. Thereafter, weight change of SD TOB started to drop to ~
12% at 65% RH and reached a plateau until 75% RH. The decrease in weight (at 65%
RH) may be due to lyotropic-induced crystallization transition with expulsion of free
water[145, 158, 171]. At the end of the study, a 65% weight increase was observed
for SD pure TOB. As-received AZI gained approximately 4% weight. SD pure AZI
gained 5% weight by 95% RH[43].

Figure 4.13. Water vapor sorption isotherms at 25oC for as received vs SD
powders[43] (weight change % vs RH; n=1).

4.3.4.2 Two-component System
4.3.4.2.1 Spray-dried Drug:Mannitol
Equilibrated water vapor sorption isotherms of SD TOB:MAN=1:0.5 and
AZI:MAN=1:0.5[143] are plotted in Figure 4.14. Overall, TOB:MAN=1:0.5 took up
more water vapor than AZI:MAN=1:0.5. TOB:MAN=1:0.5 gradually sorbed water
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vapor until 65% RH, followed by a drop in weight (possibly lyotropic-induced
crystallization transition) at 70% RH. A plateau region from 70% to 80% RH was
observed, followed by a sharp increase of weight after 85% RH. Weight change of
TOB:MAN=1:0.5 increased up to ~117% at 95% RH. As similar to the water vapor
sorption isotherm of SD AZI, AZI:MAN=1:0.5 exhibited a slight increase in weight
up to ~32% at 95% RH without any evident phase transition, remaining in an
amorphous state[143].

Figure 4.14. Water vapor sorption isotherms at 25oC for SD
tobramycin:mannitol=1:0.5 and SD azithromycin:mannitol=1:0.5[143] (weight
change % vs RH; n=1).
4.3.4.2.2 Spray-dried Drug:Phospholipids
Equilibrated water vapor sorption isotherms of SD TOB:PLS=1:0.5 and
AZI:PLS=1:0.5 are plotted in Figure 4.15. The profiles were similar to the
corresponding TOB:MAN=1:0.5 and AZI:MAN=1:0.5, respectively. TOB:PLS=1:0.5
gradually took up water vapor until 65% RH. It was followed by a drop in weight
(possibly lyotropic-induced crystallization transition) at 70% RH. A sharp increase in
weight change was observed after 75% RH. The weight change of TOB:PLS=1:0.5
was ~ 57% at 95% RH. As expected, AZI:PLS=1:0.5 slightly increased weight up to
~13% at 95% RH.
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Figure 4.15. Water vapor sorption isotherms at 25oC for SD
tobramycin:phospholipids=1:0.5 and SD azithromycin:phospholipids=1:0.5 (weight
change % vs RH; n=1).
4.3.4.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
Equilibrated water vapor sorption isotherms of SD TOB:PLS:MAN=1:0.5:0.5 and
AZI:PLS:MAN=1:0.5:0.5 are plotted in Figure 4.16. The profiles were similar to the
corresponding drug:mannitol or drug:phospholipids formulation, respectively.
TOB:PLS:MAN=1:0.5:0.5 gradually took up water vapor until 65% RH. It was
followed by a possibly lyotropic-induced crystallization transition with a drop in
weight change at 70% RH. A sharp increase of weight was observed after 75% RH.
Weight change of TOB:PLS:MAN=1:0.5:0.5 was up to ~71% at 95% RH. As
expected, weight change of AZI:PLS:MAN=1:0.5:0.5 slightly increased ~15% at 95%
RH.
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Figure 4.16. Water vapor sorption isotherms at 25oC for
tobramycin:phospholipids:mannitol=1:0.5:0.5
and
azithromycin:phospholipids:mannitol=1:0.5:0.5 (weight change % vs RH; n=1).

SD
SD

4.3.5 Chemical Spectroscopy
4.3.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging
and Mapping
4.3.5.1.1 One-component System (Spray-dried Pure Drug)
Confocal Raman microscopy and spectroscopy (CRM) analysis of SD pure TOB
particles[43] is shown in Figure 4.17. In Figure 4.17a, a typical spectrum taken via
CRM at the point indicated on the images in Figure 4.17b and Figure 4.17c is shown
in comparison to as received TOB used as input. The Raman spectra in Figure 4.17a
were obtained using a 785 nm laser to minimize the effects of fluorescence. However,
to the author’s knowledge, it is not clear yet why TOB emitted fluorescence, since no
double or triple bond(s) is present in the chemical structure. The broad vibrational
bands in the SD TOB were characteristic of an amorphous substance. Raman spectra
taken from several SD particles by CRM were indistinguishable, indicating no
heterogeneity in powder, from the spectrum in Figure 4.17a[43].
A similar result was obtained from the CRM analysis of SD AZI[43] as shown in
Figure 4.18. Although AZI showed weaker fluorescence than TOB in the amorphous
state, a spectrum was again taken via CRM using the 785 nm laser to avoid
fluorescence. Spectra taken by CRM across many particles of SD AZI were
indistinguishable, suggesting that the particles were uniformly amorphous[43].
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Figure 4.17. (a). Raman spectrum of SD pure tobramycin compared to that of as
received tobramycin obtained using CRM; (b). Brightfield micrograph of SD pure
tobramycin obtained using a 10x objective; and (c). Fluorescene micrograph of SD
pure tobramycin obtained using a 10x objective. The red points show the location at
which the SD spectrum in (a) was obtained[43]. Courtesy of Dr. Frederick Vogt at
GlaxoSmithKline.
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Figure 4.18. (a). Raman spectrum of SD pure azithromycin compared to that of as
received azithromycin obtained using CRM; (b). Brightfield micrograph of SD pure
azithromycin obtained using a 10x objective; and (c). Fluorescene micrograph of SD
pure azithromycin obtained using a 10x objective. The red points show the location at
which the SD spectrum in (a) was obtained[43]. Courtesy of Dr. Frederick Vogt at
GlaxoSmithKline.
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4.3.5.1.2 Two-component System
4.3.5.1.3 Spray-dried Drug:Mannitol
CRM analysis was performed for TOB:MAN=1:0.5 particles to investigate the
physical form and homogeneity of TOB and MAN in SD particles[143]. Amorphous
SD pure TOB was previously observed to show significant fluorescence, necessitating
the use of a near-infrared laser wavelength (785 nm) for Raman spectroscopy of these
materials. In Figure 4.19a, a brightfield micrograph obtained with a 10x objective is
shown for a region of SD TOB:MAN=1:0.5 particles. Superimposed on this image is
a 25 × 25 CRM map, with greater blue intensity indicating stronger Raman signal
from 1425 to 1480 cm-1, a characteristic region for TOB. The CRM map indicates that
the TOB was homogeneously distributed, with the only area of reduced signal
corresponding to a depression in the particle surface seen primarily on the upper left
portion of the mapped region. A fluorescence microscopy image of the particles,
shown in Figure 4.19b, also showed no indication of heterogeneity. In Figure 4.19c, a
comparison is shown between three representative Raman spectra obtained from the
map in Figure 4.19a and reference spectra of SD pure TOB and alpha polymorphic
form of MAN. The three representative spectra taken from TOB:MAN=1:0.5 particles
were similar, showing no evidence of heterogeneity. There was no evidence of
crystalline alpha MAN present in the spectra of SD particles. In addition, the broad
vibrational bands observed were in good agreement with amorphous TOB[143].
SD pure AZI was previously observed to show less fluorescence than SD pure TOB.
When spray dried with MAN, it was found that a higher-sensitivity Raman laser
utilizing a shorter wavelength (633 nm) could be used for analysis of
AZI:MAN=1:0.5 particles. In Figure 4.20, the CRM results are shown for
AZI:MAN=1:0.5 particles using a 50x objective. In Figure 4.20a, a 25 × 25 CRM
map is shown using a set of bands in the 845 to 900 cm-1 region (characteristic of
alpha MAN). The distribution was seen to be relatively homogenous. This map can be
compared with a map shown in Figure 4.20b where increasing red color
corresponding to increasing intensity of Raman bands in the 1470 to 1550 cm-1
(characteristic of SD pure AZI). The two maps generally agreed, suggesting that
components of MAN and AZI were closely associated, and did not show any
indication of heterogeneity between the two components at the high magnification
used here. Spectra (Figure 4.20c) taken from three regions supported this conclusion.
In addition, it also suggests that the MAN in the SD particles may possibly be
amorphous[143].
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Figure 4.19. (a) Brightfield micrograph of SD tobramycin:mannitol=1:0.5 particles
obtained using a 10x objective. CRM mapping was performed in the region marked
with the red box; increasing blue color corresponds to increasing intensity of Raman
signal in the 1425 to 1480 cm-1 region. (b) Fluorescene micrograph of the same region.
(c) Raman spectra from three points obtained using CRM, shown in comparison to SD
pure tobramycin and alpha mannitol prepared as pure materials[143]. Courtesy of Dr.
Frederick Vogt at GlaxoSmithKline.
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Figure 4.20. (a) Brightfield micrograph of SD azithromycin:mannitol=1:0.5 particles
obtained using a 50x objective. CRM mapping was performed in the region marked
with the red box; increasing blue color corresponds to increasing intensity of Raman
signal in the 845 to 900 cm-1 region. (b) CRM mapping results with increasing red
color corresponding to increasing intensity of Raman signal in the 1670 to 1750 cm-1
region. (c) Raman spectra from three points obtained using CRM, shown in
comparison to SD pure azithromycin and alpha mannitol prepared as pure
materials[143]. Courtesy of Dr. Frederick Vogt at GlaxoSmithKline.
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4.3.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy
4.3.5.2.1 One-component System (Spray-dried Pure Drug)
Attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR)
spectra of TOB[43] (Figure 4.21a and Figure 4.21b (zoomed in data)) and AZI[43]
(Figure 4.21c) indicated a loss of the peak at ~3500 cm-1 after spray drying, although
the as received TOB did not show an strong spectrum possibly due to poor contact
with ATR crystal. This peak may be tentatively assigned to O-H stretching vibration
mode in the particles. Instead, the SD pure TOB and AZI particles exhibited a broad
band at region of ~3600-3000 cm-1. In comparison to as received sample, the SD pure
AZI showed additional spectral differences at band region of ~1400 to 1100 cm-1.
This band region may be tentatively assigned to C-O stretching[43].

(a)

(b)
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(c)
Figure 4.21. ATR-FTIR spectra of: (a) SD pure and as received tobramycin particles
(full scan range); (b) SD pure and as received azithromycin particles (zoomed in
spectra from (a)); and (c) SD pure and as received azithromycin particles (full scan
range)[43].

4.3.5.2.2 Two-component System
4.3.5.2.3 Spray-dried Drug:Mannitol
ATR-FTIR spectra of TOB:MAN[143] (Figure 4.22a) and AZI:MAN[143] (Figure
4.22b) showed similar spectra to the corresponding SD pure TOB and AZI. No
significant peak shift was observed in the binary systems. Similar to spectrum of SD
pure AZI, AZI:MAN=1:0.5 and AZI:MAN=1:1 showed a slight spectral difference at
band of ~1100 cm-1 to the other compositions. In addition, a broad peak at band
region of ~3600-3100 cm-1, possibly reflecting water molecules in samples, was
observed in AZI:MAN=1:0.5 and AZI:MAN=1:1. This data may possibly suggest that
water molecules could be present with AZI component. Therefore, it would possibly
facilitate the conversion of AZI component (in AZI:MAN=1:0.5 and AZI:MAN=1:1)
to a hydrate form. However, as water content data (Table 4.5) being considered, it is
unclear why the two formulations exhibited differently to other formulations[143].
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(a)

(b)
Figure 4.22. ATR-FTIR spectra for: (a) SD tobramycin:mannitol formulations; and
(b) SD azithromycin:mannitol formulations[143].
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4.4 Discussion
4.4.1 Crystallinity and Polymorphism
As shown, XRPD diffractograms indicates that both SD pure drug (Figure 4.1) and
SD drug:mannitol (Figure 4.2) were lacking of long-range molecular order after spray
drying. XRPD diffractograms of SD drug:phospholipids (Figure 4.3) and SD
drug:phospholipids:mannitol (Figure 4.4) particles showed that phospholipid bilayer
structure was retained after spray drying. However, the other component(s) in
drug:phospholipids and drug:phospholipids:mannitol was/were lacking long-range
molecular order.
The presence of amorphous character in SD dry powder particles may lead to the
physical and chemical instabilities. Therefore, stability tests are of importance to
study the effect of storage conditions on SD dry powder formulations. Besides the
chemical stability issue, the physical change that can occur in powders upon storage is
expected to adversely alter the aerosol dispersion performance.

4.4.2 Solid-State Phase Transition
Understanding the thermal-induced phase transition(s) is important for a
non-crystalline formulation intended for dry powder inhalation. Phase transitions that
result in particle aggregation or solid-state bridging between particles may lead to the
failure of powder delivery to the deep lungs. Therefore, solid-state phase transition of
formulations, especially dry powders for inhalation is of importance.
4.4.2.1 One-component System (Spray-dried Pure Drug)
Before our work[43], the thermogram of as received TOB in hermetically sealed DSC
pan has not been reported in the scientific literature. However, it has been done under
non-hermetic conditions[168]. As mentioned earlier, commercially available
crystalline TOB consists of stoichiometric hydrate forms of monohydrate, dihydrate,
and trihydrate[168]. Compared to thermograms of TOB published previously, it
indicates the first endothermic peak at ~146oC (in Figure 4.6a) may correspond to the
dehydration of as received TOB dihydrate. As-received TOB presented as a dihydrate
form was possibly supported by KF titration (Table 4.5) and thermogravimetric
analysis (TGA) data (Figure 4.23a) with ~ 7.5% weight (water) loss when heated to
150oC. The TGA was conducted in a pin-holed pan with a scan rate as 5oC/min. The
dehydration was likely followed by the melting of a metastable anhydrous form at
~156oC, and the possible melting of stable anhydrous TOB occurred at ~200oC. In
thermal analysis from hermetically sealed DSC pan (Figure 4.6a), the formation of
stable anhydrous from the melt by an exothermic crystallization (at the temperature
range between ~156oC and 200oC) was not detected. However, the crystallization
process was confirmed by hot stage microscopy (HSM) under cross-polarizer (Figure
4.24) at ~217oC[43]. HSM study was conducted at 5oC/min. The temperature
difference between DSC and HSM was due to open-air conditions in HSM study. The
endothermic events at 158oC in the thermograms of SD pure TOB are suggested to be
the melting of metastable anhydrous form. However, XRPD diffractogram (Figure
4.1a) exhibited no crystalline peaks from SD pure TOB with some possible extent of
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anhydrous form (or even short-rang molecular order) due to the limitation of detection.
Therefore, it may suggest that SD pure TOB from spray drying was amorphous-phase
rich.

(a)
Sample: SD azithromycin 50%P
Size: 1.2370 mg

TGA

File: C:...\SD azithromycin 50%P.002
Operator: xiaojian
Run Date: 10-Sep-2010 15:00
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(b)
Figure 4.23. Thermogravimetric analysis for: (a) as received tobramycin; and (b) SD
pure azithromycin.
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Figure 4.24. HSM micrographs of as received tobramycin[43].
As suggested by KF data (Table 4.5), as received AZI was possibly in the dihydrate
form. The endothermic peak (Figure 4.6c) at 137oC is suggested to correspond to the
concurrent events of dehydration and melting of as received AZI[169]. The
endotherm at temperature from 160 to170oC from SD pure AZI (Figure 4.6d) was
possibly the melting of low amount of metastable AZI anhydrate (or short-range
molecular order of AZI). This conclusion was supported by TGA data (Figure 4.23b)
since there was no weight change at the temperature range of 160 to 170oC.

4.4.2.2 Two-component System
4.4.2.2.1 Spray-dried Drug:Mannitol
The order-to-disorder phase transition (endothermic event) of TOB:MAN (Figure 4.7)
was observed and slightly influenced with temperature shift by the molar ratio of
incorporated MAN. However, the existence of long-range molecular order of TOB
and MAN in TOB:MAN system after spray drying was not suggested by XRPD in
Figure 4.2a.
Both hermetic and non-hermetic DSC conditions were studied for AZI:MAN. In
hermetic DSC conditions, equilibrium in thermal event is established in a fast manner.
However, non-hermetic conditions allow the release of moisture from samples,
minimizing moisture effect on thermal events. In Figure 4.8, DSC thermograms under
hermetic conditions of AZI:MAN=1:0.1, 1:0.25 and 1:0.75, and AZI:MAN=1:0.5 and
1:1 exhibited similar thermal events, respectively. Under non-hermetic conditions,
only the AZI:MAN=1:0.25 exhibited unique behavior (Figure 4.9b). In non-hermetic
DSC studies, thermograms of AZI:MAN=1:0.1 (Figure 4.9a) and 1:0.75 (Figure 4.9d)
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were similar to SD pure AZI (Figure 4.25). This data may suggest that the MAN
component was probably present in amorphous phase. Similar to the discussion of SD
pure AZI (in Section 4.4.2.1), a possible low amount of metastable AZI anhydrate (or
short-range molecular order of AZI) may be present in AZI:MAN=1:0.1 and 1:0.75.
In non-hermetic DSC studies, the two endothermic transition peaks in
AZI:MAN=1:0.25 (Figure 4.9b) appeared consistent with the melting of delta and
beta forms of MAN, respectively. Hulse, et al observed similar thermograms for the
formulation of MAN with protein by co-spray drying[172]. As shown in Figure 4.9b,
the beta form of MAN may result from the small exothermic event (crystallization)
after the melting of the delta form. The possible melting of beta MAN was observed
at 165oC. The thermograms of both formulations AZI:MAN=1:0.5 (Figure 4.9c) and
AZI:MAN=1:1 (Figure 4.9e) exhibited a small endothermic peak at around 60oC. This
endothermic peak could possibly be the melting/dehydration of a MAN hydrate
form[173], although this hypothesis was not supported by XRPD data possibly due to
the detection limit.

Figure 4.25. DSC thermogram (non-hermetic) of SD pure azithromycin.

4.4.2.2.2 Spray-dried Drug:Phospholipids
Glass transition temperatures (Tgs) of the drugs in phospholipid incorporated
two-component formulations (in Table 4.3) were lowered as compared to the SD pure
drugs (~50oC for SD pure TOB and ~94oC for SD pure AZI, respectively). The
short-range molecular order of TOB component in TOB:PLS may possibly crystallize
at ~141-152oC as indicated by an exothermic peak. The crystallized TOB melted at
~147-156oC. As to AZI:PLS, a possible endothermic peak of AZI was observed
without showing an evident exothermic crystallization. It is believed that either a
crystallization of AZI was possibly not detected under such DSC conditions or an
endothermic peak could be a melting of the AZI component.
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Based on the weight fraction of the components, the adjusted values of main phase
transition of phospholipid bilayer (ΔHm) were presented in Table 4.3. The values of
ΔHm in phospholipid containing formulations may represent the tight packing of
phospholipid bilayer structure in particles. The values of ΔHm from TOB:PLS were
relatively constant (between 27.94J/g and 36.63J/g). Overall, AZI:PLS exhibited a
lower value of ΔHm than TOB:PLS at same molar ratio. Noticeably, ΔHm values were
relatively higher for AZI:PLS=1:2 (29.11J/g) and AZI:PLS=1:1 (22.86J/g), compared
to AZI:PLS=1:0.5 (7.58J/g). This result may indicate that the phospholipid bilayer
structures, in AZI:PLS=1:2 and 1:1, were well organized. AZI molecules have been
reported to bind to phospholipids molecules and interfere with interfacial and
hydrophobic parts of fully hydrated phospholipid bilayer[174]. Therefore, with water
molecules associated in spray-dried particles (Table 4.5), it is expected that AZI
molecules could interact with phospholipid molecules, possibly altering the
organization of bilayer structure. Therefore, compared to TOB formulations, a higher
reduction in integrity of phospholipid bilayer may be expected for AZI:PLS as a
function of ratio composition, resulting in a lower value of ΔHm.

4.4.2.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
Glass transition temperatures (Tgs) of the drugs in three-component formulations were
lowered compared to the SD pure drugs (~50oC for SD pure TOB and ~94oC for SD
pure AZI, respectively). In addition to the main phase transition of phospholipid
bilayer, an endothermic melting peak was observed for TOB:PLS:MAN=1:0.5:0.1,
1:0.5:0.25, and 1:0.5:0.5 in Figure 4.11a-c. It could possibly be the melting of either
TOB or MAN, or simply the co-melting of TOB and MAN since the two components
exhibit very close melting points[43, 44]. In TOB:PLS:MAN=1:0.5:0.75 and 1:0.5:1
(Figure 4.11d and 4.11e), TOB and MAN components may possibly crystallize,
resulting in one melting peak. There was one (MAN content from 0.1 to 0.5 in the
composition ratio) or two (MAN content from 0.75 to 1 in the composition ratio)
melting peaks present in formulations in AZI:PLS:MAN (Figure 4.12). The additional
endothermic peak at ~142-147oC (at relatively lower temperature) was possibly the
melting of a thermodynamically metastable polymorph of MAN such as the delta
form[175]. Similar to TOB:PLS:MAN, the endothermic melting peak at ~ 157-161oC
in AZI:PLS:MAN could possibly be the melting of either AZI or MAN, or simply
the co-melting of MAN and AZI components.
As expected, adjusted enthalpy (ΔHm) values of main phase transition of phospholipid
bilayer for TOB:PLS:MAN were higher than AZI:PLS:MAN at various molar ratios.
Interestingly, it appeared that the molar ratio of 1:0.5:0.25 and 1:0.5:1 for both
formulation systems resulted in lowest and highest ΔHm, respectively. These two
specific molar ratios in each drug formulation may possibly indicate the lowest and
highest integrity of phospholipid bilayer structure under studied molar ratios,
respectively.
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4.4.3 Water Content
Water content of a solid formulation is not only related to chemical degradation, but
also has an impact on aerosol dispersion performance by formation of liquid bridge.
For dry powder inhalation formulations, low water content is essential in order to
minimize capillary forces between particles.
In general, water content of final spray-dried powders was dependent on material
properties and composition of components in particles. As shown in Table 4.5, water
content of spray-dried pure drug was lowered by removing water molecules in as
received material after spray drying from organic solution. The incorporation of
non-hydroscopic MAN into drug:MAN and PLS with high water affinity into
drug:PLS resulted into water content of < 4% and < 7%, respectively. Water content
in three component drug:PLS:MAN generally was < 6% except for
TOB:PLS:MAN=1:0.5:0.25 (~ 11% water content). This exception was possibly, in
part, due to the hygroscopic nature of TOB[176].
In order to compare the water content from the worst case scenario where water is not
removed by spray drying with the value obtained by KF, the calculation for
theoretical values were conducted. It is assumed that water moisture is only from
methanol solvent and as-received materials. Another assumption is that all the
moisture is evenly distributed to the powder regardless of particle size. The water
content of methanol is 0.01%. As-received TOB, AZI, MAN, DPPC and DPPG
possessed water content of 7.47%, 4.35%, 0.53%, 3.76%, and 3.21%, respectively.
The concentration of powder in methanol is 0.1%. The calculated values for KF are
listed in Table 4.6. It is concluded that all calculated values are higher than the
measured, possibly supporting that the spray drying process from organic solution
does remove water under these studied spray-drying conditions.
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Tobramycin
Formulations
SD pure TOB
TOB:MAN=1:0.1
TOB:MAN=1:0.25
TOB:MAN=1:0.5
TOB:MAN=1:0.75
TOB:MAN=1:1
TOB:PLS=1:2
TOB:PLS=1:1
TOB:PLS=1:0.5
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.25
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:0.75
TOB:PLS:MAN=1:0.5:1

Water Content
(% w/w)
14.26
14.02
13.69
13.21
12.80
12.46
11.57
12.09
12.95
12.59
12.45
12.22
12.02
11.83

Tobramycin
Formulations
SD pure AZI
AZI:MAN=1:0.1
AZI:MAN=1:0.25
AZI:MAN=1:0.5
AZI:MAN=1:0.75
AZI:MAN=1:1
AZI:PLS=1:2
AZI:PLS=1:1
AZI:PLS=1:0.5
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.25
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:0.75
AZI:PLS:MAN=1:0.5:1

Water Content
(% w/w)
11.37
11.28
11.17
10.98
10.82
10.68
10.94
11.05
11.15
11.10
11.02
10.90
10.79
10.69
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Table 4.6. Calculated water content for tobramycin and azithromycin formulations (mean ± SD, n=3).

4.4.4 Water Vapor Sorption
Water vapor sorption isotherms indicate the amount of water vapor uptake at
individual RH %, providing potential practical storage guidance on dry powders for
inhalation. Water vapor sorption data could also reveal any possible lyotropic-induced
phase transition, impeding aerosol dispersion performance. As compared to SD pure
TOB, the relatively smaller weight drop during possible lyotropic-induced
crystallization in SD TOB two-component and three-component powders was due to
either a lower TOB component loading or an incompletion of the phase transition in
the powders. The large amount of water vapor uptaken by the particles at high RH %
(i.e. above 80% RH) suggests a possible dissolution process[177]. Overall, due to the
hygroscopic nature, TOB formulations exhibited water vapor sorption to a higher
extent compared to AZI formulations, especially at high RH %.

4.4.4.1 One-component System (Spray-dried Pure Drug)
The stoichiometric plots of mole water vapor sorbed per mole dry compound vs
relative humidity[43] (Figure 4.26), translated from water vapor sorption data (Figure
4.13), could provide insightful molecular information. No evidence suggested that the
“pre-dried” as-received TOB (possibly in dihydrate; thermodynamic stable) lost
H-bonding water molecules. As-received TOB showed no evident lyotropic-induced
phase transition. However, the SD pure TOB (possibly amorphous rich) underwent a
lyotropic-induced phase transition to a more organized physical form. Without
showing a glass transition, DSC data (Figure 4.27) suggest that SD pure TOB after
water vapor sorption was possibly present as a hydrate or a mixture of hydrates. It
showed two sharp endothermic peaks similar to the dehydration events from
as-received TOB (Figure 4.6a). Possibly due to the high amount of sorbed free water
vapor, approximately 4 water molecules were associated with SD TOB at 65% RH, as
shown in Figure 4.26. In addition, SD TOB took up higher amount of water vapor at
95% RH than as received TOB possibly due to a larger surface area.
As-received AZI decreased weight by approximately 3.5% (shown as blue curve in
Figure 4.28), indicating a loss of H-bonding water molecules during the pre-drying
process at 0% RH. Upon exposure to water vapor, “pre-dried” as-received AZI gained
approximately 1.5 water molecules per molecule and maintained this molecular ratio
constant across the whole RH %. This may indirectly indicate as-received AZI was
possibly dihydrate rich, which was in agreement with KF data (Table 4.5). However,
SD pure AZI took up water vapor slowly and eventually reached ~2 molecules of
water per molecule of AZI at 95% RH.
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Figure 4.26. Water vapor sorption isotherms at 25oC for as received vs SD powders
(water vapor sorbed/dry compound mole/mole vs RH; n=1)[43].

85

Sample: SD tobramycin 50%p VTI(37C)
Size: 1.2500 mg

DSC

File: C:...\SD tobramycin 50%p VTI(37C).001
Operator: xiaojian
Run Date: 21-Sep-2010 22:09
Instrument: DSC Q200 V24.2 Build 107
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Figure 4.27. DSC thermograms of SD pure tobramycin after completion of water
vapor sorption study.

Figure 4.28. An experimental summary graph of water vapor sorption isotherms at
25oC for as received AZI.
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4.4.4.2 Two-component System
4.4.4.2.1 Spray-dried Drug:Mannitol
As similar to SD pure TOB, a possible lyotropic-induced crystallization was observed
for TOB in TOB:MAN=1:0.5. However, the phase transition shifted from 65% RH
(SD pure TOB) to 70% RH (TOB:MAN=1:0.5). There was no evident phase
transition observed for AZI:MAN=1:0.5.
4.4.4.2.2 Spray-dried Drug:Phospholipids
As similar to SD pure TOB, a possible lyotropic-induced crystallization was observed
for TOB in TOB:PLS at 70% RH. No evident lyotropic-induced phase transition was
observed for AZI:PLS.
4.4.4.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
With incorporation of MAN to drug:PLS, drug:PLS:MAN exhibited similar water
vapor sorption profiles to the corresponding drug:PLS.
4.4.5 Chemical Spectroscopy
Uniformity in physical form for and homogeneity of multi-component systems are
essential for physical stability or even drug content uniformity of SD dry powder
formulations. Therefore, Confocal Raman microscopy (CRM) with non-invasive and
non-destructive analysis is employed to examine the SD powders. Infrared
spectroscopy yields similar, but complementary, information to Raman spectroscopy.
It probes the degree of molecular order and polymorphic system.
4.4.5.1 Confocal Raman Microscopy and Spectroscopy for Chemical Imaging
and Mapping
CRM analysis of SD pure TOB (Figure 4.17) and SD pure AZI (Figure 4.18) particles
showed no sign of heterogeneity in physical form. The data suggest there was no
presence of any crystalline phase in SD powder. Therefore, it may be consistent with
the hypothesis put forth in the DSC studies that SD pure drug was amorphous rich. As
to TOB:MAN=1:0.5 (Figure 4.19) and AZI:MAN=1:0.5 (Figure 4.20) particles, CRM
analysis suggested no evidence of heterogeneity between the two components in SD
binary mixture.
4.4.5.2 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy
FTIR data may suggest that the crystal structure was absent in SD pure TOB (Figure
4.21a and 4.21b) and SD pure AZI (Figure 4.21c) as the vibration of several chemical
bonds (TOB: O-H stretching; AZI: O-H and C-O stretching) changed after spray
drying. This is in agreement with XRPD and DSC data.
Shown in FTIR data (Figure 4.22), no significant interaction between antibiotic drug
and MAN is suggested as peak shifts were not observed. In addition, although CRM
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analysis suggested no evidence of heterogeneity, FTIR data indicated that
AZI:MAN=1:0.5 and 1:1 may possibly possess relatively more characteristic of
crystalline AZI than other molar ratios. The unique characteristic was also supported
by DSC data.

4.5 Conclusions
Physicochemical properties of spray-dried powders were characterized by a variety of
techniques. In general, the spray-dried powders without incorporation of
phospholipids were lacking of long-range molecular order or exhibited as an
amorphous solid. With incorporation of phospholipids, the spray-dried powders
retained phospholipid bilayer structure. However, the extent of phospholipid bilayer
structure was mainly dependent on the antibiotic drug in formulations. The other
component(s) in phospholipids-incorporated formulations were lacking in long-range
molecular order or exhibited as amorphous solid. The majority of spray-dried powders
showed low water content. In contrast to spray-dried azithromycin formulations, the
lyotropic-induced phase transition in spray-dried tobramycin formulation may
indicate a physical stability or even potential chemical stability issue and aerosol
dispersion at high relative humidity conditions. Overall, no evident sign of
heterogeneity and presence of significant amount of crystalline phase in spray-dried
pure drug and drug:mannitol were observed by chemical spectroscopy.

Portions of Chapter 4 were reproduced with kind permission from: Li, X, Vogt, F.G.,
Hayes, D. Jr., and Mansour, H.M. Physicochemical Characterization and Aerosol
Dispersion Performance of Organic Solution Advanced Spray Dried
Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and
Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of
Pharmaceutical Sciences, 2014, 15:191-205. Copyright © 2014 Elsevier.

Copyright © Xiaojian Li 2014
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Chapter 5 in vitro Aerosol Dispersion

5.1 Introduction
Inertial impactors have been employed to characterize pharmaceutical aerosol
formulations for several decades. The results of inertial impactors often correlate with
particle deposition within the human lungs. Several apparatuses are documented in the
European and United States Pharmacopoeias (USP), such as twin-stage liquid
impinger (TSLI), Anderson cascade impactor (ACI), and the next generation impactor
(NGI). The principle of inertial impaction for aerodynamic sizing is based on the
aerodynamic behavior of aerosol particles, as shown by a cascade inertial impactor in
Figure 5.1. When the direction of an air flow changes, the entrained particles in air
continue to move in the original direction of flow until they lose inertia as a result of
friction with air[5]. A plate is placed to collect particles in the path of the original
direction of air flow. The larger particles impact the plate, while the smaller particles
relax into a new direction of flow without being collected. With well-defined design
and geometry of each impactor or impinge, the collection efficiency on each
collection stage is dependent on air flow rate and dry powder inhaler (DPI) device
employed.

Figure 5.1. Schematic representation of the principle of inertial impaction for cascade
inertial impactors. Adapted from [178].
In the present study, the NGI is employed for in vitro aerosol dispersion performance
of spray-dried (SD) particles. As reported, it has been extensively utilized for
pulmonary aerosol formulations[179, 180]. The design and assembly of the NGI is
shown in Figure 5.2. The induction port (Figure 5.2a) is used to connect the impactor
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to a DPI inhaler. The pre-separator (Figure 5.2a) connects between the induction port
and the impactor. When necessary, with dry powder inhalers (DPIs), a pre-separator
can be added to avoid overloading the first stage and is used with lactose carrier DPI
systems. In addition, a suitable mouthpiece adapter is used to provide an airtight seal
between the DPI inhaler and the induction port.[178] The NGI is designed with seven
stages and a micro-orifice collector (MOC) as shown in Figure 5.2b. It is stated that
“over the design flow rate range of 30 to 100 L/minute, the 50% efficiency
aerodynamic cutoff diameters of the stages (D50 values) range between 0.24µm to
11.7µm, evenly spaced on a logarithmic scale”[178]. Several removable impaction
cups (Figure 5.2b) are placed in one plane on the NGI.[178] The NGI has more
collection stages than the TLSI[181] and is easier to use than the ACI[182]. In
addition, “the collection efficiency curves for each stage are sharp and minimize
overlap between stages”[178] is well known for the NGI. Therefore, the NGI allows a
high resolution of particle deposition with an easy operation.

(a)

(b)
Figure 5.2. Closed (operating) condition (a) with pre-separator and internal
construction (b) of the next generation impactor. Adapted from [178].
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The deposition patterns of spray-dried (SD) particles are assessed by employing the
NGI. The NGI data could allow the correlation of particle deposition on stages with
various locations in human lungs based on aerodynamic size. In addition, the various
aerosol dispersion performance parameters would be able to assess the ability and
efficiency of aerosol penetration of SD particles to the deep lung regions.

5.2 Materials and Methods
5.2.1 Materials
The fresh spray-dried (SD) particles prepared as outlined in Chapter 4 for in vitro
aerosol dispersion performance study are listed in Table 5.1. TOB, AZI, MAN, and
PLS stand for tobramycin, azithromycin, mannitol, and phospholipids, respectively.
All the studied particles were generated employing a 50% pump rate during spray
drying. The outlet temperatures of SD particles are referred to Table 3.1 and Table 3.2
in Chapter 3. HP clear, size 3 capsule (Quali-V®) was received from Qualicaps
(Spain).
Table 5.1. SD particles for the NGI study.
Formulation
System
One-component

Two-component

Three-component

SD TOB formulations
(molar ratio)
Pure TOB
TOB:MAN=1:0.1
TOB:MAN=1:0.5
TOB:MAN=1:1
TOB:PLS=1:0.5
TOB:PLS=1:1
TOB:PLS=1:2
TOB:PLS:MAN=1:0.5:0.1
TOB:PLS:MAN=1:0.5:0.5
TOB:PLS:MAN=1:0.5:1

SD AZI formulations
(molar ratio)
Pure AZI
AZI:MAN=1:0.1
AZI:MAN=1:0.5
AZI:MAN=1:1
AZI:PLS=1:0.5
AZI:PLS=1:1
AZI:PLS=1:2
AZI:PLS:MAN=1:0.5:0.1
AZI:PLS:MAN=1:0.5:0.5
AZI:PLS:MAN=1:0.5:1

5.2.2 Methods
5.2.2.1 Mass Analysis
In accordance with USP Chapter <601> specifications[178], the aerosol dispersion
performance of the dry powder formulations were determined using the NGI (Model
170, MSP Corporation, Shoreview, Minnesota) equipped with a stainless steel
induction port (i.e. USP throat; MSP Corporation, Shoreview, Minnesota), stainless
steel NGI gravimetric insert cups (MSP Corporation, Shoreview, Minnesota) and the
HandiHaler® (a DPI device with high shear stress; Boehringer Ingelheim
Pharmaceutics, Germany). The NGI was coupled to a Copley HCP5 vacuum pump
(Copley Scientific, United Kingdom), and a Copley TPK 2000 critical flow controller
(Copley Scientific, United Kingdom). Airflow rate was adjusted before each
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experiment by a Copley DFM 2000 flow meter (Copley Scientific, United Kingdom).
The NGI experiment was run at a controlled airflow rate at Q=60 L/min (adult air
flow rate) with a delay time of 10 seconds. Each HP clear, size 3 capsule contained
10mg SD powders. To start the experiment, the capsule was pierced by pins in the
HandiHaler®. Powder in capsule was pulled out by the flow of air and deposited on
stages in the NGI. The mass of powder deposited on each stage was quantified by a
gravimetric method employing type A/E glass fiber filters with diameter 55mm
(PALL Corporation, NY). In vitro aerosolization was evaluated in triplicate under
normal lab conditions. Three capsules were used in each experiment. The
aerosolization experiment was randomized by Design ExpertTM 8.0.7.1 software
(Stat-Ease Corp., MN).
For the NGI with Q=60 L/min, the effective aerodynamic cutoff diameter for each
impactor stage was calibrated by the manufacturer and stated as: stage 1, 8.06μm;
stage 2, 4.46μm; stage 3, 2.82μm; stage 4, 1.66μm; stage 5, 0.94μm; stage 6, 0.55μm;
stage 7, 0.34μm. Emitted dose fraction (ED[%]; Equation 5.1) is determined as the
percentage powder mass emitted from capsules relative to the total dose in capsules
(TD). Emitted dose (ED) includes the sum of the powder mass left on inhaler device,
USP throat, and deposited on the NGI stages. Fine particle fraction (FPF[%];
Equation 5.2) is expressed as a percentage of fine particle dose (FPD) to ED. FPD is
defined as the dose deposited on stage 2 and later stages (3-7). Respirable fraction
(RF[%]; Equation 5.3) is defined as the percentage of FPD to deposited dose (DD).
Deposited dose (DD) is defined as the dose deposited on all stages.
ED

Emitted dose fraction (ED[%]) =

Fine particle fraction (FPF[%]) =
Respirable fraction (RF[%]) =

x 100%

TD
FPD

ED
FPD
DD

x 100%

x 100%

(Equation 5.1)
(Equation 5.2)
(Equation 5.3)

In addition, mass median aerodynamic diameter (MMAD) of aerosol particles and
geometric standard deviation (GSD) of the distribution are determined based on a
log-probability distribution (particle size vs particle deposition percentage) obtained
from the NGI data. The MMAD and GSD values were computed by using
Mathematica (Wolfram Research Inc., Champaign, IL), a calculation program written
by Dr. Warren Finlay[183].
5.2.2.2 Method validation of Chemical Analysis
As indicated above, the particle deposition pattern on the various stages of the NGI
are evaluated gravimetrically. In one set of experiments, the amount of AZI deposited
on each stage was examined by chemical analysis using high performance liquid
chromatogram (HPLC). To that end, a standard AZI solution with concentration of
~1000 ug/mL (in methanol) was used to assess possible drug adsorbance on the glass
filter to be placed on the NGI stages. Two treatment groups (a and b) with glass filter
were compared with the control group:
a) In the first treatment experiment, the glass filter was soaked in 5mL of standard
AZI solution for ~1h;
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b) In the second treatment experiment, the first step is that the glass filter was soaked
in 5mL of standard AZI solution for ~1h in vial A. The solution (3mL) in the vial A
with soaked glass filter was collected into a new vial B. The second step is that 10mL
solvent (methanol) was added to wash off the possible adsorbed AZI on soaked glass
filter in vial A. Eventually, a total 13mL solution was collected in vial B.
The two solutions from two treatment experiments (a and b) were passed through
polytetrafluoroethylene (PTFE) syringe filter (organic solvent resistant, 0.22µm pore
size; Tisch Scientific, USA) to remove any residual fiber before injecting into HPLC
for AZI concentration determination. The details of validated HPLC analysis is
reported in Section 6.3.1.1 in Chapter 6.

5.3 Results
5.3.1 One-component System (Spray-dried Pure Drug)
Aerosol dispersion performance results of spray-dried (SD) pure TOB[43] and
AZI[43] aerosols on each stage of the NGI from the HandiHaler® under Q of 60
L/min is shown in Figure 5.3a and 5.3b, respectively. As indicated in Figure 5.3, the
particle deposition profiles of SD pure TOB and SD pure AZI powders differed
markedly.
5.3.1.1 SD Pure TOB
SD pure TOB aerosols exhibited predominant particle deposition on stage 1
(aerodynamic cutoff diameter of 8.06µm) and low particle deposition on later stages
(2-7; aerodynamic cutoff diameter < 5µm)[43]. A majority of fine particle mass was
observed on stage 4 (aerodynamic cutoff diameter of 1.66µm) and stage 5
(aerodynamic cutoff diameter of 0.94µm). The deposition mode of fine particle dose
(FPD) was on stage 5. As indicated in Table 5.2[43], the SD pure TOB aerosols
showed 96.2%, 28.5%, and 43.7% for ED, FPF, and RF, respectively. The values of
MMAD and GSD were 5.0µm and 3.3, respectively. Therefore, it may be concluded
that SD pure TOB aerosols possessed an ability to penetrate into deep lung regions
(MMAD ≤ 5µm)[64].
5.3.1.2 SD Pure AZI
In contrast to SD pure TOB aerosols, SD pure AZI aerosols showed a relatively lower
deposition on stage 1, and higher depositions on later stages (2-7)[43]. Similarly, SD
pure AZI aerosolized particles exhibited a majority of fine particle mass on stage 4
and stage 5. The deposition mode of fine particle dose (FPD) was on stage 5. The
detailed aerosol dispersion performance parameters are listed in Table 5.2[43]. The
SD pure AZI aerosols exhibited 90.3%, 47.0%, and 68.1% for ED, FPF, and RF,
respectively. With MMAD and GSD being 2.3µm and 2.3, respectively, it suggests
that SD pure AZI particles were suitable for deep lung delivery (MMAD ≤ 5µm)[64].
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Figure 5.3. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for: (a) SD pure tobramycin powder;
and (b) SD pure azithromycin powder (mean ± SD, n=3)[43].
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Table 5.2. Aerosol dispersion performance parameters of SD pure tobramycin and SD
pure azithromycin dry powders[43] (mean ± margin of error for 95% confidence,
n=3).
SD Pure Drug

Aerosol Dispersion Performance Parameters
ED[%]

FPF[%]

RF[%]

MMAD[µm] GSD

TOB

96.2±0.6

28.5±3.8

43.7±4.8

5.0±1.2

3.3±0.6

AZI

90.3±6.7

47.0±3.7

68.1±5.4

2.3±0.4

2.3±0.2

5.3.2 Two-component System (Spray-dried Drug:Mannitol and
Drug:Phospholipids)
5.3.2.1 Spray-dried Drug:Mannitol
Particle deposition profiles for SD TOB:MAN[143] and AZI:MAN[143] are shown in
Figure 5.4a and 5.4b, respectively. The particle deposition of corresponding SD pure
drug is plotted in each figure. SD TOB:MAN and SD AZI:MAN exhibited similar
deposition patterns to the corresponding SD pure drug.
5.3.2.1.1 SD TOB:MAN
SD TOB:MAN aerosols showed a relatively higher particle deposition percentage on
stage 1 with an average of approximately 60%, compared to particle depositions on
later stages (2-7)[143]. The deposition modes of FPD for SD TOB:MAN aerosol
powders were on stage 5. As indicated in Table 5.3[143], SD TOB:MAN aerosol
powders exhibited 90.7% or higher, 15.4% or higher, and 34.2% or higher for ED,
FPF, and RF, respectively. The MMAD and GSD values ranged from 4.6 to 7.0µm,
and 3.2 to 3.8, respectively. Therefore, the data indicate that only TOB:MAN=1:0.1,
with a MMAD value less than 5µm, could be able to penetrate into deep lung
regions[64].
5.3.2.1.2 SD AZI:MAN
Aerosol dispersion performance of SD AZI:MAN exhibited a relatively lower particle
deposition on stage 1 with approximately 37%, compared to SD TOB:MAN
aerosols[143]. The majority of mass of FPD were on stage 4 and 5. The deposition
modes of FPD for SD AZI:MAN aerosol powders were on stage 5. Shown in Table
5.4[143], ED, FPF, and RF of SD AZI:MAN were 88.1% or higher, 38.3% or higher,
and 60.1% or higher, respectively. In addition, the aerosols showed MMAD and GSD
values ranging from 2.0 to 2.7µm, and 2.1 to 2.5, respectively. These data suggest that
AZI:MAN aerosol powders were suitable for deep lung penetration[64].
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(a)

(b)
Figure 5.4. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for: (a) tobramycin:mannitol powders;
and (b) azithromycin:mannitol powders (mean ± SD, n=3)[143].
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Table 5.3. Aerosol dispersion performance parameters of SD tobramycin:mannitol
particles[143] (mean ± margin of error for 95% confidence, n=3).
Molar
Ratio
1:0.1
TOB:MAN 1:0.5
1:1
System

Aerosol Dispersion Performance Parameters
ED[%]
FPF[%] RF[%]
MMAD[µm]
96.9±0.4 28.7±1.8 46.8±4.9 4.6±1.0
90.7±7.5 25.0±3.6 39.6±7.4 6.1±1.8
98.7±0.7 15.4±2.9 34.2±1.5 7.0±0.5

GSD
3.2±0.5
3.8±0.2
3.7±0.2

Table 5.4. Aerosol dispersion performance parameters of SD azithromycin:mannitol
particles[143] (mean ± margin of error for 95% confidence, n=3).
Molar
Ratio
1:0.1
AZI:MAN 1:0.5
1:1
System

Aerosol Dispersion Performance Parameters
ED[%]
FPF[%] RF[%]
MMAD[µm]
92.0±3.2 38.3±0.8 60.1±1.6 2.7±0.2
88.1±1.5 46.4±1.1 72.7±0.8 2.0±0.1
91.9±1.5 43.3±2.3 64.3±5.3 2.5±0.5

GSD
2.5±0.1
2.1±0.1
2.4±0.3

5.3.2.2 Spray-dried Drug:Phospholipids
Particle deposition profiles for SD TOB:PLS and AZI:PLS aerosols are shown in
Figure 5.5a and 5.5b, respectively. In addition, the particle deposition of
corresponding SD pure drug is plotted in each figure.
5.3.2.2.1 SD TOB:PLS
As shown in Figure 5.5a, the aerosol particle deposition profiles of TOB:PLS were
greatly improved as compared to SD pure TOB. Upon incorporation of phospholipids,
the powders exhibited a sharply lowered deposition on stage 1 (from approximately
55% to 17%), and, therefore, enhanced depositions on later stages (2-7). The
deposition modes of FPD were on stage 5 for TOB:PLS aerosols. Shown in Table 5.5,
TOB:PLS aerosols showed 87.4% or higher, 41.7% or higher, and 73.3% or higher for
ED, FPF, and RF, respectively. The MMAD for TOB:PLS aerosols ranged from 1.7
to 2.0µm. The GSD remained constant at 1.9. Therefore, TOB:PLS particles were
possibly suitable to be delivered to deep lung regions[64].
5.3.2.2.2 SD AZI:PLS
AZI:PLS aerosols appeared to have relatively similar deposition on stage 1 compared
to SD pure AZI. Deposition modes of FPD of AZI:PLS were dependent on the
composition of formulations. As phospholipids molar ratio increased from 1:0.5, to
1:1, and to 1:2, the deposition mode of FPD shifted from stage 5, to stage 3, and to
stage 2. As to AZI:PLS aerosols in Table 5.6, the values of ED, FPF, and RF were
95.1% or higher, 27.1% or higher, and 62.4% or higher, respectively. As suggested by
particle deposition patterns, the MMAD varied with the composition of AZI:PLS. The
MMAD values of the aerosols shifted from 2.2µm, to 4.7µm, and to 6.7µm as the
molar ratio changed from 1:0.5, to 1:1, and to 1:2, respectively. The GSD values were
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from 2.1 to 2.5. The data suggest that AZI:PLS=1:0.5 and 1:1 aerosol powders would
be expected to reach the deep lung regions[64].

(a)

(b)
Figure 5.5. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for: (a) tobramycin:phospholipids
powders; and (b) azithromycin:phospholipids powders (mean ± SD, n=3).
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Table
5.5.
Aerosol
dispersion
performance
parameters
of
SD
tobramycin:phospholipids particles (mean ± margin of error for 95% confidence,
n=3).
Aerosol Dispersion Performance Parameters
System
Molar Ratio
ED[%]
FPF[%] RF[%]
MMAD[µm] GSD
1:0.5
86.9±1.1 47.4±3.8 82.5±7.3 1.7±0.1
1.9±0.1
TOB:PLS 1:1
87.4±2.0 61.9±6.3 91.9±2.3 1.9±0.1
1.9±0.1
1:2
95.9±0.8 41.7±2.8 73.3±1.9 2.0±0.1
1.9±0.1
Table
5.6.
Aerosol
dispersion
performance
parameters
of
SD
azithromycin:phospholipids particles (mean ± margin of error for 95% confidence,
n=3).
Aerosol Dispersion Performance Parameters
System
Molar Ratio
ED[%]
FPF[%] RF[%]
MMAD[µm] GSD
1:0.5
95.1±1.2 37.4±4.0 72.4±9.3 2.2±0.3
2.1±0.3
AZI:PLS 1:1
97.8±0.8 36.4±1.8 62.6±3.8 4.7±0.3
2.2±0.1
1:2
95.1±1.5 27.1±1.8 62.4±3.6 6.7±0.5
2.5±0.2

5.3.3 Three-component System (Spray-dried Drug:Phospholipids:Mannitol)
Particle deposition profiles for SD TOB:PLS:MAN and SD AZI:PLS:MAN aerosols
are shown in Figure 5.6a and 5.6b, respectively. The particle deposition of
corresponding SD formulation of drug with phospholipids is plotted in each figure.
5.3.3.1 SD TOB:PLS:MAN
The addition of mannitol to TOB:PLS increased particle deposition on stage 1 from
~17% to 34%. The deposition modes of FPD of TOB:PLS:MAN aerosols were on
either stage 4 or 5. Shown in Table 5.7, ED, FPF, and RF values for TOB:PLS:MAN
were 91.7% or higher, 38.1% or higher, and 60.6% or higher, respectively. The
MMAD and GSD of the aerosols ranged from 2.2 to 2.7µm, and 2.0 to 2.2,
respectively. All TOB:PLS:MAN aerosol powders were suitable for penetration into
the deep lungs[64].
5.3.3.2 SD AZI:PLS:MAN
The effect of mannitol incorporation to AZI:PLS was more complicated. The powders
of AZI:PLS:MAN=1:0.5:0.1 and 1:0.5:0.5 exhibited an increased deposition on stage
1 with an average ~45%, as compared to ~28% from two-component formulation of
AZI:PLS=1:0.5. Interestingly, further increase of mannitol content to 1:0.5:1 in molar
ratio of AZI:PLS:MAN highly lowered particle deposition to ~4% on stage 1. The
deposition modes of FPD were on stage 4. The values of ED, FPF, and RF for
AZI:PLS:MAN were 94.3% or higher, 32.6% or higher, and 48.6% or higher,
respectively, as shown in Table 5.8. The MMAD and GSD values of AZI:PLS:MAN
aerosols were from 2.4 to 4.9µm, and 1.8 to 2.7, respectively. It is noticeable that
AZI:PLS:MAN=1:0.5:1 showed superior aerosol performance, in terms of FPF, RF,
MMAD, and GSD, compared to the other two aerosol powder systems
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(AZI:PLS:MAN=1:0.5:0.1 and AZI:PLS:MAN=1:0.5:0.5). The data suggest that
AZI:PLS:MAN aerosolized powders are suitable to be delivered into deep lung
regions[64].

(a)

(b)
Figure 5.6. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of
60
L/min
with
the
HandiHaler®
DPI
device
for:
(a)
tobramycin:phospholipids:mannitol
powders;
and
(b)
azithromycin:phospholipids:mannitol powders (mean ± SD, n=3).
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Table
5.7.
Aerosol
dispersion
performance
parameters
of
SD
tobramycin:phospholipids:mannitol particles (mean ± margin of error for 95%
confidence, n=3).
Aerosol Dispersion Performance Parameters
Molar
System
ED
FPF
RF
MMAD
Ratio
GSD
[%]
[%]
[%]
[µm]
1:0.5:0.1 91.7±1.0 44.1±5.2 70.3±5.5 2.2±0.2 2.0±0.2
TOB:PLS:MAN 1:0.5:0.5 93.0±1.0 42.7±4.3 66.8±7.3 2.6±0.4 2.1±0.2
1:0.5:1
93.1±3.5 38.1±1.0 60.6±3.3 2.7±0.2 2.2±0.1
Table
5.8.
Aerosol
dispersion
performance
parameters
of
SD
azithromycin:phospholipids:mannitol particles (mean ± margin of error for 95%
confidence, n=3).
Aerosol Dispersion Performance Parameters
Molar
System
ED
FPF
RF
MMAD
Ratio
GSD
[%]
[%]
[%]
[µm]
1:0.5:0.1 96.4±0.7 36.8±2.4 60.8±2.5 3.2±0.3 2.3±0.1
AZI:PLS:MAN 1:0.5:0.5 96.7±0.2 32.6±0.7 48.6±2.0 4.9±0.3 2.7±0.1
1:0.5:1
94.3±1.0 60.4±2.3 96.1±0.6 2.4±0.1 1.8±0.0

5.3.4 Validation of Gravimetric Analysis Method
An assumption made in the aerosol dispersion performance is that the mass
distribution of deposited particles on the NGI stages is equal to chemical distribution.
To validate this assumption for AZI, AZI:PLS=1:0.5 was selected as a representative
sample. As a first step, a chemical analysis method must be validated. Two different
treatments (a and b), detailed in Section 5.2.2.2, were conducted to determine the
number of washing necessary to collect all AZI from the glass filter. As shown in
Table 5.9, the total drug recoveries from the two glass filter washing treatments (a and
b) were not statistically different from the control sample with values of 100.3% and
102.6%, respectively. This method validation indicated that there was no significant
adsorbance of AZI on glass filter after one washing. Therefore, the first treatment
method (a) was used to determine AZI mass deposited on each stage of the NGI in
chemical analysis.
Table 5.9. The data for glass filter treatment experiment.

Concentration
(µg/mL)
Total Drug Recovery
(%)

Standard
Solution

First Treatment Second Treatment
(a)
(b)

1017.9

1021.0

401.5

100.0

100.3

102.6
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The AZI:PLS=1:0.5 powder was selected to conduct aerosol dispersion performance.
By employing the glass filters, the mass of powder on each stage was determined by
gravimetric method. Thereafter, the glass filter with captured particles on each stage
was soaked in methanol with 10mL for stage 1 and 5mL for each of later stages (2-7).
Sonication was applied to make sure all the particles were completely dissolved. After
passing through PTFE syringe filter, the solution was injected into HPLC for
concentration determination. The aerosolization experiment was conducted in
triplicate. The data comparison between mass analysis and chemical analysis are
presented in Figure 5.7. The results indicate that there was no significant difference in
particle deposition on each NGI stage determined by the two analytical methods.
Therefore, it was concluded that the gravimetric method was sufficient to assess the
AZI component distribution on NGI stages for all studies. TOB formulations were not
tested by this approach due to the lack of appropriate HPLC assay method.

Figure 5.7. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for azithromycin:phospholipids=1:0.5.
The particle deposition was determined by both weight and chemical analysis (mean ±
SD, n=3).
5.4 Discussion
It is well known that aerodynamic diameters below 5µm are considered as the cutoff
for particles capable of penetrating into deep lung regions[184]. The respiratory
aerosol formulation with ability of deep lung (including respirable bronchiolar and
alveolar regions) penetration is crucial for the treatment of lung diseases such as
pneumonia[185], chronic lung infection with cystic fibrosis (CF)[134-136] or non-CF
bronchiectasis[186, 187]. Therefore, we defined the sum of particles deposited on
stage 2 and later of the NGI (cutoff aerodynamic diameter of < 4.51µm) as the fine
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particle dose.
Formulation composition may have critical impact on the efficiency of aerosol
dispersion performance of the powder. Adler et al[188] reported that the surface
composition for spray-dried multi-component powders (e.g. bovine serum albumin,
trehalose, and surfactant (polysorbate 80)) was not identical to the overall formulation
composition. Therefore, it can be argued that the interparticulate forces may be a
function of surface composition[63]. More importantly, it is believed that particle
aggregation is prevalent when components that exhibit high crystallization tendency
or phase transitions are present on the surface. Obviously such a situation would
potentially influence particle aerosol performance. Thus, the effect of composition on
aerosol dispersion performance of the powder is discussed below.
5.4.1 Effect of Mannitol on Spray-Dried Drug:Mannitol
Compared to SD pure TOB, the aerosol dispersion performance of TOB:MAN were
independent of mannitol at molar ratios of 1:0.1 and 1:0.5. For TOB:MAN=1:1, the
FPF and RF decreased from 28.5% to 15.4%, and from 43.7% to 34.2%, respectively.
On the other hand, ED and MMAD of TOB:MAN=1:1 increased, compared to SD
pure TOB.
With other aerosol dispersion parameters statistically unchanged, only FPF and RF of
AZI:MAN=1:0.1 were lowered from 47.0% to 38.3%, and 68.1% to 60.1%,
respectively, compared to SD pure AZI. In comparison to SD pure AZI, aerosol
dispersion performance parameters of AZI:MAN=1:0.5 and 1:1 were statistically
unchanged.
In summary, based on the obtained aerosol dispersion performance parameters, spray
drying drug with various amount of mannitol in drug:mannitol did not appear to
improve the aerosol dispersion performance. Lactose is reported to exhibit surface
enrichment supported by the formation of a hollow particle at relatively high inlet
temperature[189-191]. It is reported[192] that due to the mannitol crystallization in
spray-dried
recombinant
humanized
anti-lgE
monoclonal
antibody
(rhuMAbE25):mannitol upon storage, the particles exhibited a significant decrease in
FPF. As shown in our previous study[44], mannitol has a high tendency to crystallize
after spray drying under these conditions for SD pure mannitol powders. XRPD
(Figure 4.2 in Chapter 4) and DSC (Figure 4.7-4.9 in Chapter 4) data did not reveal
any evidence of crystalline mannitol in the SD drug:mannitol powders. However, it is
possible that the small amount of mannitol, not detected by the techniques employed,
on particle surface could be present in the crystalline phase for SD drug:mannitol
powders. Even if the mannitol component was initially in the amorphous phase, the
low glass transition temperature of mannitol (e.g., 7.4 oC determined from
quench-cooled mannitol without additives in DSC at 5oC/min)[193] suggests a high
risk of crystallization of mannitol during aerosol dispersion experiments. Therefore, it
seems likely that the crystallization of mannitol on SD particles upon certain storage
after production would possibly impede the deaggregation of particles due to the
formation of bridging in the solid-state. It has been reported[73] that incorporation of
mannitol lowered the aerosol dispersion (e.g., FPF) of spray-dried three-component
spray-dried powder consisting of albumin, dipalmitoylphosphatidylcholine (DPPC),
and a protein stabilizer (lactose, trehalose or mannitol) compared to other sugers (such
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as lactose and trehalose).
5.4.2 Effect of Phospholipids on Spray-Dried Drug:Phospholipids
Incorporation of phospholipids in TOB:PLS improved markedly the aerosol
dispersion performance of the powders compared to SD pure TOB. The FPF and RF
of TOB:PLS formulations increased from 28.5% to 41.7% or higher, and from 43.7%
to 73.3% or higher, respectively. In addition, MMAD and GSD decreased
significantly from 5.0µm to 2.0µm or lower, and from 3.3 to 1.9, respectively.
However, with TOB:PLS=1:2 unchanged, the ED of TOB:PLS=1:0.5 and 1:1
decreased.
In contrast to TOB formulations, incorporation of phospholipids did not significantly
change the ED, RF, and GSD of AZI:PLS aerosols, while FPF decreased from 47.0%
to 37.4% or lower. With the exception of AZI:PLS=1:0.5, MMAD increased
significantly from 2.3µm to 4.7µm or higher for the other compositions.
In summary, incorporation of phospholipids into formulations exhibited remarkably
different effects on the aerosol dispersion performance of TOB:PLS and AZI:PLS. At
present, it is not clear why TOB:PLS and AZI:PLS particles performed differently.
The interfacial properties of antimicrobial compounds have been extensively
explored[194-200]. Therefore, tobramycin may possibly compete with surface-active
phospholipids for the air/methanol interface on droplets during spray drying.
Moreover, tobramycin has a smaller molecular weight compared to phospholipids
(e.g., tobramycin: 467g/mol vs DPPC: 734g/mol and DPPG: 745g/mol). This may
suggest that tobramycin possibly had a faster molecular diffusion. Therefore, it could
be reasonably suggested that significant amount of tobramycin is present on the
surface of particles.
Azithromycin may also possess interfacial activity. The molecular weight of
azithromycin is approximately equal to that of the phospholipids (e.g. azithromycin:
749g/mol vs DPPC: 734g/mol and DPPG: 745g/mol). Moreover, the hydrophobic
nature of azithromycin would possibly indicate azithromycin may interact through
favorable hydrophobic interactions with the hydrophobic chains on the phospholipids
molecule. The interaction of azithromycin and phospholipids have been reported in
the literature[174] suggesting that these two different molecules could co-localize on
particle surface. However, during spray drying, phospholipids would possibly
undergo main phase transition from gel phase to liquid crystalline phase as the
temperature (such as outlet temperature of spray drying (To)) (Table 3.2 in Chapter 3)
was higher than main phase transition temperature of phospholipid bilayer (Tm)
(Table 4.3 in Chapter 4). After phase transition, sticky phospholipids (due to
increased molecular mobility) on particle surface would possibly facilitate the
irreversible formation of particle aggregation. This lowered the aerosol dispersion
performance of AZI:PLS compared to SD pure AZI, while the FPF values of
AZI:PLS were still regarded as high.

104

5.4.3 Effect of Mannitol on Spray-Dried Drug:Phospholipids:Mannitol
When compared with TOB:PLS formulations, aerosol dispersion performance of
TOB:PLS:MAN decreased with increasing amount of manntiol. For
TOB:PLS:MAN=1:0.5:0.1, MMAD increased significantly from 1.7µm to 2.2µm. For
TOB:PLS:MAN=1:0.5:0.5, RF decreased significantly from 82.5% to 66.8% and
MMAD
increased
significantly
from
1.7µm
to
2.6µm.
As
for
TOB:PLS:MAN=1:0.5:1, the FPF and RF were significantly lowered from 47.4% to
38.1%, and from 82.5% to 60.6%, respectively. Moreover, MMAD and GSD
increased significantly from 1.7µm to 2.7µm, and from 1.9 to 2.2, respectively. With
incorporation of mannitol in TOB:PLS:MAN, ED overall increased from 86.9% to
91.7% or higher.
The mannitol effect on aerosol dispersion performance for AZI:PLS:MAN differed
with compositions. Based on aerosol dispersion performance parameters,
AZI:PLS:MAN=1:0.5:0.1 and 1:0.5:0.5 did not improve aerosol dispersion
performance compared to AZI:PLS=1:0.5. As for AZI:PLS:MAN=1:0.5:0.1, only
MMAD was affected, increasing significantly from 2.2µm to 3.2µm. In addition, FPF
and RF of AZI:PLS:MAN=1:0.5:0.5 decreased significantly from 37.4% to 32.6%,
and from 72.4% to 48.6%, respectively. Moreover, the GSD increased significantly
from 2.1 to 2.7. However, in AZI:PLS:MAN=1:0.5:1, sharply elevated FPF and RF
from 27.1% to 60.4%, and 62.4% to 96.1%, respectively, were observed. With
AZI:PLS:MAN=1:0.5:0.1
and
1:0.5:1
unchanged,
the
ED
of
AZI:PLS:MAN=1:0.5:0.5 increased.
In summary, addition of mannitol did not appear to improve the aerosol dispersion
performance of TOB:PLS:MAN. However, the effect of incorporation of mannitol on
the aerosol dispersion performance of AZI:PLS:MAN is composition dependent. As
discussed in Section 5.4.2.1, mannitol may possibly play a same role in
three-component
systems
such
as
all
TOB:PLS:MAN
formulations,
AZI:PLS:MAN=1:0.5:0.1, and AZI:PLS:MAN=1:0.5:0.5. Other mechanism(s) (such
as particle density change[201], surface energetics change[202], and etc.) may have
contributed to the sharp increase in aerosol dispersion performance of
AZI:PLS:MAN=1:0.5:1.

5.5 Conclusions
The aerosol dispersion performance of spray-dried particle was studied employing the
next generation impactor (NGI) with the HandiHaler® at adult air flow rate (60
L/min). It was demonstrated that the validated gravimetric method was sufficient to
assess the azithromycin component distribution on the NGI stages. In almost all cases,
spray-dried inhalable multi-component particles exhibited mass median aerodynamic
diameter (MMAD) less than 5µm suitable for deep lung deposition. In general, based
on the obtained aerosol dispersion performance parameters, addition of mannitol did
not improve aerosol dispersion performance of spray-dried particles except for
AZI:PLS:MAN=1:0.5:1. The effect of addition of phospholipids was mainly
dependent upon the drug properties.
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Chapter 6 Storage Stability

6.1 Introduction
Stability in pharmaceutics is defined as the ability of a drug substance or a
pharmaceutical product to resist specific physical, chemical, and biopharmaceutical
alterations during the product shelf-life. Therefore it is essentially important to
consider formulation stability during early drug formulation development. The
chemical and physical stability of the dry powder formulation could be affected by
moisture content and hygroscopicity of the formulation[64, 155, 156], chemistry of
the excipient and carrier particles[64, 203-205], interparticulate forces within the
formulation[64, 206], particle size (including size distribution) and surface
morphology[64, 207, 208]. Moreover, the storage conditions, such as relative
humidity (RH) and temperature, could often affect the physical and chemical stability
of a dry powder formulation, leading an unsuccessful delivery to the lungs of patients.
There are three recommended storage test conditions[209] from Food and Drug
Administration (FDA): 25 ± 2oC and 60 ± 5% RH (long-term conditions); 30 ± 2oC
and 60 ± 5% RH (intermediate conditions); 40 ± 2oC and 70 ± 5% RH (accelerated
conditions). In this storage stability study, we examine the effect of relative humidity
on spray-dried (SD) particles at 40oC. Three different RH % represents low (11%),
medium (40%), and high (75%) in practical storage conditions. By x-ray powder
diffraction (XRPD) and thermal analysis such as differential scanning calorimetry
(DSC), the storage stability of SD powders is studied during the storage. It would be
expected that the component, lacking of long-range molecular order, in SD powders
may possibly be subjected to phase transition(s) during storage. With the occurring of
phase transition(s), the aerosol dispersion performance of SD powders could be highly
impeded due to possible solid-state bridging. Therefore, after storage, the aerosol
dispersion performance of SD powders is examined by using the next generation
impact (NGI).

6.2 Materials and Methods
6.2.1 Materials
The fresh spray-dried (SD) tobramycin (TOB) formulations (including pure TOB,
tobramycin:mannitol
(TOB:MAN)=1:0.5,
tobramycin:phospholipids
(TOB:PLS)=1:0.5,
and
tobramycin:phospholipids:mannitol
(TOB:PLS:MAN)=1:0.5:0.5) and azithromycin (AZI) formulations (including pure
AZI,
azithromycin:mannitol
(AZI:MAN)=1:0.5,
azithromycin:phospholipids
(AZI:PLS)=1:0.5,
and
azithromycin:phospholipids:mannitol
(AZI:PLS:MAN)=1:0.5:0.5) were selected for storage stability test. All the studied
particles were generated employing a 50% pump rate during spray drying. Lithium
chloride (ACS, 99% min) and potassium carbonate (ACS, 99% min) were purchased
from Alfa Aesar (Massachusetts, USA). Sodium chloride (≥ 99.5%) was received
from Fisher Scientific (USA). Incubator (Napco, Model 320) (USA) was used as
temperature controller in sample storage. HP clear, size 3 capsule (Quali-V®) was
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received from Qualicaps (Spain). Aluminum foil (624 heavy duty; food-service) was
obtained from Reynolds® (made in China; packed in USA).

6.2.2 Methods
Each capsule was filled with ~10mg pre-weighed powder. A piece of uniformly cut
aluminum foil (3 x 3cm) was used to wrap each capsule containing powder. Several
filled capsules from the same formulation were stored in a pin-holed sandwich bag.
Three sandwich bags containing the same formulation were placed in three glass
desiccators with pre-equilibrated relative humidity (RH) by making saturated lithium
chloride, potassium carbonate, or sodium chloride solutions in DI water. The three
glass desiccators were stored in an incubator at 40 ± 1oC. At equilibrium, the RH of
saturated solution lithium chloride, potassium carbonate, and sodium chloride were
11%, 40%, and 75%, respectively, at 40oC.[210] In addition to differential scanning
calorimetry (DSC) and thermal gravity analysis (TGA), the physicochemical
properties of SD powders were examined by x-ray powder diffraction (XRPD) at
pre-determined time points of 2 weeks, 1 month, 2 months, and 3 months of storage.
The in vitro aerosol dispersion performance was conducted by using the next
generation impactor (NGI) only after 3 months storage. The experimental conditions
of XRPD, DSC and TGA are reported previously in Chapter 4. The experimental
conditions of in vitro aerosol dispersion performance are described previously in
Chapter 3.

6.3 Results
6.3.1 X-Ray Powder Diffraction (XRPD)
Figure 6.1 to 6.4 shows the XRPD data of stored SD pure TOB, TOB:MAN=1:0.5,
TOB:PLS=1:0.5, and TOB:PLS:MAN=1:0.5:0.5, respectively. The SD tobramycin
particles stored at 11% RH and 40oC exhibited non-crystalline XRPD patterns (Figure
6.1a to 6.4a, respectively) similar to that of the corresponding fresh samples. These
results suggested there was no significant change in physical form of the component(s)
in formulations upon storage. The appearance of crystalline peaks of TOB component
from the SD tobramycin particles were observed when the particles were stored under
conditions of either RH of 40% or 75% at 40oC. In addition, these particles also
exhibited a color change, indicating a potential chemical stability issue. A
representative picture of SD pure TOB (Figure 6.5) shows that the powder changed
from colorless to yellow stored at conditions of 40% and 75% RH. It was also noticed
that a small crystalline peak from beta form of mannitol emerged at ~ 23o of 2 Theta
(Appendix I) from TOB:MAN=1:0.5 (Figure 6.2b-c) stored at RH of 40% and 75%.
Supported by differential scanning calorimetry (DSC) data (endothermic peak at 69oC
indicative of main phase transition of phospholipid bilayer in Figure 6.6a), the
phospholipid bilayer structure showed a characteristic crystalline peak at range from
20o to 23o of 2 Theta in XRPD in phospholipid containing TOB formulations (Figure
6.3-6.4) under all studied storage conditions.
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(a)

(b)

(c)
Figure 6.1. XRPD patterns of SD pure tobramycin (offset by 500 counts between
patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during storage.
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(a)

(b)

(c)
Figure 6.2. XRPD patterns of SD tobramycin:mannitol=1:0.5 (offset by 500 counts
between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during
storage.
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(a)

(b)

(c)
Figure 6.3. XRPD patterns of SD tobramycin:phospholipids=1:0.5 (offset by 500
counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during
storage.
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(a)

(b)

(c)
Figure 6.4. XRPD patterns of SD tobramycin:phospholipids:mannitol=1:0.5:0.5
(offset by 500 counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c)
at 40oC during storage.

112

Figure 6.5. Photograph of capsules of SD pure tobramycin stored at three different
RH % and 40oC for 2 weeks.

(a)

(b)
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(c)
Figure
6.6.
DSC
thermograms
of
main
phase
transition
of
tobramycin:phospholipids=1:0.5 (a) and azithromycin:phospholipids=1:0.5 (b) after 3
months storage at 11% RH and 40oC; DSC thermogram of SD pure tobramycin (c)
after 3 months storage at 75% RH and 40oC.

As no new XRPD peaks, compared to freshly-prepared material, were observed, SD
pure AZI and AZI:MAN=1:0.5 were physically stable in solid phase under the storage
conditions as shown in Figure 6.7 and 6.8, respectively. Supported by DSC data (two
possibly separated peaks, at 60oC and 68oC, of main phase transition of phospholipid
bilayer in Figure 6.6b), AZI:PLS=1:0.5 (Figure 6.9) and AZI:PLS:MAN=1:0.5:0.5
(Figure 6.10) maintained the phospholipid bilayer structure with the presence of a
characteristic crystalline peak at range from 20o to 23o of 2 Theta in XRPD under all
the studied conditions. However, the AZI component in these two formulations
started to crystallize into its dihydrate crystalline form (with the appearance of
characteristic peaks at 7.4o, 9.4o and 9.5o of 2 Theta; Figure 4.1b in Chapter 4) after 1
month storage at conditions of 75% RH and 40oC in temperature (Figure 6.9c and
Figure 6.10c, respectively). The crystalline peaks from mannitol were not observed in
all SD AZI formulations. In addition, there was no observed color change in SD AZI
particles.
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(a)

(b)

(c)
Figure 6.7. XRPD patterns of SD pure azithromycin (offset by 500 counts between
patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during storage.
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(a)

(b)

(c)
Figure 6.8. XRPD patterns of SD azithromycin:mannitol=1:0.5 (offset by 500 counts
between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during
storage.
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(a)

(b)

(c)
Figure 6.9. XRPD patterns of SD azithromycin:phospholipids=1:0.5 (offset by 500
counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c) at 40oC during
storage.
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(a)

(b)

(c)
Figure 6.10. XRPD patterns of SD azithromycin:phospholipids:mannitol=1:0.5:0.5
(offset by 500 counts between patterns) at 11% RH (a), 40% RH (b), and 75% RH (c)
at 40oC during storage.
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6.3.2 Aerosol Dispersion Performance
On this Section, the aerosol performances of stored formulations were examined.
Aerosol dispersion performance parameters have been described in Section of 5.2.2.1
in Chapter 5. The SD tobramycin particles stored at 40% and 75% RH formed
aggregates through particle crystallization with a color change precluding their use in
aerosol pulmonary delivery. Therefore, only the particles stored at 11% RH and 40oC
were used to conduct aerosol dispersion performance. Studies were carryout
employing the next generation impactor (NGI) with the Handihaler® after 3 months of
storage. The aerosol particle deposition of SD tobramycin particles on each stage in
the NGI is depicted for both fresh formulations (Figure 6.11a) and stored formulations
(Figure 6.11b). Fresh particles deposited less than stored particles on stage 1. In
addition, it was observed that fine particle deposition mode was on stage 4 or 5 for
fresh particles. However, the fine particle deposition mode was not evident for stored
particles. The stored particles had a relatively even deposition on stages 2-7 with
approximately less than 10% particle deposited on each stage.
The aerosol dispersion performance parameters of the tobramycin formulations are
summarized in Table 6.1. The aerosol dispersion performance parameters (i.e. FPF
and RF) of the stored SD tobramycin formulations were significantly lowered,
resulting in higher values of MMAD (>5µm) compared to their corresponding
freshly-prepared powder. However, only stored TOB:PLS=1:0.5 and
TOB:PLS:MAN=1:0.5:0.5 resulted in higher GSD values compared to the fresh
powder. The GSD values were not significantly different for fresh and stored SD pure
TOB and TOB:MAN=1:0.5. Overall, the fresh and stored SD tobramycin powders
resulted in similar ED values.
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(a)

(b)
Figure 6.11. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for: (a) fresh SD tobramycin powders;
and (b) stored SD tobramycin powders at 11% RH and 40oC (mean ± SD, n=3).
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The NGI aerosol particle deposition results of SD pure AZI, AZI:MAN=1:0.5,
AZI:PLS=1:0.5, and AZI:PLS:MAN=1:0.5:0.5 are shown in Figures 6.12, 6.13, 6.14,
and 6.15, respectively. The fresh particles deposited less on stage 1 than stored
particles except for the formulation of AZI:PLS:MAN=1:0.5:0.5. For AZI (Figure
6.12) and AZI:MAN=1:0.5 (Figure 6.13), the fine particle deposition was lowered
after storage, especially on stage 4-7. On the other hand, for stored AZI:PLS=1:0.5
(Figure 6.14), the fine particle deposition mode shifted from stage 5 to stage 4 or 2,
indicating a growth in particle size. However, AZI:PLS:MAN=1:0.5:0.5 particles
from storage conditions of 11% and 40% RH exhibited a fine deposition mode on
stage 4 (Figure 6.15). In contrast, AZI:PLS:MAN=1:0.5:0.5 particles from storage
conditions of RH 75% shifted fine particle deposition mode from stage 4 to stage 3.
Listed in Table 6.2 are the aerosol performance parameters of the AZI formulations.
SD pure AZI and AZI:MAN=1:0.5 aerosols exhibited a decrease in FPF and RF
values with storage RH % increased. MMAD and GSD values increased as storage
RH % increased. However, all MMAD values remained about ≤5µm after storage.
Overall, AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 exhibited a lowered aerosol
dispersion performance with increased storage RH %. At RH of 11% and 40%, the
MMAD values increased (but remained about ≤5µm) compared to the values from
fresh samples. The MMAD values dramatically increased (>5µm) when
AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 were stored at 75% RH and 40oC. In
general, there was no observed trend for FPF and RF values when comparing fresh
and stored samples under the conditions of 11% and 40% RH.

Figure 6.12. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD pure
azithromycin at three different RH % and 40oC (mean ± SD, n=3).
121

Figure 6.13. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD
azithromycin:mannitol=1:0.5 at three different RH % and 40oC (mean ± SD, n=3).

Figure 6.14. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD
azithromycin:phospholipids=1:0.5 at three different RH % and 40oC (mean ± SD,
n=3).
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Figure 6.15. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for fresh and stored SD
azithromycin:phospholipids:mannitol=1:0.5:0.5 at three different RH % and 40oC
(mean ± SD, n=3).
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System
(Molar Ratio)
Pure TOB
TOB:MAN
(1:0.5)
TOB:PLS
(1:0.5)
TOB:PLS:MAN
(1:0.5:0.5)

Treatment
fresh
stored @11% RH
fresh
stored @11% RH
fresh
stored @11% RH
fresh
stored @11% RH

ED[%]
96.2±0.5
93.6±2.1
90.7±6.7
94.7±3.1
86.9±1.0
91.3±1.9
93.0±0.9
95.2±2.9

Aerosol Dispersion Performance Parameters
FPF[%]
RF[%]
MMAD[µm] GSD
28.5±3.4
43.7±4.2 5.0±1.1
3.3±0.5
20.3±3.5
30.3±4.3 10.6±2.8
3.6±0.4
25.0±3.2
39.6±6.5 6.1±1.6
3.8±0.2
17.7±5.0
26.0±6.2 14.9±5.3
3.7±0.0
47.4±3.4
82.5±6.5 1.7±0.1
1.9±0.1
28.0±0.7
37.8±2.0 6.6±1.0
3.3±0.3
42.7±3.8
66.8±6.4 2.6±0.3
2.1±0.2
11.5±5.1
17.3±7.5 28.4±15.1
4.0±0.2
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Table 6.1. Aerosol dispersion performance parameters of SD tobramycin powders (fresh vs stored at 11% RH and 40oC) (mean ± SD, n=3).
Definition: ED[%]=emitted dose fraction; FPF[%]=fine particle fraction; RF[%]=respirable fraction; MMAD[µm]=mass median aerodynamic
diameter; GSD=geometric standard deviation.

System
(Molar Ratio)

Pure AZI

AZI:MAN
(1:0.5)

AZI:PLS
(1:0.5)

AZI:PLS:MAN
(1:0.5:0.5)

Treatment
fresh
stored @11% RH
stored @40% RH
stored @75% RH
fresh
stored @11% RH
stored @40% RH
stored @75% RH
fresh
stored @11% RH
stored @40% RH
stored @75% RH
fresh
stored @11% RH
stored @40% RH
stored @75% RH

ED[%]
90.3±5.9
93.7±1.1
95.1±2.4
94.9±1.4
88.1±1.3
92.2±2.4
87.9±1.4
92.5±2.3
95.1±1.0
89.7±2.1
89.2±1.9
95.3±1.1
96.7±0.2
95.0±2.9
94.5±1.3
100.1±1.3

Aerosol Dispersion Performance Parameters
FPF[%]
RF[%]
MMAD[µm]
47.0±3.3
68.1±4.8
2.3±0.3
30.3±1.6
46.1±3.7
4.0±0.7
29.7±2.6
44.5±3.4
4.6±0.5
27.4±1.2
41.4±1.9
5.1±0.5
46.4±1.0
72.7±0.7
2.0±0.1
34.9±4.3
51.3±3.1
3.3±0.2
32.6±4.0
46.7±4.3
4.4±0.8
29.2±2.2
41.9±5.5
5.2±1.5
37.4±3.5
72.4±8.2
2.2±0.3
38.8±1.6
57.0±1.9
4.4±0.3
35.4±1.8
52.5±2.2
5.3±0.3
19.2±2.4
29.9±2.2
14.7±2.2
32.6±0.6
48.6±1.8
4.9±0.3
36.7±4.3
65.3±3.7
3.5±0.3
31.1±3.6
53.2±1.8
4.3±0.1
14.3±1.4
25.0±2.7
14.6±2.3

GSD
2.3±0.2
3.0±0.3
3.2±0.1
3.2±0.1
2.1±0.1
2.6±0.2
2.9±0.4
2.9±0.4
2.1±0.2
2.6±0.1
2.8±0.0
3.5±0.7
2.7±0.1
2.0±0.1
2.2±0.1
3.0±0.3
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Table 6.2. Aerosol dispersion performance parameters of SD azithromycin powders (fresh vs stored at three different RH % and 40oC) (mean ±
SD, n=3). Definition: ED[%]=emitted dose fraction; FPF[%]=fine particle fraction; RF[%]=respirable fraction; MMAD[µm]=mass median
aerodynamic diameter; GSD=geometric standard deviation.

6.4 Discussion
Moisture may have a significant impact on the physical and chemical stability of
aerosol particles, particular for small particles due to their high surface area to volume
ratio and the presence of large interstitial space[41]. Moisture may cause irreversible
particle agglomeration, leading to failure to generate aerosol particles in respirable
size[45]. Individual particles may also undergo changes in crystallinity and
polymorphism[41]. Chemical instability could be a potential issue when particle
component is hygroscopic[155, 156].
Spray-dried sugar excipients (trehalose and raffinose)[211] and spray-dried sodium
cromoglicate[212] aerosol particles have been studied for physical stability under
various conditions. The particles were placed in open jars stored in glass chambers,
maintained either at 60% RH at 25oC or contained silica gel at 25oC and 4oC. At
different time intervals, samples were assessed by SEM, XRPD, DSC and
aerosolization. The spray-dried particles, stored at silica gel/25oC or 4oC, exhibited no
significant change in particle morphology, physical phase (amorphous), and
aerosolization. However, stored at 60% RH/25oC, the spray-dried particles collapsed
with a disappearance of porous particle structure, leading to a decrease in the aerosol
performance. Singh et al.[213] studied room temperature (60% RH & 25oC for 12
months) and accelerated (75% RH & 40oC for 6 months) stability tests of terbutaline
sulfate-loaded chitosan microspheres for pulmonary delivery. At specified time
intervals, samples were evaluated for drug content, particle size, FPF. These stability
tests were conducted with the powder directly exposed to studied RH %. It was
found that the fine particle fraction was slightly decreased at both storage conditions,
due to an increase in moisture content and a subsequent increase in particle size after
storage. In addition, no significant change in drug content was observed in this study.
El-gendy et al.[214] reported on HPMC capsules preloaded with budesonide
nano-cluster dry powder stored at conditions of shelf-life (60% RH & 25oC for
12months) and accelerated (75% RH & 40oC for 6month) stability conditions. The
results suggested that the chemical and physical stability were unchanged during
storage. The MMAD and GSD values appeared to be constant. FPF of particles at
accelerated conditions exhibited no significant change compared to fresh powder.
Only a slight decrease in FPF was observed for particles stored at shelf-life storage
conditions. Pilcer et al.[215] hand-filled spray-dried tobramycin powder into capsules
sealed in aluminum/aluminum blisters. Using moisture-protective packaging, this test
method was close to the compliance from FDA guideline on stability test of dry
powder for inhalation. The stability study was conducted at 75% RH/40oC, 65%
RH/30oC, and 60% RH/25oC. The data revealed that the spray-dried powders
remained unchanged in physical phase, drug content, particle size distribution, and
FPF.
FDA recommends that stability tests should be performed on the drug product with
the packaging configuration (i.e., primary, secondary or additional protective)
intended for marketing under the appropriate test storage conditions[209]. As an
alternative to packaging suitable for marketing, we employed aluminum foil as a
moisture-protective wrapping. Three different RH % were chosen to represent low
(11%), medium (40%), and high (75%) values to encompass a range of practical
126

storage conditions. In order to have at least one standard storage test conditions (75%
RH & 40oC; accelerated storage conditions), the temperature of 40oC was chosen in
this study. We used XRPD and the NGI to correlate the physical phase stability and
aerosol dispersion performance of the particles during storage.
Under the storage stability test conditions of 40% and 75% RH at 40oC, the SD
tobramycin formulations partially crystallized into agglomerates (Figure 6.1-6.4) and
underwent a color change (on surface layer of agglomerates) as shown in Figure 6.5 at
times as short as 2 weeks. The XRPD data (Figure 6.1 to 6.4) indicate that the
crystallized component was probably from tobramycin. The hygroscopic nature of
tobramycin along with a high tendency to crystallize was also shown in GVS data
(Figure 4.13-4.16 in Chapter 4). The color change of the particles strongly indicated
that tobramycin chemically degraded. The chemical degradation pathway of
tobramycin has been reported[216]. However, another possibility for color change
could arise from the presence of a different polymorph for TOB by phase transition
(e.g. ROY[217] polymorphs with striking feature in color of red, orange, and yellow).
Pilcer et al.[215] suggested no degradation of tobramycin was observed over 12
months by HPLC when the capsule-containing foil blisters were stored at 75% RH
and 40oC. As expected, the results in Figure 6.5 clearly suggested that moisture could
penetrate into the capsules hand-wrapped with aluminum foil. The storage stability
data for SD pure mannitol (not shown) indicate that the hand-wrapped aluminum foil
probably delayed rather than prevented moisture penetration into the capsule. As
shown in Figure 6.2, the mannitol component possibly partially crystallized into beta
polymorphic crystal form in TOB:MAN=1:0.5 at conditions of 40% and 75% RH.
However, it was not observed for TOB:PLS:MAN=1:0.5:0.5. These results were
possibly due to the mannitol component being enriched in TOB:MAN=1:0.5
compared to TOB:PLS:MAN=1:0.5:0.5. In addition, the possible interaction between
phospholipids and mannitol in TOB:PLS:MAN=1:0.5:0.5 may impede mannitol
crystallization. A similar mechanism of hydrogen-bonding interaction between
trehalose and phospholipids has previously been cited in the literature[218].
Based on XRPD data (Figure 6.1 to 6.4), there was no evident crystal formation in SD
tobramycin particles stored at 11% RH and 40oC. However, in comparison to
freshly-prepared samples, the aerosol dispersion performance of stored samples
significantly decreased. The MMAD values for stored particles were all above 5µm
(Table 6.1). This indicated the stored tobramycin particles would not be able to reach
deep lung regions at adult airflow rate using the Handihaler®. Given in the simplified
Equation 6.1, the aerodynamic diameter of a particle is the product of particle
diameter and square root of particle density.

d ae =

ρpd

(Equation 6.1)

Where dae is the aerodynamic diameter of a particle, d is the spherical particle
diameter, and ρp is the particle density.
The increased geometric size (d) and/or density (ρp) of particles could potentially
decrease the aerosol dispersion performance of dry powder formulations[41]. It was
not likely the RH as low as 11% (comparable to the RH % maintained by desiccants
in real DPI products) caused the decrease in aerosol dispersion performance of the
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powders. Although the storage temperature 40oC was below the glass transition
temperatures (~45 to 50oC) of SD tobramycin formulations, the drug could still be
susceptible to crystallization. For instance, the DSC thermogram (Figure 6.6c) of
stored SD pure tobramycin exhibited similar characteristics to that of the as received
tobramycin rather than that of the SD pure tobramycin. As a classical drug model,
amorphous indomethacin has clearly been shown to exhibit sufficient molecular
mobility to trigger crystallization over a period of days at temperature 30oC below its
Tg[219]. Therefore it is possible that stored SD pure tobramycin may partially
crystallize through the storage period, however, at a level not detected by XRPD. It is
also possible that the partially crystallized SD pure tobramycin particles may form
particle aggregation through solid-solid bridging (between particles). It has been
reported that storage of the excipient (mannitol) crystallization resulted in increased
particle size (e.g., interparticle growth) and adverse effects on the aerosol dispersion
performance of spray dried protein powders[192]. Moreover, the crystallized
aggregates were expected to have a higher density than fresh particles due to the loss
of free volume in particles after crystallization with more organized molecular
packing. Similar to SD pure tobramycin particles, the possible partial crystallization
process was also noticed in other tobramycin containing particles under storage at 11%
RH and 40oC.
The XRPD data (Figure 6.7 to 6.8) shows that SD pure AZI and AZI: MAN=1:0.5
lacked long-range molecular order after storage at all conditions through three months.
As seen from Table 6.2, the aerosol dispersion performance was lowered with
increased RH % after three-month storage for the two formulations. It is well known
that interparticulate forces that influence particle interactions during the dispersion of
powder aerosols include van der Waals, electrostatic, capillary, and mechanical
interlocking forces[41, 63, 64]. The capillary force arises from moisture condensation
which form high tensile liquid bridge in the gap between two contiguous surfaces, and
becomes dominant as the relative humidity increases[41, 64]. Therefore, capillary
force is highly expected to play a key role in aerosolization efficiency for the two
formulations exposed to various RH %. Moisture content of the formulations was not
measured after storage.
As seen from Figure 6.9 to 6.10, the phospholipid bilayer structure was retained for
AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 during storage. In addition, the
mannitol component appeared to lack long-range of molecular order in
AZI:PLS:MAN=1:0.5:0.5. After one month storage, the crystalline peaks of AZI
dihydrate (identical to XRPD of as received AZI, but with a lower intensity) were
observed for AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 only at conditions of 75%
RH and 40oC. These results suggest that the phospholipid component decreased the
physical phase stability of azithromycin component in AZI:PLS=1:0.5 and
AZI:PLS:MAN=1:0.5:0.5 under these conditions possibly by the association of water
molecules with hydrophilic head groups of phospholipids[167]. Presumably, the
azithromycin could interact with absorbed water molecules to form azithromycin
dihydrate. The hand-wrapped aluminum foil wrapping slowed the rate of physical
phase inter-conversion, but did not ultimately stop the process (Figure 6.9 to 6.10).
On the other hand, the GVS data (Figure 4.14-4.16 in Chapter 4) did not directly
support this hypothesis, although the experimental temperature of DVS (25oC) and
stability test (40oC) were different. Both water vapor sorption isotherms of
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AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 were lower than SD AZI:MAN=1:0.5
(no azithromycin crystallization was observed).
With MMAD values of about ≤5µm, the FPF value of AZI:PLS=1:0.5 and
AZI:PLS:MAN=1:0.5:0.5 stored at 11% and 40% RH, respectively, was relatively
comparable to the corresponding fresh samples. However, after the partial
crystallization of azithromycin into dihydrate form in particles, the aerosol dispersion
performance of stored AZI:PLS=1:0.5 and AZI:PLS:MAN=1:0.5:0.5 at 75% RH was
poor as evident by MMAD values of ~15µm. Similar to the discussion in aerosol
dispersion performance of SD tobramycin particles, the effect of irreversible
crystallization of azithromycin on the particle dispersion may possibly be explained
by the hypothesized mechanisms, such as particle aggregation and formation of
densified particles.

6.5 Conclusions
An indicated, possible chemical degradation of tobramycin by a color change was
observed in SD tobramycin particles stored at 40% and 75% RH (at 40oC). Compared
to the corresponding freshly-prepared particles, tobramycin particles stored at 11%
RH and 40oC exhibited decreased the aerosol dispersion performance. The decreased
in aerosol dispersion performance was possibly caused by a low level of partial
crystallization of tobramycin in formulations. Possibly due to enhanced capillary
force, the aerosol dispersion performance was lowered with increasing RH % for the
stored SD pure AZI and AZI: MAN=1:0.5. Stored AZI:PLS=1:0.5 and
AZI:PLS:MAN=1:0.5:0.5 from conditions of 11% and 40% RH (at 40oC) showed
relatively comparable aerosol dispersion performance to the corresponding fresh
samples. The aerosol dispersion performance of phospholipids-containing
azithromycin formulations stored at 75% RH (40oC) was highly impeded due to
partial crystallization of azithromycin. In addition, the phospholipid bilayer structure
was retained in all formulations. Mannitol component was lacking in long-range
molecular order in all formulations expect for TOB:MAN=1:0.5 stored at 40% and 75%
RH (at 40oC).
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Chapter 7 in vitro Drug Release

7.1 Introduction
The proposed lung surfactant-mimic phospholipids (dipalmitoylphosphatidylcholine
(DPPC):dipalmitoylphosphatidylglycerol sodium (DPPG) in 4:1 molar ratio; PLS)
and mucolytic agent mannitol (MAN) were selectively incorporated into spray dried
(SD) azithromycin (AZI) particles. Despite the advantages from a pharmacological
perspective by incorporating PLS and MAN into SD AZI particles, the impact of
incorporation of PLS or/and MAN on in vitro free drug release profiles of SD AZI
particles needs to be assessed.
There are no specific pharmacopoeial methods used for testing in vitro drug release
from inhaled powders delivered to the respiratory tract[220]. Several in vitro drug
release methods were reported for pulmonary drug delivery formulations[221-231].
O’Hara et al.[224] reported the suspension of dispersed rifampicin loaded
microspheres was centrifuged and an aliquot sample was taken from the supernatant.
After the aliquots were removed, the entire supernatant was replenished in order to
maintain sink condition. However, it was not clear if the centrifugal force was
sufficient to sediment small particles, especially for nano-sized particles. Additionally,
it was not experimentally demonstrated that sink condition was maintained by
replenishing the supernatant at each time point. In another study, diffusion cell was
employed to assess the release of terbutaline sulphate from microspheres into release
medium[223]. A membrane (pore size of 0.45µm) was chosen to allow free diffusion
of the drug into the receiver and prevent entry of microparticles. Nonetheless, it may
have limited use for in vitro drug release of SD AZI particles. The SD particles
(micro- and nano-sized) and thereafter the possible AZI-containing liposomes
(formed from PLS released from SD AZI particles incorporated with PLS) may be
sufficiently small to pass through the membrane during the experiment. Moreover,
simulated interstitial lung fluid (SILF) and simulated surfactant lung fluid (SSLF)
were used as alternative release medium[232-234] besides phosphate buffer, which
may make complicate the in vitro drug release mechanism.
The in vitro drug release method used in this Chapter was relatively simple to carry
out. It examined free AZI drug release from SD particles in PBS at pH of 7.4 and
temperature of 37oC with initial drug loading below the apparent solubility of SD pure
AZI particles. A sink condition[235], defined as the volume of medium at least three
times greater than that required to form a saturated solution of a drug substance, was
not used mainly due to the detection limit of AZI by high performance liquid
chromatogram (HPLC) assay. In addition, without replacing refresh release medium
during studies may potentially reduce experimental procedures and minimize
experimental errors. Due to the small size and lacking in long-range molecular order
of AZI component, it is expected that SD AZI particles may exhibit a relatively fast
initial drug release with application of rotation force. The effect of phospholipid
bilayer structure with low integrity on significantly lowering drug release rate would
not be anticipated for SD AZI particles. Moreover, the drug release of SD AZI
particles would possibly be enhanced with the potential presence of molecular
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interaction between AZI and MAN components in the SD AZI particles.

7.2 Materials and Methods
7.2.1 Materials
The
spray-dried
(SD)
formulations
of
pure
azithromycin
(AZI),
azithromycin:mannitol
(AZI:MAN)=1:0.5,
azithromycin:phospholipids
(AZI:PLS)=1:0.5,
1:1,
and
1:2,
azithromycin:phospholipids:mannitol
(AZI:PLS:MAN)=1:0.5:0.5 and 1:2:2 (in molar ratio) were selected for in vitro drug
release. The selected formulations were all generated from spray drying employing a
50% pump rate (15 ml/min). Phosphate buffered saline (PBS) tablets were purchased
from Sigma (USA). The phosphate buffer with concentration of 0.01M was prepared
by dissolving 1 tablet in 200ml of water. The organic solvents (methanol, chloroform,
and acetonitrile) used were all HPLC grade. Methanol and chloroform were obtained
from Fisher Scientific (USA). Acetonitrile was obtained from Acros (USA). Millipore
deionized water was used in this study.
7.2.2 Methods
The in vitro drug release of selected formulations was conducted in polyethylene (PE)
vials (anti-static, 20ml; PerkinElmer, USA). In order to achieve initial drug loading
below the apparent solubility of SD pure AZI particles, certain amount of SD powder
equal to ~8mg of pure AZI were suspended in 20ml preheated PBS (37oC) in PE vials.
The suspensions were kept rotated by using Labquake tube shaker (Barnstead
Thermolyne). The in vitro drug release was conducted at 37oC in a temperature
well-controlled incubator (Precision, USA). At each planned time point, 0.5ml of drug
release medium was taken from PE vials. Sufficient sample of free AZI was collected
in filtrate after passing through a regenerated cellulose membrane of Amicon® Ultra
(Millipore Corporation, USA) with 30K molecular weight cutoff (MWCO) by using
Eppendorf centrifuge 5417R (USA) at 14,000g (based on the recommended method
from the manufacturer of filters) for 1min. The concentration of free AZI was
determined by using high performance liquid chromatogram (HPLC) with UV
detector at 210nm of wavelength. The HPLC chromatograms were acquired by
Shimazu CLASS-VP V5.032. All formulations were done in triplicate.

7.3 Results
7.3.1 Validations
7.3.1.1 Linearity of HPLC Assay for Azithromycin
The employed high performance liquid chromatogram (HPLC) system was consisted
of an LC compact system (Shimadzu, Japan), and equipped with an autosampler
(SIL-10AD VP), a binary pump (LC-10AD VP), and a UV detector (SPD-10A VP).
The HPLC analysis for AZI concentration determinination was slightly modified from
a previously published method[236]. The column was a Luna C18(2) (5µ, 100A,
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250×4.60mm) (Phenomenex, USA) operated at 30oC. The analytical mobile phase,
composed of potassium phosphate dibasic-acetonitrile (35/65%, v/v), was passed
through the analytical column at a flow rate of 1.0 mL/min with the UV detector
wavelength set at 210nm. The pH of potassium phosphate dibasic (0.05 mole/L) was
adjusted to 8.2 with 20% phosphoric acid. 30µL sample was injected into HPLC.
To validate the HPLC assay, three independent groups of standard solutions were
prepared with concentration of 1000, 400, and 100 µg/mL, respectively. A typical
chromatogram of AZI parent compound is shown in Figure 7.1. The coefficients of
variation (CV) for the peak height and peak area for the successive injections of a
single standard were 3.1% and 3.1%, respectively. Peak carry-over was not observed.
The mean and CV of mean response factors for the standard concentrations are shown
in Table 7.1. The student t-tests for linearity were performed to compare the mean
response factors of standard solutions with different concentrations. At degrees of
freedom of 4, the t statistic values for 1000 vs 400 µg/mL, 1000 vs 100 µg/mL, and
400 vs 100 µg/mL were 0.783, 1.471, and 0.838, respectively. This suggests that there
was no statistically significant difference between the two mean response factors at
the p=0.025 significant level (degree of freedom: 4, t0.975=2.776).
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Figure 7.1. A representative HPLC chromatogram of a standard azithromycin
solution.
Table 7.1. The mean response factor and coefficient of variance for each standard
azithromycin solution.
Standard Concentration
(µg/mL)
100
400
1000

Mean Response Factor
(mL/µg)
1959
1919
1884
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Coefficient of Variance
(%)
3.4
2.6
3.1

7.3.1.2 Stability Indicating Capability of HPLC Assay for Azithromycin
The HPLC assay validated in Section 6.3.1.1 was tested for ability to resolve
degradation products from the parent compound of AZI. A 1:5 dilution of stock
solution (5 mg/mL in methanol) in (a) 0.1N HCl, (b) 0.1N NaOH, and (c) deionized
H2O were prepared. The storage condition was 25oC for all solutions. Additionally, a
H2O solution at 37oC was studied. All samples were light-protected during the study.
There were 5 vials in each study condition. At planned time points, samples were
withdraw and analyzed by the same HPLC assay.
The data indicated that the validated HPLC assay was able to differentiate the AZI
parent molecule and its degradation products, which is similar to the report[236]. A
typical chromatogram of AZI is shown in Figure 7.2. The retention time of
azithromycin parent molecule peak was ~16min, while the retention times of
azithromycin degradation products ranged from ~5 to 7min. The stability indicating
assay suggests that ~21%, ~24%, ~8%, and ~3% of AZI degraded in HCl (25oC),
NaOH (25oC), H2O (37oC), and H2O (25oC), respectively.
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Figure 7.2. A representative HPLC chromatogram of an azithromycin solution in
stability indicating assay.

7.3.1.3 Selection of Centrifugal Filter Unit
The centrifugal filter units with three different molecular weight cutoff (MWCO)
sizes (3K, 10K, and 30K, respectively) were used to assess possible drug adsorbance
on the filter membrane (regenerated cellulose). Three independent AZI standard
solutions with concentration of ~300 µg/mL were used in this assay. Three centrifugal
filter units of each MWCO size filled with each standard solution were immediately
centrifuged. The filtrates were analyzed by HPLC assay. In addition, the standard
solutions were directly analyzed by HPLC assay as a control group. The data are
summarized in Table 7.2.
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Table 7.2. The azithromycin adsorbance data for centrifugal filter units.
Standard
No.
1
2
3
Mean
SD

Solution Control
(µg/mL)
295
299
297
297
1.9

3K
(µg/mL)
201
181
185
189
10.6

10K
(µg/mL)
280
305
293
17.7

30K
(µg/mL)
292
286
289
4.5

The differences between the mean AZI drug concentration in solution filtered through
from 10K and 30K (one value missing from each group) and control group were not
statistically significant (t-test, alpha=0.05). The results of the 3K filter unit group
suggests high drug adsorbance on regenerated cellulose since the mean concentration
in the filtrate was significantly lower than the control. The high total membrane
surface area of 3K, compared to 10K and 30K, may be responsible for the decreased
concentration after filtration. The 30K filter unit was selected for the AZI in vitro
drug release study due to its low adsorbance variability compared to 10K filter unit.

7.3.1.4 Selection of Release Medium Container
In order to choose a suitable type of drug release medium container, the 20ml glass
scintillation and polyethylene (PE) vials were compared for their potential drug
adsorbance. Two vials of each type were filled with a standard AZI solution with
concentration of ~ 507 µg/mL and rotated in Labquake tube shaker at 37oC. At time
points of 3h and 24h, samples were withdrawn and analyzed by HPLC assay.
The data are shown in Table 7.3. Apparently PE vials adsorbed less of the drug (~3 to
4%) at each time point compared to glass scintillation vials. Therefore, PE vials were
chosen for AZI in vitro drug release studies. The reason why two type vials behaved
differently was not explored.
Table 7.3. The azithromycin absorbance data for release vials.
Vial Type
PE Vial
Scintillation Vial

Time Points
3h
24h
3h
24h

Concentration
(µg/mL)
487
492
353
256

Percentage
(%)
96.0
97.0
69.7
50.4

7.3.2 Release Data
Figure 7.3 shows the in vitro apparent release profile of SD pure AZI formulation.
There was a fast burst observed with ~45% of drug being release at 5min. The
relatively high variation of drug release at first 40min was possibly due to poor
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dispersion of SD pure AZI powder in the release medium and due to the sampling
frequency. Thereafter particles continuously released the drug until 60min with ~92%
released. The drug release profile appeared to approach a plateau after 1h.

Figure 7.3. The apparent in vitro release profile of SD pure azithromycin formulation
in PBS at 37oC.

7.3.2.1 Effect of Phospholipids on Apparent in vitro Release of Azithromycin
Compared to SD pure AZI, the effect of PLS on in vitro drug release was studied in
the formulations of AZI:PLS=1:0.5, 1:1, and 1:2 for up to 24h. The AZI:PLS
formulations released AZI in similar fashion with approximately ~85% release in the
first 30min (Figure 7.4b). The formulations reached highest release percentage
(average of ~94%) at 3h and, thereafter, followed by a slight loss of drug up to 13h
(Figure 7.4a). Incorporation of PLS into SD particles significantly enhanced initial
release in the first 5min (Figure 7.4b). Within AZI:PLS formulations, AZI:PLS=1:1
had statistically relatively higher release percentage in the first 10min, followed by
AZI:PLS=1:2 and AZI:PLS=1:0.5, respectively (Figure 7.4b).
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Figure 7.4. The apparent in vitro release (a) full profiles and (b) first 60min profiles
of azithromycin:phospholipids vs azithromycin in PBS at 37oC.

7.3.2.2 Effect of Mannitol on Apparent in vitro Release of Azithromycin
To examine the effect of MAN on in vitro AZI release, AZI vs AZI:MAN=1:0.5,
AZI:PLS=1:0.5
vs
AZI:PLS:MAN=1:0.5:0.5,
and
AZI:PLS=1:2
vs
AZI:PLS:MAN=1:2:2 were paired, respectively. The MAN component appeared to
have no significant effect on the both corresponding formulations of SD pure AZI
(Figure 7.5a) and AZI:PLS=1:2 (Figure 7.5c). However, the comparison of
AZI:PLS=1:0.5 vs AZI:PLS:MAN=1:0.5:0.5 (Figure 7.5b) revealed that the
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incorporation of MAN component statistically significantly enhance the AZI release
for the up to 30min. After 30 minutes, there was no difference in the release profiles.
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(c)
Figure 7.5. The apparent in vitro release profiles of (a) azithromycin
azithromycin:mannitol=1:0.5,
(b)
azithromycin:phospholipids=1:0.5
and
azithromycin:phospholipids:mannitol=1:0.5:0.5,
azithromycin:phospholipids=1:2 vs azithromycin:phospholipids:mannitol=1:2:2
PBS at 37oC.
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7.4 Discussion
7.4.1 Validation of Release Assumptions
Several assumptions are made in the in vitro drug release study: 1) degradation of AZI
does not affect release profiles; 2) only free drug concentration of AZI is determined
in release study; 3) three components are all in one particle. In order to validate the
assumptions, several experiments or calculations were conducted to validate the
results shown in Figure 7.3-7.5.
7.4.1.1 Validation of Degradation of AZI Does Not Affect Release Profiles
As Section 6.3.1.2 suggested, AZI may degrade under conditions in in vitro drug
release. In order to assess the degradation effect on drug release profiles, the
degradation rate constant needs to be obtained. The degradation rate constants of AZI
(at 25oC and 37oC) were estimated based on the findings in the report[236] and by
using Arrehenius equation (Equation 7.1).
E

lnk obs = lnA − RTa (Equation 7.1)

Where A is the frequency factor, Ea is the energy of activation, R is the universal gas
constant, and T is the absolute temperature. Assuming the degradation reaction
mechanism (base catalysis with positive slope) is the same at pH value of 6.3 and 7.4
(Figure 3 in [236]) and given that the values of Ea (96.8 kJ/mol at pH value of 6.3) and
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k80 (9.37*10-4min-1 at pH value of 7.4 and at 80oC) (recalculated from the value from
Figure 3 in [236]), the reaction rate constants of k25 (at 25oC) and k37 (at 37oC) were
calculated to be ~2.13*10-6min-1 and ~9.66*10-6min-1, respectively.
C = C0 e−kt

(Equation 7.2)

The exponential decay equation for the integrated first-order rate law is shown in
Equation 7.2. Where C and Co are the concentrations of drug at time t and time 0
(initial time), e is exponential number, k is first-order reaction rate constant, and t is
release time.
To determine if putative degradation had any effect on the release profiles, the values
for AZI (Figure 7.3) were modified according to Equation 7.2. The two corrected
profiles were named as “one-correction” profile and “two-correction” profile,
respectively. The one-correction profile was carried out to correct for the possible
degradation of AZI during in vitro drug release using k37 (at 37oC) and collection time
during the study. The two-correction method was used to correct for possible
degradation of AZI both in the time of in vitro drug release by using k37 (at 37oC) and
the time between the samples were collected and analyzed by HPLC using k25 (at
25oC). The data suggest that there were no significant differences between the
apparent, “one-correction” and “two-correction” profiles. Similar results were
validated for other AZI formulations with release up to 24h. These results suggest that
no excessive degradation of AZI occurred during the time of release assay. Therefore,
only the apparent in vitro drug release profiles of formulations were plotted in Results
Section.

7.4.1.2 Validation of Only Free Drug Concentration of AZI Is Determined in
Release Study
It has been assumed that only free AZI was present in the filtrate. In order to
determine if phospholipids-associated AZI was also present in the filtrate, the ability
of the filter to prevent passage of phospholipids was studied. In order to detect the
presence of the phosphatidylcholine (PC) headgroup irrespective of hydrophobic
chain type for PLS content in filtrate, AZI:PLS=1:1 formulation was assessed by
HPLC using an evaporative light scattering detector (ELSD) as previously reported by
Modi et al.[237]. At 24h in vitro drug release, the release medium was collected and
centrifuged at 5,000g for 5min through a 30K filter unit of 15ml to obtain 10mL
filtrate. The filtrate was immediately dried by nitrogen gas and reconstituted in 1mL
chloroform. The precipitated phosphate salt (from PBS release medium) was filtered
through polytetrafluoroethylene (PTFE) syringe filter (organic solvent resistant,
0.22µm pore size; Tisch Scientific, USA) and a gas-tight glass syringe. The standard
DPPC and DPPG solutions were prepared by dissolving known amounts of DPPC and
DPPG in chloroform, based upon solubility limit and ELSD assay calibration range
for distearoylphosphatidylcholine (DSPC)[237]. The final concentrations for DPPC
and DPPG in each standard solution were prepared as 0.3 mg/mL and 0.05 mg/mL,
respectively. The pure chloroform, chloroform through PTFE filter, and AZI solution
in chloroform were also used as negative controls.
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Shown in Figure 7.6, is the ELSD chromatograms (last two chromatograms at bottom)
for the pure chloroform and chloroform through the PTFE syringe filter. No
significant peaks were detected. AZI standard showed a peak with a retention time of
approximately 1.75min. The DPPG standard showed no peak over 10min, suggesting
that the concentration may be below the limit of detection. The DPPC standard
exhibited a peak with a retention time at ~3min.
On the representative chromatogram of AZI:PLS=1:1 (named as A:L=1:1 in Figure
7.6) with high injection volume (50µL), the first peak (with retention time of ~1.9min)
and the second peak (with retention time of ~2.5min) were possibly from the parent
AZI and the degradation product(s) of the parent AZI. With low volume injection (et.
~2µL; data not shown), the possible degradation product(s) peak was not detected by
this assay. These results demonstrate that the DPPC, the major phospholipid in the
formulation, was not detected in the AZI:PLS=1:1. Therefore, there was no PLS
penetrated into filtrate and the AZI concentration analyzed by the HPLC assay was
only from free drug.

Figure 7.6. The representative HPLC chromatograms of the samples in phospholipids
assay.
7.4.1.3 Validation of Three Components Are All in One Particle
It is interesting to know that whether all three component (AZI, PLS, and MAN) are
all in one particle. Due to limitation of particle size (approximately > 2µm), it is
difficult to verify it with current available techniques. However, it is still reasonable
to assume that all three components are present in one particle. The starting solution
was prepared by dissolving all three components in methanol spray drying. Therefore
it is expected that, in the process of atomization, each of the droplets generated should
possess all three components since they were in uniform methanol dilute solution.
Thus the solid-state particle was highly expected to possess the three components
after the droplet was dried.
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7.4.2 Drug Release
It was noticed that there was ~90 to 100% of drug release from formulations that was
achieved in in vitro drug release in PBS at 37oC. The degradation and absorbance of
the drug were not likely to be the reasons to explain why there was drug remaining
during release study as we have discussed. AZI has limited intrinsic solubility with
~200 µg/mL at 25oC[238, 239]. A water solubility of 514 µg/mL of AZI was also
predicted[240]. Our preliminary data of as-received AZI (in dihydrate rich) and SD
pure AZI showed solubility of ~225 and ~490 µg/mL in water at 25oC, respectively.
The preliminary data highly agreed with reported values. The SD pure AZI particles
were amorphous rich and was expected to have extremely high surface area.
Therefore, the apparent solubility of SD pure AZI was much higher than its intrinsic
solubility of crystalline AZI. The AZI loading with 400 µg/mL was selected for SD
AZI formulations in the study. Although the selected drug loading (400 µg/mL) was
lower than the apparent solubility (~490 µg/mL), it was higher than the intrinsic
solubility (~200 µg/mL). Moreover, the solubility of azithromycin at 37oC was
reported to be slightly lower than the one at 25oC[239]. Therefore, the remaining
percentage of AZI loading possible either was not dissolved or precipitated after being
dissolved during release.

7.4.2.1 Effect of Phospholipids on Apparent in vitro Drug Release of
Azithromycin
In Section 6.4.1., compared to SD pure AZI, relatively statistically significant fast
initial (at 5min) free drug burst was observed for the SD AZI particles containing PLS
components. This result was somewhat surprising as it was expected that the presence
of phospholipids might slow the release process. At present, it is only possible to
speculate about the mechanism driving these results. Surfactants are well known to
have wetting effect[241] on hydrophobic drug particles. It was observed that the PLS
incorporated SD AZI particles were well suspended in release medium in comparison
to the particle floating issue for SD pure SD AZI, especially at the initial time points.
This possibly resulted in a fast burst release for SD AZI with PLC incorporated with
~72% at 5min. In addition, it could also be reasonably assumed that high fraction of
AZI molecules located on the particle surface, although drug release is an indirect
means of attempting to assess component location and direct methods would need to
be used to assess surface components. To help understand the proposed effect of PLS
on AZI release, Figure 7.7 illustrates three possible particle structures.
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Figure 7.7. The proposed scenarios of location of azithromycin drug molecules and
phospholipid bilayer in SD azithromycin:phospholipids particles.
Two extreme particle structures with phase separation are shown by structure (a) and
(b) in Figure 7.7. The AZI phase either surrounds phospholipid bilayer structure
(structure (a)) or is covered by phospholipid bilayer structure in particle (structure (b)).
The possibility of phase separation particle structure was ruled out by DSC (Table 4.3
& 4.4 in Chapter 4) and XRPD (Figure 4.3 & 4.4 in Chapter 4) data. The data
suggests that the integrity of phospholipid bilayer structure was diminished compared
to intact one from pure SD PLS particles. In addition, no delay at early time points in
drug release profiles further indicates the possible AZI:PLS phase separation in
particle structure (Figure 7.7b) was not likely to be the case. As shown in Figure 7.7c,
the in vitro drug release data of AZI:PLS might suggest the possibility that the
phospholipid bilayer is uniformly distributed in the SD particle and AZI molecules are
predominately located on or close to the particle surface. However, it is equally
possible that AZI and PLS are both evenly distributed within the particle, possibly
supported by the confocal Raman microscopy data (not shown).
Other factor might also influence the rate of AZI release. SEM micrograph of the SD
AZI:PLS=1:2 particles (Figure 3.4d in Chapter 3), with aerodynamic diameter >5µm
(Table 5.6 in Chapter 5), appeared to show fused aggregates. The formation of
aggregates would dramatically decrease the area-to-volume ratio especially for
particles under micron-sized. AZI:PLS=1:1 and 1:0.5 particles with better particle
formation (Figure 3.4e & 3.4f in Chapter 3) released more AZI for the first 10min.
Perhaps the relatively lower area-to-volume ratio of AZI:PLS=1:2 may offset the
wetting effect from PLS. Thus the apparent drug release profile of AZI:PLS=1:2
appeared to be somewhere between AZI:PLS=1:0.5 and 1:1 rather than exhibiting
fastest initial release (up to 10min). The slight loss of drug after 3h could be attributed
to partition of released drug into the liposomes in PBS from the released PLS, or into
the PLS matrix in dispersed particles. The similar slopes for drug loss were not well
understood given the fact that SD particles had different PLS content. Apparently the
slight loss of drug ended at 24h could possibly suggest the equilibrium among the
release of free AZI from SD particles, the formation of liposomes, and the partition of
free azithromycin molecules into liposomes or into PLS matrix in SD particles had
been reached. This study may also indicate the release of AZI and the release of PLS
from particles may follow different release modes with time.
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7.4.2.2 Effect of Mannitol on Apparent in vitro Drug Release of Azithromycin
The addition of MAN to AZI:PLS=1:0.5 significantly enhanced MAN release in
timescale up to 30min. Similar primary particle size (AZI:PLS=1:0.5 vs
AZI:PLS:MAN=1:0.5:0.5) (SEM: Figure 3.4f vs Figure 3.5h in Chapter 3; Size: Table
3.7 vs Table 3.8 in Chapter 3) suggests the enhanced dissolution of free AZI may
result from another factor. One possibility is an increased amorphous fraction of AZI
in the MAN-containing sample. MAN has been reported to exhibit intermolecular
hydrogen bonding in solid dispersion[242, 243]. The possible increased amorphous
fraction could arise from the hydrogen bonding interaction between AZI and MAN in
the SD AZI:PLS:MAN=1:0.5:0.5 particles. Support for this hypothesis is the
observation of an increase in glass transition temperature of AZI from ~76 to ~85oC
was observed by adding MAN to AZI:PLS=1:0.5. This change in glass transition
temperature could be possibly attributed by an increased amorphous phase of AZI in
AZI:PLS:MAN=1:0.5:0.5 compared to AZI:PLS=1:0.5. The addition of MAN had no
significant effect on the profiles of in vitro AZI release to SD pure AZI and
AZI:PLS=1:2. In addition, AZI:PLS=1:2 and AZI:PLS:MAN=1:2:2 formulations
were excipient abundant. Therefore, the addition of MAN to AZI:PLS=1:2 had no
significant effect on the amorphous content of AZI component in particles. However,
as discussed in Section 6.5.2.1, it could not be ignored that the effect of MAN on
apparent in vitro drug release could essentially originate from how particle wettability
is changed.

7.5 Conclusions
In general, the SD azithromycin formulations had a burst release (~50 to 80% at 5min)
and approached a plateau (until ~30 to 60min) in PBS at 37oC in vitro drug release
profiles. The AZI:PLS containing phospholipids exhibited a faster initial release (at
5min) in comparison to SD pure AZI particles. At the expense of increased particle
size, the increased wetting effect from increased phospholipids in AZI:PLS could be
minimized in the drug release profile. Data indirectly suggest that AZI may possibly
predominantly locate on the surface of particle with a uniform distribution of
phospholipid bilayer structure in particle. However, it is equally possible that AZI is
uniformly distributed with PLS as confocal Raman microscopy data may indicate. As
mannitol incorporated into particles, a relatively faster initial drug release could be
achieved. This could possibly result from the increase fraction of azithromycin
amorphous phase existing in particles with hydrogen bonding interaction between
mannitol and azithromycin in solid dispersion. Overall the in vitro drug release of
azithromycin was mainly dependent upon the particle composition and corresponding
particle size.
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Chapter 8 Summary and Conclusions

8.1 General Conclusions
The work in this dissertation showed that multi-component dry powder aerosols of
(non-destructive) mucolytic agent, antimicrobial drug, and lung surfactant mimic
phospholipids have been successfully produced by spray drying from organic solution.
In general, the microparticulate and nanoparticulate (typically 0.5 to 2 µm)
multi-component respirable aerosol particles possessed essential particle properties
suitable for deep lung penetration by sedimentation and diffusion, respectively. The
essential particle properties (e.g., narrow size distribution (typically 0.5 to 2 µm),
spherical particle and smooth surface morphologies, and low water content (or water
vapor sorption)) are expected to minimize interparticulate forces such as van der
Waals forces, electrostatic forces, mechanical interlocking, and capillary forces. As a
result of these properties, the majority of spray-dried (SD) multi-component aerosols
(including two-component and three-component systems) exhibited ability of deep
lung penetration with values of mass median aerodynamic diameter (MMAD) and
fine particle fraction (FPF) being approximately less than 5.0 µm and above 30.0% up
to 60.4%, respectively.
In the studied formulation compositions of multi-component particles with
phospholipid incorporation, phospholipid bilayer structure was retained after spray
drying. It was observed that the intensity of phospholipid bilayer structure was mainly
dependent upon the biophysical properties of incorporated antimicrobial drug. A
relatively lower intensity of phospholipid bilayer structure was observed for
azithromycin formulations compared to tobramycin formulations. This may possibly
explain the observed in vitro drug release profiles of phospholipid-containing
azithromycin formulations with no characteristics of extended drug release under the
conditions studied and using the particular in vitro release method described. In fact,
phospholipid-containing azithromycin formulations exhibited an enhanced burst
release likely due to the wetting effect from phospholipids in the particles.
The other components in SD multi-component particles are shown to lack long-range
molecular order. Partial crystallization of azithromycin (starting after one-month
storage at 40oC) in (phospholipid-containing) particles stored at 75% relative
humidity (RH) strongly impeded aerosol dispersion performance of the SD powder.
However, the SD azithromycin particles stored at conditions of 11% and 40% RH
retained the ability of deep lung penetration. Tobramycin in SD multi-component
particles were chemically unstable with an indication of color change at 40% and 75%
RH. Although no evident phase transition was detected, SD tobramycin
multi-component particles stored at 11% RH exhibited MMAD > 5 µm. This may be
caused by the well-known hygroscopic nature of tobramycin. Mannitol in SD
multi-component formulations remained unchanged in physical phase after storage at
all studied conditions.
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8.2 Future Work
To further support the specific application of SD multi-component aerosol particles
for chronic infection diseases in the deep lungs, some future studies might need to be
carried out.
1) Expand the molar ratio for SD multi-component particles
In this dissertation, high (antimicrobial) drug loading formulation was focused on
with the goal of achieving high local concentrations while reducing the aerosol
treatment burden and the potential for causing bacterial resistance in the lungs.
Patients with chronic infections in deep lungs may have various conditions during
disease progress[244, 245]. Therefore, there are some demands on tailoring
formulation compositions specifically treat individual patient with certain disease
conditions in various stages. However, expansion of the formulation compositions
may possibly have a significant change in physicochemical properties of the
formulations, affecting aerosol dispersion performance, storage stability, and in vitro
drug release profiles of the powders. Therefore, physicochemical evaluation and
formulation performance for SD multi-component formulations with expansion in
molar ratios are important to be studied.
2) Equilibrium spreading pressure of phospholipid-containing SD particles by using
Langmuir surface biophysical analysis
Pulmonary surfactants can lower the surface tension of interfacial layer. Studies has
been shown that pulmonary surfactants promote the displacement of particles from air
to mucus or aqueous phase and that the extent of particle immersion depends on the
surface tension of the surface active film[246-249]. The data showed that a greater
immersion of the latex particles into the subphase of an alveolar lining layer could be
achieved by lowering the surface tension of the layer. The enhancement in particle
penetration into mucus would potentially help decrease bacteria (such as
Pseudomonas aeruginosa colonized in mucus with formation of biofilm[250]) density
in mucus as particles could release antimicrobial drug to the sites where bacteria
reside. The enhancement of particle penetration into mucus may only benefit for the
subsequent dosing in our study. The equilibrium spreading pressure[251-253] (πe = γ0
- γeq; γ0 and γeq are the surface tension before and after adding formulation,
respectively), a measure of surface tension change, will be examined with
phospholipids-containing SD particles. The method has been established by our
research group[251, 253] using Langmuir surface analysis. In addition, surface
tension in deep lung region may play a critical role in respiratory control, regulation
of pulmonary immunity, and etc.[9, 10]. Therefore, it will be also necessary to
monitor the surface tension (γeq) of air-liquid interface as SD multi-component
particles release phospholipids. The studies will be conducted on the mucus from
patients with chronic infections in deep lungs (or phosphate buffer saline (PBS) at PH
7.4, and in vitro model of lung fluid[233]) at 37oC.
3) in vitro release of mannitol and phospholipids from SD multi-component particles
Mannitol
and
phospholipids
(dipalmitoylphosphatidylcholine
(DPPC):dipalmitoylphosphatidylglycerol (DPPG)=4:1 (molar ratio)) are proposed to
act as (non-destructive) mucolytic agent and lung surfactant mimic phospholipids for
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the treatment of chronic deep lung infection diseases, respectively. Therefore, the
release patterns of mannitiol and phospholipids from SD multi-component particles
needs to be studied. A dry powder for inhalation (DPI) formulation of mannitol as a
marketed pharmaceutical product (BronchitolTM) is approved in Europe and has been
very recently approved for clinical trials in the US.[44] It is used as an osmotic agent,
also known as non-destructive mucolytic agent, to dilute mucus density.[108] In
addition, a similar release pattern of DPPC and DPPG from the particles would be
beneficial to maintain a constant ratio of DPPC to DPPG. The release study can be
conducted in PBS at PH 7.4 (or in vitro model of lung fluid[233], and mucus from
patients with chronic infections in the deep lungs). The concentration of mannitol and
phospholipids could be determined by high pressure liquid chromatography (HPLC)
equipped with a refractive index detector[254] and a evaporative light scattering
detector[255], respectively.
4) in vivo animal study of SD multi-component particles
It is important to examine whether the respiratory functions of in vivo animal model
with chronic infections in the deep lungs can be improved after administration of the
multi-component powders. The diseases such as cystic fibrosis (CF) could be possibly
studied. The mice, pigs or ferrets CF models[256] could be used for this study. The
larger animal models (pigs and ferrets) have phenotypes that appear to closely
resemble human CF disease seen in newborns. Formulation with different
compositions could be tested. The initial dosing of aerosol particles to animals would
be determined for eliciting bacterial killing on infected sputum from CF patients,
quantifying the bacterial killing concentrations needed.

Copyright © Xiaojian Li 2014
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Appendices

This section contains the following additional information:

Appendix A: Spray-Dried Mannitol Aerosols
Appendix B: Spray-Dried Trehalose Aerosols
Appendix C: Spray-Dried Itraconazole Aerosols
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Appendix A Spray-Dried Mannitol Aerosols
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Abstract
Background: The purpose was to design and characterize inhalable
microparticulate/nanoparticulate dry powders of mannitol with essential particle
properties for targeted dry powder delivery for cystic fibrosis mucolytic treatment by
dilute organic solution spray-drying, and, in addition, to tailor and correlate aerosol
dispersion performance delivered as dry powder inhalers (DPIs) based on
spray-drying conditions and solid-state physicochemical properties. Methods:
Organic solution advanced spray drying from dilute solution followed by
comprehensive solid-state physicochemical characterization and in vitro dry powder
aerosolization was used. Results: The particle size distribution of the spray-dried (SD)
powders was narrow, unimodal, and in the range of ~500 nm to 2.0 µm. The particles
possessed spherical particle morphology, relatively smooth surface morphology, low
water content and vapor sorption (crystallization occurred at exposure above 65%
relative humidity), and retention of crystallinity by polymorphic interconversion. The
emitted dose, fine particle fraction (FPF) and respirable fraction (RF) were all
relatively high. The mass median aerodynamic diameters were below 4 µm for all SD
mannitol aerosols. Conclusion: The in vitro aerosol deposition stage patterns could be
tailored based on spray-drying pump rate. Positive linear correlation was observed
between both FPF and RF values with spray-drying pump rates. The interplay
between various spray-drying conditions, particle physicochemical properties, and
aerosol dispersion performance was observed and examined, which enabled tailoring
and modeling of high aerosol deposition patterns.
Keywords: cystic fibrosis, aerosol performance modeling; osmotic agent; respiratory;
lung; confocal Raman chemical imaging; DPI; particle engineering design; solid-state
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Introduction
Cystic fibrosis (CF) is the most common life-shortening, chronic hereditary disease
among the Caucasian population, affecting approximately 60,000 individual
worldwide[116]. CF leads to accumulation of thick and sticky mucus that affects the
lungs. This lung disease is characterized by a cycle of bacterial infection and lung
damage, causing death in early ages for CF patients[257]. Pulmonary delivery of
therapeutic dose to local lung has tremendous advantages over other administration
routes[69]. Pulmonary drug delivery systems include nebulizers, pressurized
metered-dose inhalers (pMDIs), soft-mist inhalers (SMIs), and dry powder inhalers
(DPIs). Within each class further differentiation is based on metering, means of
dispersion, or design. DPIs have unique advantages including high dose delivery,
higher chemical stability relative to the liquid state, and the potential to tailor particle
properties in the solid-state. The performance of DPI formulations is influenced by
several particle properties including size, size distribution, morphology, and particle
surface properties (i.e. surface morphology and interparticulate forces including van
der Waals, mechanical interlocking, electrostatic, and capillary forces), as described
in detail by the authors[68, 69, 184, 258-263].
There are several methods available to make respirable particles, including
micronization, precipitation, freeze drying, and spray drying[68-70]. Spray drying is a
high-throughput process with the ability to produce particles in a more controlled
manner, such as directing particle size and size distribution, and particle morphology,
which are important particle features for pulmonary dry powder drug delivery by
inhalation. As the chronic lung infection of CF resides in lower respiratory tract and
small peripheral airways[133] where disease progression starts[264, 265], the
microparticulate and nanoparticulate aerosols (~0.5-2µm in diameter)[134-136] have
particle deposition by sedimentation and diffusion[266] mechanisms, respectively.
The advantages of particle engineering by spray drying for the design of DPI
formulations are related to the optimization of important particle properties such as
surface morphology, particle morphology, particle size, and size distribution by
controlling and tailoring spray-drying parameters such as feeding solution conditions
(i.e. solvent type, concentration, and feeding rate) and drying gas conditions (i.e. gas
type, inlet and outlet temperatures, and flow rate)[68, 70]. Organic solution advanced
spray drying in closed-mode for pulmonary applications as DPIs has been reported in
our previous studies[161-164]. The essential particle properties for targeted delivery
to smaller airways and deep lung region include microparticulate/nanoparticulate size
range with relatively narrow unimodal sizing distribution (enhance dosing
reproducibility), spherical particle morphology with relatively smooth surface
morphology (reduce mechanical interlocking, van der Waal and electrostatic forces),
and low water content (lower capillary condensation)[41, 63].
D-mannitol is a non-reducing sugar alcohol that is used as an osmotic agent[267].
D-mannitol has also been used as sugar carriers in carrier-based dry powder for
inhalation[46]. Dry powder mannitol, when inhaled, creates an osmotic gradient that
facilitates an efflux of water into the airway lumen by which it increases the water
content in the airway surface liquid (ASL) and promotes the clearance of mucus by
ciliary movement and cough action. The detailed mechanisms are described in
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literature[108, 268-272]. A DPI formulation of mannitol as a marketed
pharmaceutical product (BronchitolTM) is approved in Europe and has been very
recently approved in the United States. The polymorphic system of D-mannitol has
been well documented[175, 273].
In this comprehensive and systematic study, the organic solution closed-mode
advanced spray-drying technique was employed using organic solvent (i.e. an alcohol)
to minimize the residual water content and reduce the primary particle size in the solid
state. In addition, inhalable mannitol aerosol powders were designed and optimized to
target the lung regions where excess viscous mucus is present in CF lungs. In this
study, the interplay between spray-drying conditions, mannitol polymorphic
interconversion behavior, physicochemical properties in the solid-state, and their
influence on in vitro aerosol dispersion performance deposition patterns as high
performing microparticulate/nanoparticulate DPIs are reported for the first time.

Materials and Methods
Materials
Raw D-mannitol (C6H14O6; M.W.: 182.17 g/mol) was from Sigma-Aldrich (St. Louis,
Missouri). Methanol (HPLC grade, ACS-certified grade, purity 99.9%) and
chloroform (HPLC grade, ACS-certified grade, purity 99.9%) were obtained from
Fisher Scientific (Fair Lawn, New Jersey). HYDRANAL@-Coulomat AD was from
Sigma-Aldrich (St. Louis, Missouri). AQUA STAR methanol was from EMD
chemical Inc. (Gibbstown, New Jersey). Raw D-mannitol was used as received and
stored under room conditions. Ultra-high purity (UHP) nitrogen gas (Scotts Gross,
Lexington, KY) was used for all experiments.

Methods
Preparation of Spray Dried Particles by Organic Solution Advanced
Spray-Drying (no water) in Closed-Mode
Organic solution advanced spray-drying process in the absence of water using dilute
drug solutions was performed in closed-mode using a Büchi B-290 Mini Spray Dryer
with a high performance cyclone and UHP dry nitrogen gas as the atomizing drying
gas, and connected to the B-295 Inert Loop (Büchi Labortechnik AG, Flawil,
Switzerland). The feeding solution was prepared by dissolving mannitol in methanol
to make a dilute drug solution with a concentration of 0.1% w/v. The following
optimized conditions, as reported in our previous studies[161-164], were used during
spray drying: atomization rate, 600 L/h; aspirate rate, 35 m3/h; pump rate (%): 3
ml/min (10%) (low pump rate), 15 ml/min (50%) (medium pump rate), and 30 ml/min
(100%) (high pump rate). The inlet temperature was set at 150oC. The corresponding
outlet temperatures for each spray-dried (SD) mannitol formulations were
summarized in Table A.1. The stainless steel nozzle diameter was 0.7mm. SD
mannitol particles were separated from the nitrogen drying air in the cyclone and
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collected in a sample collection vial. All SD powders were carefully stored in sealed
glass vials that were stored in sealed glass desiccators over indicating
Drierite/DrieriteTM desiccant at -20oC under ambient pressure.
Table A.1. Summary of organic solution advanced spray drying in closed-mode
conditions.
Chemical agent

Pump Rate (%)

Mannitol

10
50
100

Inlet Temperature
(oC)
150
150
150

Outlet Temperature
(oC)
82
58
38

Scanning Electron Microscopy (SEM)
Using conditions previously reported,[161-164] visual imaging and analysis of
particle size, morphology, and surface morphology were achieved by SEM using a
Hitachi S-800 microscope (Tokyo, Japan). Samples were placed on double-sided
adhesive carbon tabs (TedPella, inc.) which were adhered to aluminum stubs
(TedPella, inc.) and were coated with gold/palladium alloy thin film using a Hummer
VI sputtering system from Technics. The coating process operated at 10mA in AC
with 8kV of voltage for 3min. The electron beam with an accelerating voltage of
20kV was used at a working distance of 30mm. SEM images were captured by Evex
NanoAnalysis. Several magnification levels were used.
Laser Light Diffraction Particle Sizing and Size Distribution
Using conditions previously reported,[161-164] the mean size and size distribution of
SD mannitol particles in chloroform suspension were determined by ultraviolet laser
diffraction of nano particle size analyzer SALD-7101 (Shimadzu Scientific
Instruments, Japan) as reported[161-164]. Samples were dispersed in chloroform and
ultrasonicated for 10s in water bath ultrasonicater Branson 5210 (Danbury,
Connecticut) before measuring particle size. Sample particle dispersion was
immediately transferred to particle size measuring cell and kept stirring during
measuring in nano particle size analyzer. The low refractive index 1.60-0.10 was used.
A volume-based dimension of particle amount distribution was obtained for samples.
DV10, DV50, and DV90 were used as particle size characterization parameters. The span
value was calculated using the equation defined as [(DV90-DV10)/DV50]. All
experiments were done in triplicate (n=3).
X-Ray Powder Diffraction (XRPD)
Using conditions previously reported,[161-164] XRPD patterns of mannitol samples
were collected with a Rigaku X-ray diffractometer (Japan) with Cu Kα radiation
(40kV, 44mA, and λ=1.5406Å) between 5.0 – 60.0º (2θ) with a scan rate of 2.00o/min
at ambient temperature as reported[161-164]. The sample was placed on a quartz plate
in an aluminum sample holder without further grinding.
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Differential Scanning Calorimetry (DSC)
Using conditions previously reported,[161-164] thermal properties of mannitol
samples were measured using a TA Q200 DSC (TA Instruments, New Castle, DE,
USA) equipped with T-Zero® technology and an automated computer-controlled
RSC-90 cooling accessory as reported[161-164]. Approximate 2mg sample was
packed into hermetic anodized aluminum T-Zero® DSC pan which was then
hermetically sealed with the Tzero hermetic sealer (TA Instruments, New Castle, DE,
USA). An empty hermetically sealed aluminum pan was used as the reference pan.
UHP nitrogen was used as a purging gas at a rate of 50 ml/min. The sample was
heated from 10-200oC at a scanning rate of 5.00oC/min. All experiments were done in
triplicate (n=3).
Hot-Stage Microscopy (HSM) Under Cross-Polarizers
Using conditions previously reported,[161-164] HSM studies were performed under
OLYMPUS BX51 polarized microscope (Olympus, Japan) equipped with INSTEC
STC200 heat unit and INSTEC HCS302 hot stage (Boulder, Colorado) as
reported[161-164]. The polarized light was filtered by γ 530nm U-TP530 (Olympus,
Japan). Mannitol samples were mounted on cover glass and heated from 25oC (room
temperature) to 200oC at a heating rate of 5.00oC/min. The heating program was
controlled by WinTemp software. Pictures of the samples were captured by a SPOT
insight digital camera (Diagnostic Instruments, Inc.).
Karl Fischer (KF) Coulometric Titration
Using conditions previously reported,[161-164] the water content of mannitol
powders was assessed by KF coulometric titration. The measurements were
performed with a 737 KF Coulometer coupled with 703 Ti Stand (Metrohm Ltd.,
Antwerp, Belgium) as reported[161-164]. Around 6 to 7mg of sample was dissolved
in AQUA STAR methanol with a 5mL volumetric. The sample solution was injected
into reaction cell filled with HYDRANAL KF reagent. The water content of sample
was obtained from simple calculation. The experiments were done in triplicate (n=3).
Gravimetric Vapor Sorption (GVS)
Using conditions previously reported,[161, 162, 164, 165] water vapor sorption
isotherms were measured gravimetrically using an automated microelectronic balance
coupled to a computerized VTI SGA-CX symmetric vapor sorption analyzer (Hialeah,
Florida). All measurements were taken at 25oC using a sample size of ～1.0 to 1.5mg.
Samples were subjected to drying treatment at 25oC under 0% relative humidity (RH)
(nitrogen gas purging) for up to a maximum of 7h with equilibrium criterion of weight
change less than or equal to 0.0001% in 10min interval. At the end of the drying cycle,
the samples were exposed to a sequence of increasing RH with increment of 5% RH
on each step, which started at 5% RH until 95% RH. The criterion used to establish
equilibrium during adsorption was a weight change of less than or equal to 0.03% in
10min interval for up to 3h. The data point was acquired at every 2min or 0.01%
weight change. The standby temperature was set as 25oC.
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Confocal Raman Microscopy (CRM) and Spectroscopy for Chemical Imaging
and Mapping
CRM has demonstrated utility in the non-invasive and non-destructive
microspectroscopic analysis of DPI aerosol formulations as described in detail by the
authors[274, 275]. Using conditions previously reported[163, 275], dispersive Raman
spectra and mapping images of mannitol samples were obtained using an Aramis
confocal Raman spectrometer and fluorescence microscope system (Horiba Jobin
Yvon, Edison, NJ, USA). The system is equipped with an Olympus BX41 confocal
optical microscope, an Olympus U-LH 100W Hg lamp, and U-RFL-T power source
used for fluorescence excitation and brightfield illumination (Olympus America, Inc.,
Chester Valley, PA). Raman spectra were obtained using both a 785nm diode laser
and a 633nm HeNe laser. Raman spectral maps were obtained using a ×10 objective
with the stage moved in increments of 5 to 10µm. Each map point was acquired using
32 to 128 accumulations each with 2s of detector exposure time. A confocal hole of
500µm, a grating of 600-900 grooves/mm, and a slit width of 100µm were used.
Spectra were subjected to baseline correction and smoothing prior to further analysis.
Fourier-transform Raman (FT-Raman) experiments were performed using a Nicolet
FT-Raman 960 spectrometer equipped with InGaAs and Ge detectors (ThermoFisher
Scientific, Madison, WI). Samples were analyzed using a 180° collector or a
horizontal video-controlled stage with a 50µm spot size, and 32 to 1024 co-added
scans were collected at 4cm-1 resolution. A 1.064µm laser was used with a power
setting of 0.6W.
Attenuated Total
(ATR-FTIR)

Reflectance-Fourier Transform Infrared

Spectroscopy

A Varian FTS-7000e FTIR spectrometer (Varian Inc., CA) equipped with a DTGS
detector and a PIKE MIRacle ATR ZnSe accessory was used for all experiments.
Each spectrum was collected for 32 scans at a spectral resolution of 8cm-1 over the
wavelength number range of 4,000-700cm-1. A background spectrum was done under
the same experimental conditions and was subtracted from each sample spectrum.
Spectral data were acquired with Varian Resolutions Pro software.
In Vitro Aerosol Dispersion Performance by the Next Generation Impactor
(NGI)
In accordance with United States Pharmacopeia (USP) Chapter <601> specifications
on aerosols[178] and using conditions previously reported[161, 163], the aerosol
dispersion performance of SD mannitol was conducted using the next generation
impactor (NGI; Corporation, Shoreview, MN) with a stainless steel induction port (i.e.
USP throat) attachment (NGI Model 170, MSP Corporation), equipped with
specialized stainless steel NGI gravimetric insert cups (MSP Corporation) and the
HandiHaler® (a high shear stress DPI device, Boehringer-Ingelheim Inc., Germany).
The airflow rate (Q) of 60 L/min (adult airflow rate) was adjusted and measured
before each experiment by a Copley DFM 2000 flow meter (Copley Scientific, United
Kingdom). The NGI was coupled with a Copley HCP5 vacuum pump (Copley
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Scientific) and a Copley TPK 2000 critical flow controller (Copley Scientific). The
aerosolization was experimentally designed by Design Expert 8.0.7.1 software
(Stat-Ease Corp., MN). The mass of powder deposited on each stage was quantified
by gravimetric method using type A/E glass fiber filters with diameter 55mm (PALL
Corporation, NY). Each HP-clear size 3 capsule (Quali-V®) (QUALICAPS, Spain)
contained about 10 mg of powder. Three capsules were used in each experiment. In
vitro aerosolization experiments were conducted in triplicate under ambient
conditions.
For the NGI Q=60 L/min, the effective cutoff diameter (Da50) for each NGI stage was
calibrated by the manufacturer and stated as: stage 1 (8.06μm); stage 2 (4.46μm);
stage 3 (2.82μm); stage 4 (1.66μm); stage 5 (0.94μm); stage 6 (0.55μm); and stage 7
(0.34μm). The emitted dose (ED) was determined as the difference between the initial
mass of powder loaded in the capsules and the remaining mass of powder in the
capsules following aerosolization. The emitted dose fraction (ED[%]; Equation A.1)
was used to express the percentage of ED based on the total dose (TD) used. The fine
particle dose (FPD) was defined as the dose deposited on stage 2 through 7. The fine
particle fraction (FPF[%]; Equation A.2) was expressed as the percentage of FPD to
ED. The respirable fraction (RF[%]; Equation A.3) was used as the percentage of
FPD to total deposited dose (DD) on all impactor stages.
Emitted dose fraction (ED[%]) =

Fine particle fraction (FPF[%]) =
Respirable fraction (RF[%]) =

ED

x 100%

TD
FPD

FPD
DD

ED

x 100%

x 100%

(Equation A.1)
(Equation A.2)
(Equation A.3)

In addition, the mass median aerodynamic diameter (MMAD) of aerosol particles and
geometric standard deviation (GSD) calculated by using a mathematic program
written by Dr. Warren Finlay[183]. All experiments were done in triplicate (n=3).
Data and Statistical Analysis
All experiments were performed in at least triplicate. The results were analyzed
statistically using Microsoft Office Excel 2007 (Microsoft Corp., WA, USA). The
results are expressed as mean ± standard deviation. The aerosolization studies were
experimentally designed using design of experiments by Design Expert™ 8.0.7.1
software (Stat-Ease Corp., MN). The level of statistical significance was performed at
0.05.
Results
Scanning Electron Microscopy (SEM)
Three different batches of SD mannitol particles were successfully produced by using
low (10%), medium (50%), and high (100%) pump rates from dilute organic solution
advanced spray drying. The detailed spray-drying conditions were introduced in
Methods sections and Table A.1. The particle morphology and surface structure of the
mannitol samples were visualized via SEM in Figure A.1. The particle shape of raw
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D-mannitol (Figure A.1a) was irregular. The particle size of raw D-mannitol was far
beyond the respiratory size for dry powder inhalation (DPI) which is less than 10µm.
Generally, the smooth and spherical mannitol particles (Figure A.1b-d) were produced
at each spray-drying condition. However, as the pump rate increased from 10% (low)
to 100% (high), the surface of SD mannitol particles became slightly rougher. In
addition both nanoparticles and microparticles of SD mannitol (linear geometry) were
produced by spray drying under optimized conditions.

(a)

(b)

(c)

(d)

Figure A.1. SEM micrographs of raw (magnification 100X) and SD mannitol
particles (magnification 10,000X) for: (a) Raw D-mannitol; (b) SD mannitol (10%P);
(c) SD mannitol (50%P); (d) SD mannitol (100%P).
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Laser Light Diffraction Particle Sizing and Size Distribution
The laser sizing data of SD mannitol particles are summarized in Table A.2. The
particle size distributions of SD mannitol were all in unimodal distribution by laser
light diffraction. The median diameter (DV50) increased from 0.486µm to 0.702µm for
SD mannitol as spray-drying pump rate increased from 10% (low) to 100% (high).
The D90 was slightly above micro-size with 1.147~1.302µm for SD mannitol particles.
Therefore, the majority of SD mannitol particles were under micro-size range. The
span value for SD mannitol was between 1 and 2.
Table A.2. Laser sizing of SD mannitol particles (mean ± SD, n=3).
Pump Rate
(%)
10
Mannitol 50
100
Particles

DV10
(µm)
0.346±0.002
0.354±0.003
0.482±0.132

DV50
(µm)
0.486±0.006
0.521±0.016
0.702±0.141

DV90
(µm)
1.147±0.205
1.302±0.101
1.247±0.016

Span Value
1.646±0.398
1.819±0.145
1.156±0.498

X-Ray Powder Diffraction (XRPD)
X-ray powder diffraction patterns (Figure A.2) of raw D-mannitol showed sharp and
intensive peaks indicating the existence of long-range molecular order. SD mannitol
samples remained peaks after spray-drying process. The XRPD data reflected that raw
D-mannitol and SD mannitol samples were in crystalline phase. However the peaks
positions and intensity varied with samples.

Intensity

100% Pump rate
SD
50% Pump rate SD

10% Pump rate SD

raw
5

10

15

20

25

30

35

40

45

50

55

2 Theta (degrees)
Figure A.2. X-ray powder diffraction patterns for raw and SD mannitol particles.
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Differential Scanning Calorimetry (DSC)
The thermograms obtained from mannitol samples are shown in Figure A.3 and the
detailed values of melting peak enthalpy and temperature are tabulated in Table A.3.
It was seen that raw D-mannitol had one sharp endotherm with peak temperature at
~166.4oC and enthalpy of 303.4J/g in Figure A.3a. Interestingly, the endothermic
temperature and enthalpy of SD mannitol samples decreased from ~165.3oC, 164.7oC,
and 164.3oC and ~304.2J/g, 288.7J/g, and 282.4J/g as the spray drying pump rates
increased from 10% (low) to 100% (high), respectively.

(a)

(b)

(c)

(d)

Figure A.3. DSC thermograms of raw and SD mannitol particles for: (a) Raw
D-mannitol; (b) SD mannitol (10%P); (c) SD mannitol (50%P); (d) SD mannitol
(100%P).
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Table A.3. DSC thermal analysis of raw and SD mannitol particles (mean ± SD, n=3).
Samples

Enthalpy (J/g)

Raw
SD 10%P
SD 50%P
SD 100%P

303.40±2.21
304.23±9.06
288.67±10.47
282.43±4.45

Melting Point (oC)
Onset
Peak
165.04±0.03
166.41±0.19
163.69±0.03
165.34±0.04
162.66±0.04
164.68±0.06
161.40±0.45
164.29±0.14

Hot-Stage Microscopy (HSM) Under Cross-Polarizers
Raw and SD mannitol (from 50% (medium) pump rate as a representative sample)
powders were visualized under cross-polarized light microscopy as a function of
increasing temperature for the presence/absence of birefringency. There were no
obvious differences at room temperature (25oC) and physiologic temperature (37oC)
in terms of morphology or shape for both samples in Figure A.4. The raw D-mannitol
crystal was highly crystalline as seen from HSM pictures in Figure A.4a. The evident
phase transition (thermodynamic melting phase transition) of D-mannitol initialized
from 181oC with subtle change in birefringency and finished at 182oC, which was in a
relatively narrow temperature range. The SD mannitol had phase transition of melting
at a slightly lower temperature (178oC) than the raw D-mannitol. As raw D-mannitol,
the melting temperature range for SD mannitol was narrow as well.

25 oC

37 oC

181 oC

182 oC

178 oC

179 oC

(a)

25 oC

37 oC
(b)

Figure A.4. HSM micrographs of raw and SD mannitol (50%P) particles for: (a) raw
D-mannitol; (b) SD mannitol (50%P).
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Karl Fischer (KF) Coulometric Titration
The residual water content in the powders is summarized in Table A.4. It was noted
that the water content of raw D-mannitol had a lower value (~0.53% (w/w)) than its
SD counterparts. The water content for SD mannitol increased with spray-drying
pump rates from low to high and was higher than raw D-mannitol. However, the
water content values were all below 2% (i.e. very low) which is significantly
important for chemical and formulation stability. The low water content value ruled
out the possibility of hemihydrates of mannitol[276].

Table A.4. Water content of raw and SD mannitol particles (mean ± SD, n=3).
Samples
Raw
SD (10% pump rate)
SD (50% pump rate)
SD (100% pump rate)

Water Content (% (w/w))
0.53±0.26
1.16±0.04
1.69±0.08
1.96±0.32

Gravimetric Vapor Sorption (GVS)
The dynamic water vapor sorption profiles are plotted in Figure A.5 for raw and SD
mannitol (from 50% (medium) pump rate as a representative sample). Overall the
mass of raw mannitol almost did not change across the whole RH range from 0% to
95% RH. The SD mannitol followed the same behavior upon RH increments except
the small increase at 95% RH. This was in agreement with the fact that mannitol is the
least hygroscopic of polyols and does not start to sorb moisture until the RH is over
90%[277]. However, there was a small weight loss observed from the RH range of 65%
to 90%.
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Figure A.5. Water vapor sorption isotherms at 25oC for raw and SD mannitol (50%P)
particles (Weight Change % vs RH).

Confocal Raman Microscopy (CRM) and Spectroscopy for Chemical Imaging
and Mapping
Raman spectroscopy is highly sensitive to the polymorphic form of mannitol, as
shown by the FT-Raman spectra of bulk samples of each phase in Figure A.6a
obtained using a 1.064µm laser. The bulk samples of alpha, beta, and delta mannitol
were prepared by rapid evaporation from water, slow evaporation from water, and
lyophilization, respectively, and were checked by XRPD. As shown in Figure A.6a,
the Raman spectral region between 2850 and 3000cm-1 was particularly specific for
each polymorphic form. These results can be compared to the spectra obtained by
CRM of a mapped region (2910 to 2940cm-1) of SD mannitol from a 50% (medium)
pump rate experiment, as shown in Figures A.6b and A.6c. The CRM spectra were
obtained using a 633nm laser as mannitol shows minimal fluorescence. From
examination of the map and spectra in Figures A.6b and A.6c, the material was seen
to be primarily the alpha polymorph of mannitol. No indication of heterogeneity was
observed in the map in Figure A.6b for bands in the 2910 to 2940cm-1 region
associated with alpha mannitol, with the only trend observed being the result of
sample topology differences. Spectra taken from three individual points in this map
were compared in Figure A.6c, highlighting the lack of significant differences
observed and the close similarity with the reference spectrum of the alpha phase
shown in Figure A.6a. A similar analysis of Raman bands in the region of 860 to
900cm-1 (not shown), which are also selective for D-mannitol polymorphic form,
yielded the same result.
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Figure A.6. (a) FT-Raman spectrum of bulk phases of mannitol; (b) CRM map of a
region of flattened SD mannitol (50%P) particles obtained using a ×50 objective,
showing Raman band intensity between 2910 and 2940 cm-1 as blue intensity; (c)
Expanded CRM spectra of three points on the map in (b).
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Attenuated Total
(ATR-FTIR)

Reflectance-Fourier Transform Infrared

Spectroscopy

Figure A.7 shows the FT-IR spectra of mannitol particles. Differences were mainly
detected in the band range of 1500-1200cm-1, indicating the differences of C-H
deformation vibration. These were attributed to different mannitol polymorphs[278].

SD mannitol (100%p)
SD mannitol (50%p)
SD mannitol (10%p)
Raw mannitol

3900 3700 3500 3300 3100 2900 2700 2500 2300 2100 1900 1700 1500 1300 1100
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Figure A.7. ATR-FTIR spectra for raw and SD mannitol particles.

In Vitro Aerosol Dispersion Performance by the Next Generation Impactor
(NGI)
Figure A.8 shows SD particle deposition profiles on each of the NGI stage at airflow
rate (Q) of 60 L/min. As indicated in the profile, the SD mannitol powder produced
from high spray-drying pump rate exhibited low particle deposition on stage 1
(effective cutoff diameter of 8.06µm) and high particle deposition on stages 2-4.
However, compared to the other two formulations, particle deposition fraction was
reduced for particles generated from high pump rate on stages 5-7 that was in the
aerodynamic nanometer size range. The aerosol dispersion performance parameter
values are listed in Table A.5. The FPF and RF of SD mannitol particles exhibited
high, while having similar ED, as pump rates increased for spray drying. All SD
mannitol powder had MMAD <4µm from the HandiHaler® under Q of 60 L/min.
However, the GSD decreased, indicating aerodynamic size distribution being
narrower, as the pump rates increased from 10% to 100%.
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Figure A.8. In vitro aerosol dispersion performance using the NGI under an airflow
rate (Q) of 60 L/min with the HandiHaler® DPI device for SD mannitol (n=3).
Table A.5. Aerosol dispersion performance parameters of SD mannitol particles
(mean ± SD, n=3).
SD Mannitol

Aerosol Dispersion Performance Parameters

Pump Rate
(%)

ED
(%)

FPF
(%)

10

85.07±2.13

36.02±3.70 60.54±5.77 3.16±0.47 2.57±0.18

50

83.72±2.58

44.18±2.77 65.67±1.74 2.76±0.09 2.32±0.12

100

82.33±10.61 54.84±4.84 80.95±6.36 3.49±0.36 1.85±0.08

RF
(%)

MMAD
(µm)

GSD

Discussion
The present work clearly demonstrated that mannitol micro/nanoparticulate aerosols
can be successfully produced by advanced spray drying dilute organic solutions. By
using advanced spray-drying technique with low concentration of organic solvent
solution, the microparticulate/nanoparticulate aerosols were successfully produced
with narrow particle size distribution, low water content, suitable particle shape and
morphology. The narrow particle size distribution is essentially critical for pulmonary
dry powder inhalation, as it enables the aerosols to target a specific lung region
without spreading the dose in the whole lungs. Targeted aerosols lower the
therapeutic dose and toxic effects. Therefore they enhance the therapeutic outcome.
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More importantly microparticulate/nanoparticulate aerosols ensure particle
penetration to middle and deep lung regions of CF patients where excessive mucus
locates. In addition, particle engineering process of spray drying can optimize particle
size, shape, as well as morphology, which will result in better aerosol dispersion
performance given as dry powder formulations. Low water content (< 6% w/w) of
particles slows down chemical degradation process via hydrolysis and, in addition,
decreases capillary forces between particles.
In general the majority of SD mannitol particle was in nanoparticulate primary size
range of ~0.5-1µm (Table A.2), which is beneficial for deep lung penetration by
diffusion of particle deposition mechanism, while the particles with size range of
~1-2µm would have particle deposition by sedimentation. On the other side, the
narrow particle size distribution with span value of 1-2 (Table A.2) theoretically
indicates reproducible aerosol particle aerodynamic performance, which is clinically
important for therapeutic reproducibility.
As pump rates in spray-drying process increased from 10% (low) to 100% (high), the
DV50 increased from ~0.486µm to ~0.702µm for SD mannitol. The increased particle
size (DV50 in Table A.2), particle surface roughness (Figure A.1b-d), and water
content (Table A.4) of SD mannitol were attributed to the formation of larger droplet
size of solution as pump rates increased during atomization given at same primary
drying temperature and period in spray drying.
From the XRPD patterns (Figure A.2), it can be seen that SD mannitol particles
presented many intensive peaks in their patterns, indicating SD particles retained
long-range molecular order/crystalline phase. Mannitol polymorphic behavior has
been previously reported[175, 273]. The simulated X-ray diffractograms of alpha,
beta, and delta forms (thermodynamic stability order: beta>alpha>delta) of anhydrous
mannitol are shown in Figure A.9. Interestingly, the beta form has highest melting
point and lowest enthalpy value, while delta form has lowest melting point and
highest enthalpy value. The characteristic peaks of each polymorph in diffractograms
were symboled for identification purpose. The alpha form was identified using the
peaks at 13.6o and 17.2o 2θ. The peaks at 14.6o and 23.4o 2θ were used to label the
beta form. The delta form was validated using a peak at 9.7o 2θ. Based upon the
XRPD patterns in Figure A.2, it indicated that the raw D-mannitol was in the beta
polymorphic form that was the most thermodynamic stable form verified by DSC data
(Figure A.3a and Table A.3) and in agreement with the literature[279]. The SD
mannitol powders were a mixture of different polymorphs. As the pump rate
increased, the alpha and beta polymorphic content decreased along with increasing
polymorphic delta form content based on intensity of characteristic peaks of each
polymorph. According to the XRPD data (Figure A.2), SD mannitol from low to high
pump rates consisted of beta and alpha polymorphic forms (10% pump rate), a
majority of alpha polymorph (50% pump rate), and alpha and delta (100% pump rate)
polymorphs, respectively. This observed trend of polymorphic composition was also
supported by melting temperature data in Table A.3 since their meting peak
temperatures descended as more metastable mannitol crystalline forms were present.
On the other hand, the enthalpy data in Table A.3 also suggested that a small amount
amorphous phase may remain in SD mannitol and the content of amorphous phase
may increase with pump rate. Contrastingly, Michiko Kumon[280] et al. reported that
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SD mannitol was in the beta polymorph form under their spray-drying condition
which is different from the spray-drying conditions reported here. The CRM results in
Figure A.6 for the 50% (medium) pump rate sample indicated the presence of
homogeneous alpha mannitol, supported by XRPD results showing dominant alpha
form in Figure A.2. In addition, the comparison the FT-IR spectrum of SD mannitol
from 50% (medium) pump rate (as shown in Figure A.7) with the literature data[278]
suggested the existence of mainly the alpha form of mannitol.

Figure A.9. Reference X-ray patterns of different polymorphs of mannitol obtained
from Cambridge structure database program of ConQuest 1.10 (The Cambridge
Crystallographic Data Center, UK). The symbol, , indicates characteristic peaks of
alpha, beta, and delta mannitol, respectively, which were used for identification in this
study.
The small weight loss of raw and SD mannitol from 65% to 90% RH may suggest
crystallization of mannitol. It is reported that SD composited formulation of salmon
calcitonin and mannitol had a weight loss at 60% RH due to the crystallization of
mannitol in GVS at 25oC[158]. Upon storage, amorphous mannitol transformed to the
delta polymorphic form during RH exposure at 51%, which crystallized further into
alpha polymorphic form at 69% RH[158]. A solution-mediated transformation was
suggested based on their findings. The deliquescence point of the delta polymorphic
form is approximately 85% RH, above which beta polymorph may form. The
stoichiometric plot of water vapor sorbed/dry compound vs relative humidity (RH)
(Figure A.10), translated from the gravimetric water vapor sorption equilibrium data
(Figure A.5), provides insightful molecular information. The SD mannitol reached
~0.5 mole/mole ratio at equilibrium of 95% RH. It suggested that SD thermodynamic
metastable microparticulate/nanoparticulate mannitol particles [50% (medium) pump
rate] with more surface area and higher surface energy took up a high percentage of
moisture at 95% RH level, or this may simply indicate the formation of mannitol
hemihydrate[276]. Due to the increased surface area/energy[145] the SD mannitol had
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slightly higher water content than raw D-mannitol (Table A.4), but they were all
under 2% (i.e. very low). The low water vapor sorption (Figure A.5) and water
content (Table A.4) of SD mannitol is critical for formulation stability issues such as
chemical stability[281], polymorphic interconversion[282] and interparticulate
capillary forces[41, 63].

Water Vapor Sorbed/Dry Compound
(mole/mole)

2
Raw mannitol

SD mannitol (50% Pump rate)
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Figure A.10. Water vapor sorption isotherms at 25oC for raw and SD mannitol (50%P)
particles (Water Vapor Sorbed/Dry Compound mole/mole vs RH).

Excellent aerosol dispersion performance of SD mannitol particles was achieved at Q
of 60 L/min (adult airflow rate) with the HandiHaler® which gave low particle
deposition on stage 1 (below 40% deposition) as in Figure A.8. The HandiHaler® is a
high shear stress DPI device[283]. The particles on stage 1 would be predicted to
deposit in larger airways (i.e. bronchi) in vivo[64]. The respiratory aerosol
formulation with ability to effectively reach the smaller airways (i.e. bronchioles) or
even the bronchioalveolar regions penetration is crucial for enhanced effective
treatment of CF[134-136]. As demonstrated here for the first time, the SD mannitol
particles from different pump rates and organic solution (closed-mode) had a
significant effect on their aerosol dispersion performance. High pump rate (100%)
particles exhibited FPF ~55% and RF ~81%. The MMAD values for all aerosols were
suitable for efficiently targeting the smaller airways as inhaled dry powder aerosols.
Interestingly, positive linear correlation of FPF and RF with spray drying pump rates
(Figure A.11a and A.11b) exhibited excellent linear regression correlation values of
r^2 of 0.9998 and 0.9543, respectively.
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Figure A.11. Linear correlation plots of (a) FPF and (b) RF vs spray drying pump
rates for SD mannitol.
The difference in aerosol dispersion performance among SD mannitol particles may
arise from the presence of different polymorphic composition after organic solution
advanced spray drying in closed-mode from dilute mannitol solution in methanol
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resulting in distinctive physicochemical properties (thermal properties, XRPD, water
vapor sorption, etc.) of aerosols and particle properties (water content, sizing, etc.).
SD mannitol particles from medium and particularly from low pump rate exhibited
higher particle deposition on stage 1. Those deposited particles on stage 1 represented
the aerosolized agglomerates (not primary particles)[284]. However, for all aerosols,
the primary particles or reduced aggregates were entrained and deposited on stages
5-7 which have lower Da50 cutoffs into the nanometer aerodynamic size. It is known
that the interparticulate forces (i.e. interfacial forces) increase as particle size
decreases because the surface area per volume increases[64], the SD
microparticulate/nanoparticulate particles do aerosolize, as shown from deposition
profiles on stages 5-7 in Figure A.8. The excellent aerosol dispersion properties of
such particles can be advantageous in the treatment of CF and other pulmonary
diseases by DPIs.

Conclusions
This study has demonstrated for the first time that the SD
microparticulate/nanoparticulate DPI aerosols of mannitol were successfully produced
at three pump rates (high, medium, and low) from dilute mannitol solution (methanol)
using organic solution advanced spray drying in closed-mode. The primary SD
mannitol particles possessed necessary particle and surface properties that minimize
the interparticulate interactions and provide excellent aerosol performance as DPIs.
Comprehensive physicochemical characterization of SD mannitol particles indicated
that crystallinity was retained following organic solution advanced spray drying due
to polymorphic interconversion. The type of crystalline polymorphs present was
correlated with spray drying pump rate. As high-performing DPIs, aerosol deposition
patterns for all three pump rates were distinct. Positive linear correlation between
aerosol dispersion parameters (FPF and RF) and spray drying pump rate revealed this
interplay.
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Abstract
Novel advanced spray dried inhalable trehalose microparticulate/nanoparticulate
powders with low water content were successfully produced by organic solution
advanced spray-drying from dilute solution under various spray-drying conditions.
Laser diffraction was used to determine the volumetric particle size and size
distribution. Particle morphology and surface morphology was imaged and examined
by scanning electron microscopy (SEM). Hot-stage microscopy (HSM) was used to
visualize the presence/absence of birefringency before and following particle
engineering design pharmaceutical processing, as well as phase transition behavior
upon heating. Water content in the solid-state was quantified by Karl Fisher (KF)
coulometric titration. Solid-state phase transitions and degree of molecular order were
examined by differential scanning calorimetry (DSC) and X-ray powder diffraction
(XRPD), respectively. Scanning electron microscopy showed a correlation between
particle morphology, surface morphology, and spray drying pump rate. All advanced
spray-dried (SD) microparticulate/nanoparticulate trehalose powders were in the
respirable size range and exhibited a unimodal distribution. All spray-dried powders
had very low water content, as quantified by KF. The absence of crystallinity in
spray-dried particles was reflected in the X-ray powder diffractograms and confirmed
by thermal analysis. DSC thermal analysis indicated that the novel advanced spray
dried inhalable trehalose microparticles and nanoparticles exhibited a clear glass
transition (Tg). This is consistent with the formation of the amorphous glassy state.
Spray-dried amorphous glassy trehalose inhalable microparticles and nanoparticles
exhibited vapor-induced (lyotropic) phase transitions with varying levels of relative
humidity as measured by gravimetric vapor sorption (GVS) at 25oC and 37oC.
Keywords: microparticulate/nanoparticulate inhalable powders; non-reducing sugar
excipient; organic solution advanced spray drying; Respiratory delivery; trehalose
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Introduction
Pulmonary inhalation drug delivery offers attractive advantages in delivering high
concentrations of drug directly to the disease site in lungs while minimizing systemic
bioavailability[69]. Many mortal lung infectious diseases such as cystic fibrosis reside
at both mid and low airway regions[91, 285-287]. Therefore, local drug delivery for
treatment can be enhanced through the use of microparticles and nanoparticles[288,
289] in pulmonary delivery[70]. These particles can efficiently deposit in the lungs by
physical sedimentation and diffusion of particle deposition mechanism,
respectively[290]. Three main delivery systems have been utilized for the inhalation
of aerosolized drugs, namely, nebulizers, pressurized metered-dose inhalers (MDIs)
and dry powder inhalers (DPIs)[68, 69]. Various interparticulate interactions[291]
influence DPI dispersion performance and include intermolecular van der Waals
force, capillary force, and electrostatic force[64, 261, 262].
Freeze drying and spray drying are two most common processes which allow the
conversion of the formulation from liquid state to solid state particularly for dry
powder inhalation formulation design and development[68]. Nevertheless, freezing
and thermal stresses associated with both processes are often observed. Therefore,
cryoprotectants[292] and thermoprotectants[73] are frequently incorporated in the
formulation for the purpose of protection of drug stability. Carbohydrates[293, 294]
are commonly used as cryoprotectants and thermoprotectants. Trehalose can be
successfully included in inhalation formulations that contain biotherapeutic drugs
(biologics)[295], including aqueous solution spray-freeze dried formulations to
produce large trehalose particles for nasal vaccination delivery[296]. It has many
advantages over other sugars, such as less hygroscopicity, an absence of internal
hydrogen bounds that allows more flexible formation of hydrogen bonds with drugs,
low chemical reactivity and high glass transition temperature[297]. Moreover,
trehalose dihydrate has notable similarities to the pulmonary sugar carrier, lactose
monohydrate, as both are crystalline disaccharides and both are hydrates. Notable
differences with lactose monohydrate are that trehalose dihydrate is a non-reducing
sugar, and hence, it is not susceptible to the solid-state chemical degradation Mallaird
reaction. Additionally, it is not metabolized by bacteria due to its non-reducing
property. Freeze-dried trehalose[298-300] and aqueous solution spray-dried
trehalose[300-302] have been reported for non-inhalation dry powder dosage forms.
Exploring alternative sugar carriers for pulmonary inhalation formulation is of
considerable interest[303]. It has been demonstrated that trehalose can effectively
improve dry powder aerosolization by increasing the fine particle fraction (FPF)[304].
Recently, trehalose dihydrate as an aerosol drug carrier for dry powder inhalation
delivery has been systematically studied and was found to be an effective alternative
to lactose monohydrate carrier[46]. Additionally, trehalose has been used as a
lyoprotectant stabilizing excipient in dry powder inhalation aerosol
formulations[274].
The unique features of spray drying involve the ability of particle design, formation
and drying in a continuous single-step that starts with a liquid and ends with the
powder formulation. It provides the theoretical framework for a rational design of
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structured aerosol particles[68, 70, 305]. Typically, the spray drying process consists
of atomization of feed into a spray, spray-air contact, solvent evaporation of the spray,
and separation of the dried particles from the drying air[306]. However, particle
engineering requires a deeper understanding of particle formation processes since
many process and formulation variables need to be tuned correctly to achieve the
desired structured particles for inhalation.
By using organic solvent in feedstock with no water present, much lower moisture
content and significantly smaller particle size can be achieved down to ~400 nm.
The non-aqueous nature and inherently lower surface tension of an organic solvent
combined with a low (dilute) solute concentration enables particle production in the
solid-state down to the inhalable nanometer size range while maintaining a unimodal
and narrow particle size distribution in the solid-state. To the authors’ knowledge, this
study is the first to use and report this novel approach to rationally design and produce
inhalable dry powder microparticles/nanoparticles for pulmonary delivery. These
novel particles are produced by organic solution advanced spray drying from dilute
solution under rationally chosen spray drying conditions. The goal of this study was to
produce and optimize low water content trehalose microparticles and nanoparticles to
be suitable for pulmonary delivery as dry powder inhalers (DPIs) and to
comprehensively and systematically investigate the physicochemical and particle
properties of spray-dried and raw trehalose particles.
Materials and Methods
Materials
The chemical structure of D-(+)-trehalose dihydrate (C12H26O13; Molecular Weight:
378.33 g/mol; ≥98.5% purity, Sigma-Aldrich Inc., St. Louis, MO) is shown in Figure
B.1 (ChemDraw Ultra 10.0, ChemOffice, Cambridge, MA) and its molecular model
has been previously reported by Mansour and Hickey[274]. Methanol (HPLC grade)
and chloroform were obtained from Fisher Scientific (Fair Lawn, New Jersey).
HYDRANAL@-Coulomat AD was from Sigma-Aldrich (St. Louis, Missouri). AQUA
STAR methanol was from EMD chemical Inc. (Gibbstown, New Jersey).

Figure B.1. The chemical structure of D-(+)-trehalose dihydrate
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Methods
Organic Solution Advanced Spray-Drying from Dilute Solution
The advanced spray-drying process was performed using the Büchi Mini Spray Dryer
B-290 (Büchi, Switzerland) coupled with the Inert Loop B-295 (Büchi, Switzerland)
and the high performance (HP) cyclone (Büchi, Switzerland). The spray drying
process was in closed mode. The feeding solution was prepared by dissolving
D-(+)-trehalose dihydrate in methanol to form a dilute solution with a concentration
of 0.3% w/v. The following spray-drying conditions were rationally chosen and used:
atomization gas flow rate was 600 L/h; aspiration rate was 35 m3/h; three different
pump rates were rationally chosen to represent the “high”, “medium” and “low” pump
rates which were 100% (30 mL/min), 50% (15 mL/min), and 10% (3 mL/min),
respectively. The inlet temperature was set at 150oC and this represents the
temperature maintained the first drying process. The corresponding outlet temperature
for the secondary drying process at the three different pump rates were 39oC (high
pump rate), 45oC (medium pump rate), and 53oC (low pump rate). The nozzle
diameter of the stainless steel nozzle was 0.7mm. The spray-dried (SD) particles were
separated from the hot nitrogen drying gasin a cyclone and collected in a sample
collector. Ultra-high purity grade compressed nitrogen gas from Scott-Gross
(Lexington, Kentucky) was used as the spray-drying gas during closed mode
spray-drying.
All spray-dried powders were carefully stored in sealed glass vials that were stored in
sealed glass desiccators over Indicating Drierite/DrieriteTM desiccant at 25oC under
ambient pressure.

Laser Light Diffraction Particle Sizing and Size Distribution
The mean size and size distribution of the particles in chloroform suspension were
determined by ultraviolet laser diffraction of nano particle size analyzer SALD-7101
(Shimadzu, Japan). Using the method previously reported by Mansour et al[46],
powders were dispersed in chloroform and ultrasonicated for 10 s (Branson 5210
Ultrasonicator Bath, Danbury, Connecticut) to break up the agglomerates without
reducing the primary particle size before particle size measurements were carried out.
Sample particle dispersion was immediately transferred to the particle size measuring
quartz glass cell under stirred conditions. The low refractive index 1.60-0.10 was used.
Number-based dimension of particle amount distribution was obtained for samples. In
addition to acquiring the particle size distributions, the Dv10, Dv50, and D90 parameters
were measured. The Span value was calculated using the equation defined as
[(Dv90-Dv10)/Dv50].

Scanning Electron Microscopy (SEM)
The shape and surface morphology of particles was evaluated by SEM, using a
Hitachi S-800 microscope (Tokyo, Japan). Samples were placed on double-sided
adhesive carbon tabs (TedPella, Inc.) which were adhered to aluminum stubs
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(TedPella, inc.) and were coated with gold/palladium alloy thin film using a Hummer
VI sputtering system from Technics. The coating process was operated at 10 AC mA
for 3 min. The electron beam with an accelerating voltage of 20 kV was used at a
working distance of 30mm. SEM images were captured using Evex NanoAnalysis
software. Several magnification levels were used.

X-ray Powder Diffraction (XRPD)
XRPD patterns of powder samples were measured by a Rigaku Multiflex X-ray
diffractometer (Japan) with a slit-detector Cu Kα radiation (40 kV, 44 mA, and
λ=1.5406 Å) source. Scan range was 5.0 – 50.0 (2θ) º with a scan rate of 2.00o/min at
ambient temperature. The sample was placed on a horizontal quartz glass sample
holder plate.

Differential Scanning Calorimetry (DSC)
Thermal analysis and phase transition measurements were carried out using a TA
Q200 DSC system (TA Instruments, New Castle, Delaware) equipped with T-Zero®
technology and an automated computer-controlled RSC-90 cooling accessory (TA
Instruments, New Castle, Delaware). Approximately 3 mg of powder was carefully
weighed into hermetic anodized aluminum T-Zero® DSC pans (TA Instruments
T-Zero®, New Castle, Delaware) and were sealed with the T-Zero® hermetic sealer
(TA Instruments New Castle, Delaware). Ultra-high purity (UHP) nitrogen gas (Scotts
Gross, Lexington, KY) was used as the purging gas at a purge rate of 50 mL/min. The
heating range was 10-250oC at a heating scan rate of 5.00oC/min.
Karl Fisher (KF) Coulometric Titration
The water content of all powders was chemically quantified by Karl Fisher (KF)
coulometric titration. The measurements were performed with a 737 KF Coulometer
coupled with 703 Ti Stand (Metrohm Ltd., Antwerp, Belgium). Approximately 10 mg
of powder was dissolved in AQUASTAR® anhydrous methanol in a 5-mL volumetric
flask. The sample solution was injected into the reaction cell that contained
HYDRANAL® KF reagent. The water content was then calculated.
Gravimetric Vapor Sorption (GVS)
Water vapor absorption isotherms were measured gravimetrically using an automated
ultra-high sensitivity Cahn microelectronic balance (Thermoscientific Instruments)
coupled to a computerized VTI SGA-CX symmetric vapor sorption analyzer (VTI
Corporation, Hialeah, Florida). All measurements were taken at 25oC and 37oC (ie.
biological temperature) at using a sample size of 1.0-1.5 mg. Samples were subjected
to drying treatment at 25oC (for absorption at 25oC) and at 37oC (for absorption at
37oC) under ultra-high purity (UHP) nitrogen gas (Scotts Gross, Lexington, KY) for 7
h. At the end of the drying cycle, the samples were exposed to an automated
computerized sequence of increasing relative humidity (RH) in steps of 5% RH. The
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RH range was from 0% RH to 95% RH. Sample data acquisition was collected in
2-minute intervals. The equilibrium criterion was a weight change of ≤0.03% (w/w) in
a 10-minute interval, per manufacturer recommendations and as reported previously
by Mansour and Zografi[167].
Hot-stage Microscopy (HSM) under Cross-Polarizers
HSM studies were performed under OLYMPUS BX51 polarized microscope
(Olympus, Japan) equipped with an INSTEC STC200 heating unit and an INSTEC
HCS302 hot stage (Boulder, Colorado). The polarized light was filtered by a γ 530nm
U-TP530 (Olympus, Japan) filter lens. Powder samples were mounted on a cover
glass and heated from 25oC to 250oC at a heating rate of 5oC/min. The heating
program was controlled by WinTemp software. Images were digitally captured by a
SPOT Insight digital camera (Diagnostic Instruments, Inc.).

Results
Laser Light Diffraction Particle Sizing and Size Distribution
The particle sizing data and calculated span values are tabulated in Table B.1. The
particle size distributions for all spray-dried powders were unimodal with narrow
particle distribution, as reflected in the span values. The raw trehalose dihydrate had a
large volume-median particle size of ~60µm as tabulated in Table B.1. Great
reduction of particle size was achieved by organic solution advanced spray drying
from dilute solution to create microparticulate/nanoparticulate powders that are in the
respirable size range.
Table B.1. Particle size parameters of spray-dried (SD) trehalose and raw trehalose
dihydrate particles (mean ± SD, n=3)
Pump rate
10%
SD 50%
100%
Raw

D10
(µm)
0.549±0.003
0.710±0.006
0.646±0.109
35.139±2.602

D50
(µm)
0.752±0.008
0.993±0.013
0.947±0.071
59.854±3.296

D90
(µm)
1.177±0.012
1.544±0.019
1.648±0.228
110.460±1.568

Span Value
0.836±0.010
0.840±0.030
1.080±0.455
1.263±0.122

Scanning Electron Microscopy (SEM)
The particle morphology and surface morphology (ie. surface roughness) of the
samples were visualized and analyzed using SEM. As shown in Figure B.2, smooth
and spherical particles were produced by 10% SD pump feeding rate. However, as the
pump % feeding rate approached 100% (high), the surface roughness increased and
the proportion of irregular particles also increased. Interestingly, raisin-like dimpled
particles were produced at the high pump % feeding rate of 100%. SEM analysis of
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the particle size agreed with the laser sizing data in that all spray-dried powders were
in the suitable size range for inhalation delivery, in addition to having suitable particle
morphology. Contrastingly, the raw trehalose dihydrate particles were much larger
(too large for pulmonary inhalation delivery) and non-spherical with a smooth but
rectangular shape which are not suitable for inhalation delivery.

(a)

(b)

(c)

(d)

Figure B.2. SEM photographs of spray-dried (SD) trehalose and raw trehalose
dihydrate particles. (A) SD trehalose from 10% pump feeding rate, magnification
20,000X; (B) SD trehalose from 50% pump feeding rate, magnification 20,000X; (C)
SD trehalose from 100% pump feeding rate, magnification 20,000X; (D) raw
D-(+)-trehalose dihydrate, magnification 1,000X.
X-ray Powder Diffraction (XRPD)
X-ray powder diffraction patterns (Figure B.3) indicated that the organic solution
spray drying process produced amorphous phase trehalose particles, as exemplified by
the absence of sharp peaks and the presence of the characteristic non-crystalline “halo”
which can be attributed to the loss of crystal character following the loss of the two
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bound water molecules (ie. tightly bound to the crystal lattice by thermodynamically
favorable H-bonding) during the organic solution advanced spray drying process from
dilute solution. In contrast, the raw trehalose dihydrate had many intense peaks
indicative of the presence of long-range molecular order due to crystallinity. The
peaks represented that the raw trehalose dihydrate was highly crystalline which is in a
good agreement with the University of Cambridge database and by results reported by
Mansour et al[46]. The loss of characteristic crystalline peaks (“halo”) is in good
agreement with previous reports on aqueous solution spray-dried trehalose under
different conditions[307].

Intensity

SD trehalose (100% feeding
rate)
SD trehalose (50% feeding rate)

SD trehalose (10% feeding rate)

D-(+)-trehalose dihydrate

5

15

25

35

45

55

2 Theta (degrees)
Figure B.3. X-ray powder diffractograms of SD trehalose and raw trehalose dihydrate
powders.
Differential Scanning Calorimetry (DSC)
The thermograms obtained from raw trehalose dihydrate and SD trehalose are shown
in Figure B.4. There were three endothermic peaks observed for raw trehalose
dihydrate which are characteristic for order-to-disorder thermotropic phase transitions.
Similar DSC thermograms were obtained for single crystals of trehalose
dihydrate[308] and for raw trehalose dihydrate powder[296]. The two endothermic
order-to-disorder peaks at ~100oC and 140oC correspond to two dehydration
processes due to the loss of unbound water at ~100oC (ie. vaporization of unbound
water) and vaporization of the bound water molecules at 140oC which vaporize at a
temperature significantly greater than 100oC due to thermodynamically favorable
H-bonding of the water molecules within the trehalose dihydrate crystal lattice. The
third endothermic order-to-disorder peak at 210oC represented the fusion of
anhydrous β form of trehalose[309]. All SD trehalose samples showed an amorphous
glassy-to-rubbery phase transition, Tg, (ie. characteristic baseline shift) at ~50oC,
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followed by an exothermic disorder-to-order phase transition near 95oC which
suggests crystallization at Tc from the amorphous rubbery state. A small endothermic
order-to-disorder peak was observed in the temperature range of 140-150oC for the
SD trehalose samples. To the authors’ knowledge, this peak has not been reported
previously in the literature. The fusion of the β form of trehalose was observed in this
same temperature range as the raw trehalose dihydrate.
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Figure B.4. DSC thermograms of SD trehalose and raw trehalose dihydrate particles
at a heating scan rate of 5.00oC/minute. (A) raw D-(+)-trehalose dihydrate; (B) SD
trehalose (10% pump feeding rate); (C) SD trehalose (50% pump feeding rate); (D)
SD trehalose (100% pump feeding rate).
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Karl Fisher (KF) Coulometric Titration
The water content data are plotted in Figure B.5. The mean total water content of raw
trehalose dihydrate was 9.62% (w/w) with a standard deviation (std. dev.) value of
±0.08% (w/w). This data is in excellent agreement with the literature[308]. By
comparing the theoretical minimum water content of raw trehalose dihydrate (9.52%
(w/w)), it suggested that there was a trace amount of water (0.1% (w/w)) adsorbed to
its surface, as the sample was stored under ambient conditions (approximately 55%
RH and 25oC). As stated in the Experimental section, all spray-dried trehalose
powders were stored in a sealed glass desiccator containing Drierite®/Indicating
Drierite® desiccant under room temperature of 25oC. The water content values were
0.73% (w/w) (std. dev. = ± 0.25% (w/w)), 0.86% (w/w) (std. dev. = ± 0.09% (w/w)),
and 1.51% (w/w) (std. dev. = ± 0.01% (w/w)) for samples produced by 10% (low), 50%
(medium), and 100% (high) pump feeding rates, respectively.

Water Content (% w/w)

12.00
10.00
8.00
6.00
4.00
2.00
0.00

Samples
Figure B.5. Water content quantification (% w/w) of SD trehalose and raw trehalose
dihydrate powders by Karl Fisher coulometric titration.
Gravimetric Vapor Sorption (GVS)
The gravimetric vapor sorption isotherms of the three spray-dried trehalose and raw
trehalose dihydrate samples are plotted in Figure B.6a. From 0% to 55% of RH, all
three SD samples underwent a rising curve with respect to their mass changes,
reflecting an increasing capability of water vapor uptake. Interestingly, a transition
point of water vapor sorption took place at 30% RH. This may be due to the SD
trehalose samples passing through the lyotropic vapor-induced glass transition, from
lower molecular mobility of glassy state to higher molecular mobility of the rubbery
state. The uptake of water vapor of the sample continued to increase after the
lyotropic vapor-induced glass transition. The amorphous trehalose relaxed to its more
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stable crystalline state through crystallization at 55%-60% RH and the water vapor
sorption capacity decreased sharply over a very narrow RH range followed by a
plateau in vapor absorption. A slight desorption of water was observed for SD
trehalose samples after 60% RH followed by the plateau region suggestive of the
recrystallization process from the amorphous state to the crystalline state. It also
suggests the transition from unbound water to bound water, as occurs during the
process of crystallization.

Weight Change % (w/w)

The water vapor sorption isotherms of SD trehalose particles (50% pump feeding rate)
at 25oC and 37oC were measured as shown in Figure B.6b. The water vapor
absorption isotherm at 37oC appeared to reach the equilibrium faster than at 25oC in
terms of RH %. For example, the SD amorphous trehalose reached its highest weight
change percentage at 50% RH at 37oC vs 55% RH at 25oC. In addition, the SD
amorphous trehalose exhibited more water vapor uptake at 37oC than at 25oC across
the whole RH % range studied while retaining the similar isothermal profile trend.
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Figure B.6. Water vapor sorption isotherms of SD trehalose and raw trehalose
dihydrate particles (weight change (%) vs relative humidity (RH)): (A) Comparison of
water vapor absorption between SD trehalose and raw trehalose dihydrate particles at
25oC; (B) Comparison of water vapor absorption of SD trehalose particles (50%
feeding rate) at 25oC and 37oC.
Hot-Stage Microscopy (HSM) under Cross-Polarizers
The HSM pictures of raw trehalose dihydrate and SD trehalose (50% feeding rate)
upon heating are shown in Figure B.7. Under cross-polarized light, the birefrigency of
raw trehalose dihydrate were observed at 25oC and 37oC. The birefrigency of raw
trehalose dihydrate started to diminish at 108oC and disappeared finished at 116 oC.
This phase transition may correspond to its first endothermic order-to-disorder phase
transition, as seen in Figure B.4 for raw trehalose dihydrate. This may be due to the
first dehydration process ie. loss of unbound water. As seen in Figure B.7, the crystal
shape was retained during this transition. However, during the second endothermic
order-to-disorder phase transition, the crystal shape disappeared in the temperature
range 146-160oC. Subtle birefringency reemerged in the temperature range of
200-227oC which may suggest a subtle recrystallization event which was not observed
in the DSC thermogram. Melting was visualized in the temperature range of
231-234oC as evident by liquid droplet formation.
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Figure B.7. HSM of raw trehalose dihydrate particles
SD trehalose from 50% feeding rate (Figure B.8) showed dark agglomerates lacking
birefringency at 25oC and 37oC, as would be expected for non-crystalline amorphous
materials. The recrystallization of SD trehalose with increasing temperature was not
visually evident due to the small particle size of SD trehalose (Table B.1). The first
phase transition visualized by HSM appears to correlate with the small
order-to-disorder endotherm (perhaps due to a metastable phase transition or a
pretransition), as observed in the DSC thermogram at 140-150oC in Figure B.4c. The
melting process occurred at higher temperatures as evident by liquid droplet
formation seen in the micrographs.
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Figure B.8. HSM of SD trehalose particles (50% pump feeding rate)
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Discussion
The present work demonstrates that low water content trehalose microparticles and
nanoparticles with particle properties necessary for inhalation dry powder delivery
can be successfully produced by organic solution advanced spray drying from dilute
solution using rationally selected spray drying conditions. By using low concentration
of organic solvent solution, the unimodal narrow particle size distribution of SD
trehalose microparticulate/nanoparticulate powders was achieved. The unimodal
narrow particle size distribution is critical for pulmonary dry powder inhalation, as it
enables the particles to target a specific lung region which consequently can lower the
therapeutic dose. In addition, the water content of final product can be reduced via
spray drying the organic solution of trehalose instead of water solution. Since the size
of inhalable particles is small, residual water can have a significant influence on the
dispersion of dry powder during aerosolization through capillary force[64]. However,
the water content of SD trehalose increased a bit as the pump rate increased but was
still at the level that is considered to be low.
The surface morphology, as visualized by SEM, changed with increasing pump
feeding rates. Specifically, smooth particles and corrugated particles were produced
by low feeding rate and high feeding rate, respectively. Research studies[141, 263]
have demonstrated that the particle morphology of dry powder can impact the aerosol
performance.
From the XRPD and DSC data, they showed that the organic solution advanced spray
drying process from dilute changed raw crystalline trehalose dihydrate into SD
amorphous glassy trehalose. The change of pump rate did not significantly affect the
XRPD and DSC data for SD trehalose particles. However, DSC thermal analysis for
SD trehalose appears to suggest that amorphous rubbery trehalose crystallizes to a
relatively more ordered phase at a Tc ~95oC, as seen by the distinct disorder-to-order
exothermic phase transition present in the thermograms.
Gravimetric vapor sorption study illustrated water vapor lyotropic effect on SD
trehalose particles microparticulate/nanoparticulate powders. A vapor-induced phase
transition suggestive of a glass transition occurred at 30% RH, after which point water
vapor uptake continued to increase up to ~55% RH. The crystallization process
appeared to occur during vapor absorption in the RH range of 55-60% RH, as evident
by the sharp decrease in water vapor uptake over a narrow RH range followed by the
plateau in vapor uptake. It is generally recognized that temperature and RH are two
important factors on the phase transition behavior and stability on amorphous
phases[310, 311]. As expected for crystalline hydrate powders, raw trehalose
dihydrate did not absorb any significant amounts of water vapor over the entire range
of RH, as it is in its thermodynamically stable state.
Figure B.9 shows water vapor uptake lyotropic phase behavior at 25oC (ambient
temperature) and 37oC (biological temperature) on a molar basis for stoichiometric
water content analysis and insight. Figure B.9a shows that the raw trehalose dihydrate
does not exhibit any significant water vapor uptake on a molar basis. This is expected
for crystalline materials especially for crystalline hydrate powders, as crystalline
185

materials are in a relatively lower thermodynamic energy state.
All spray-dried trehalose amorphous glassy particles, produced using three different
pump feeding rates, had similar water vapor sorption profiles but were significantly
greater than raw crystalline trehalose dihydrate, as shown in Figure B.9a. The
stoichiometric molar ratio reached to 2.1 (i.e. dihydrate) at 55% RH and remained at
this level in the plateau region which suggests a lyotropic phase transition from the
amorphous rubbery state (i.e. higher energy state) to the thermodynamically stable
dihydrate crystal (lower energy state). It decreased slightly followed by a plateau
region. There appears to be a slight ratio decrease for SD trehalose at 25oC starting
from the crystallization point, reaching to 1.8 moles (i.e. dihydrate) in the plateau
region. Figure B.9b shows that the SD trehalose particles had a lesser decrease in the
stoichiometric molar ratio at 37oC (biological temperature) at the recrystallization
point and was essentially constant at 2 moles (i.e. dihydrate) at higher RH % levels.
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Figure B.9. Water vapor sorption of SD trehalose and raw trehalose dihydrate
particles (water vapor absorbed/dry sample (mole/mole) vs relative humidity (RH)):
(A) Comparison of water vapor absorption between SD trehalose and raw trehalose
dihydrate particles at 25oC; (B) Comparison of water vapor absorption of SD
trehalose particles (50% feeding rate) at 25oC and 37oC.
Conclusions
This study has demonstrated for the first time that the inhalable trehalose
microparticles and nanoparticles with different particle morphology were rationally
designed and successfully produced via organic solution advanced spray drying from
dilute solution. The use of organic solvent has several important advantages to
produce unimodal microparticulate/nanoparticulate inhalable powders with greatly
reduced residual water content which can improve product stability and performance.
The SD trehalose particles from various feeding rates possessed similar amorphous
phase and capacity of water vapor sorption. Pharmaceutical processing conditions
correlated in a meaningful manner with changes in important physicochemical and
particle properties essential for targeted pulmonary delivery as DPIs. The
thermotropic and lyotropic phase transition at 25oC and 37oC (biological temperature)
were correlated with the amorphous glass vs rubbery state and solid-state phase
transitions.
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Appendix C Spray-Dried Itraconazole Aerosols

C.1 Materials
Two itraconazole formulation systems were produced at the same spray-drying
conditions (50% pump rate) as shown in Section 3.2.2.1 in Chapter 3. The
itraconazole
two-component
systems
are
itraconazole:mannitol
and
itraconazole:trehalose.
The
itraconazole
three-component
systems
are
itraconazole:phospholipids:mannitol and itraconazole:phospholipids:trehalose.

C.2 Results
C.2.1 Spray-dried Itraconazole Two-component Systems
C.2.1.1 X-ray Powder Diffraction
The XRPD patterns suggest that SD itraconazole:mannitol (ITR:MAN) (Figure C.1a)
and SD itraconazole:trehalose (ITR:TRE) (Figure C.1b) were lacking in long-range
molecular order except for ITR:MAN=1:5. By comparing to the XRPD of mannitol
(in Appendix A), it suggests that the characteristic peaks correspond to alpha form of
MAN.
C.2.1.2 In Vitro Aerosol Dispersion Performance
As shown in Figure C.2a, SD ITR:MAN=1:5 aerosol powder exhibited a relatively
higher particle deposition on stage 1 compared to the formulations with other ratios.
The deposition mode of fine particles was on stage 4 and stage 2 for the powders of
ITR:MAN=1:0.1, 1:0.5, and 1:1, and ITR:MAN=1:5, respectively. Compared to other
formulations, ITR:MAN=1:5 aerosol particles exhibited an lower value in FPF and
RF, and an higher value in MMAD
of 14.3µm. The data indicate that
ITR:MAN=1:0.1, 1:0.5, and 1:1, with a MMAD value being approximately ≤ 5µm,
could be able to penetrate into deep lung regions. However, ITR:MAN=1:5, after
partial crystallization, showed a MMAD value far beyond respirable size of 10µm.
The detailed values are listed in Table C.1.
SD ITR:TRE aerosol powders (Figure C.2b) shifted fine particle deposition mode
from stage 4 to stage 5 with increasing amount of TRE. The FPF, RF, and MMAD of
ITR:TRE aerosol particles ranged from 27.9% to 45.9%, 41.7% to 74.7%, and 2.0µm
to 4.6µm, respectively. These data suggest that ITR:TRE powders were suitable for
deep lung penetration. The detailed values are listed in Table C.2.
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(a)

(b)
Figure C.1. X-ray powder diffraction patterns for: (a) SD itraconazole:mannitol
formulations; and (b) SD itraconazole:trehalose formulations.
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(a)

(b)
Figure C.2. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of 60 L/min with the HandiHaler® DPI device for: (a) itraconazole:mannitol powders;
and (b) itraconazole:trehalose powders (mean ± SD, n=3).
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Table C.1. Aerosol dispersion performance parameters of SD itraconazole:mannitol
particles (mean ± margin of error for 95% confidence, n=3).
ITR:MAN

Aerosol Dispersion Performance Parameters

Molar Ratio ED[%]

FPF[%]

RF[%]

MMAD[µm]

GSD

1:0.1

98.1±1.4

28.2±1.0

46.2±1.3

5.2±0.3

3.2±0.4

1:0.5

97.0±0.4

35.9±1.3

56.1±2.1

3.8±0.3

2.6±0.1

1:1

97.0±1.4

29.7±2.8

48.5±2.3

5.1±0.4

3.0±0.2

1:5

98.9±0.4

16.9±1.3

28.8±1.9

14.3±0.3

3.9±0.7

Table C.2. Aerosol dispersion performance parameters of SD itraconazole:trehalose
particles (mean ± margin of error for 95% confidence, n=3).
ITR:TRE

Aerosol Dispersion Performance Parameters

Molar Ratio ED[%]

FPF[%]

RF[%]

MMAD[µm] GSD

1:0.1

97.7±1.0

31.5±2.6

53.7±2.9

4.4±0.4

2.6±0.1

1:0.5

96.3±0.7

45.9±3.5

74.7±3.1

2.7±0.3

2.2±0.1

1:1

97.0±0.7

27.9±3.6

41.7±5.0

4.6±0.7

3.1±0.2

1:5

97.7±1.1

39.4±2.1

69.9±5.0

2.0±0.2

2.0±0.1
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C.2.2 Spray-dried Itraconazole Three-component Systems
C.2.2.1 X-ray Powder Diffraction
The
XRPD
patterns
suggest
(Figure
C.3a)
that
SD
itraconazole:phospholipids:mannitol (ITR:PLS:MAN) formulations lacked long-range
molecular order at molar ratio of 3:1:9. Some characteristic crystalline peaks were
observed
in
both
ITR:PLS:MAN=3:3:9
and
3:9:9
powders.
SD
itraconazole:phospholipids:trehalose (ITR:PLS:TRE) particles (Figure C.3b) were
lacking in long-range molecular order. The phospholipid bilayer structure was
retained after spray drying for both formulation systems.
C.2.2.2 In Vitro Aerosol Dispersion Performance
As shown in Figure C.4a, SD ITR:PLS:MAN=3:1:9 aerosols exhibited an extremely
low particle deposition of 2.4% on stage 1 compared to other two partially crystalline
formulations. The deposition mode of fine particles was on stage 4 and stage 2 for
aerosol powders of ITR:PLS:MAN=3:1:9, and ITR:PLS:MAN=3:3:9 and 3:9:9,
respectively. ITR:PLS:MAN=3:1:9 aerosols exhibited FPF, RF, and MMAD as
66.3%, 97.6%, and 2.8µm, respectively. As shown for MMAD of being from 28.3µm
to 34.3µm, ITR:PLS:MAN=3:3:9 and 3:9:9 aerosol were not suitable for dry powder
for inhalation. Therefore, only ITR:PLS:MAN=3:1:9 aerosol powder was suitable to
be delivered to deep lung regions. The detailed values are listed in Table C.3.
SD ITR:PLS:TRE (Figure C.4b) aerosol particles exhibited deposition mode of fine
particles on stage 4 or stage 5. With FPF, RF, and MMAD being of 36.5%, 70.4%,
and 1.9µm, ITR:PLS:MAN=3:3:9 aerosols appeared to have a superior aerosol
dispersion performance to the others. ITR:PLS:MAN=3:1:9 and 3:3:9 aerosol
particles, exhibiting MMAD values ≤ 5µm, were suitable for deep lung delivery. The
detailed values are listed in Table C.4.

193

(a)

(b)
Figure
C.3.
X-ray
powder
diffraction
patterns
for:
(a)
itraconazole:phospholipids:mannitol
formulations;
and
(b)
itraconazole:phospholipids:trehalose formulations.
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SD
SD

(a)

(b)
Figure C.4. Aerosol dispersion performance using the NGI under an airflow rate (Q)
of
60
L/min
with
the
HandiHaler®
DPI
device
for:
(a)
itraconazole:phospholipids:mannitol
powders;
and
(b)
itraconazole:phospholipids:trehalose powders (mean ± SD, n=3).
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Table
C.3.
Aerosol
dispersion
performance
parameters
of
SD
itraconazole:phospholipids:mannitol particles (mean ± margin of error for 95%
confidence, n=3).
ITR:PLS:MAN

Aerosol Dispersion Performance Parameters

Molar Ratio

ED[%]

FPF[%]

RF[%]

MMAD[µm] GSD

3:1:9

95.4±0.9

66.3±0.6

97.6±0.8

2.8±0.1

1.8±0.0

3:3:9

99.4±0.2

12.3±0.9

19.8±1.3

28.3±2.0

4.9±0.2

3:9:9

99.2±0.4

10.1±2.4

18.5±3.6

34.3±7.8

5.5±2.7

Table
C.4.
Aerosol
dispersion
performance
parameters
of
SD
itraconazole:phospholipids:trehalose particles (mean ± margin of error for 95%
confidence, n=3).
ITR:PLS:TRE

Aerosol Dispersion Performance Parameters

Molar Ratio

ED[%]

FPF[%]

RF[%]

MMAD[µm] GSD

3:1:9

96.7±0.5

23.9±2.3

45.7±4.0

3.6±0.6

2.8±0.2

3:3:9

93.2±0.9

36.5±3.1

70.4±5.6

1.9±0.1

2.0±0.1

3:9:9

98.0±0.2

29.6±1.9

46.9±2.2

5.6±0.3

2.9±0.3
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